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ABSTRACT 
 
Introduction. Arrhythmogenic cardiomyopathy (ACM) is a predominantly 
genetically determined disease characterized by fibrofatty replacement which 
leads to right ventricular failure, arrhythmias, and sudden cardiac death (SCD). 
ACM is inherited as an autosomal dominant trait with incomplete penetrance. 
Advances in genetic technology have revealed substantial genetic heterogeneity: 
at least 15 independent loci and 13 disease genes have now been identified 
associated with the disease, with the large involvement of the genes encoding for 
desmosomal and area composita proteins. Since causative mutations in ACM 
genes have been detected in about 60% of probands, additional and still unknown 
disease-genes could be involved. 
Aim of the study. This study aimed at detecting causative mutations underlying 
the disease expression in a cohort of 59 Italian unrelated index cases through a 
new targeted next generation sequencing (NGS) approach. Moreover, the 
identification of novel disease loci and genes in four families with recurrence of 
ACM was attempted by integrating different genetic approaches. 
Methods. Three different NGS approaches have been applied: targeted gene 
panels (TGP), whole exome sequencing (WES), and whole genome sequencing 
(WGS). Two custom targeted gene panels, including 56 genes associated with 
different cardiomyopathies or 69 known and candidate ACM genes have been 
used to screen both familial and sporadic cases. Genetic analysis was extended to 
available family members to evaluate the segregation of each mutation identified 
in the index case. The whole exome of 11 subjects belonging to 4 families was 
sequenced. In one of these families (Family#6) also WGS in 3 subjects in addition 
to multipoint linkage analysis was performed. 
Results. Targeted gene panels resulted a valuable tool for mutation screening in 
patients affected with ACM. At least a mutation was found in 15 out of 19 
probands screened with the ‘Cardiomyopathies gene panel’. Moreover, by using 
the ‘ACM known and candidate genes panel’, a mutation in a candidate gene has 
been identified in 40.6% of probands negative for mutations in known-disease 
genes. Two novel missense variants in TJP1 gene (p.R265W, p.Y669C), encoding 
for protein ZO-1 and two in CDH2 gene (p.E493G, p.V491G), encoding for N-
cadherin resulted of particular interest, other than a stop mutation in TP63 gene 
(p.R266*). Both TJP1 mutations affected highly conserved amino acid residues 
and in silico analysis of p.Y669C mutation, which segregates within the proband’s 
family, showed its predicted damaging effect into the protein structure. 
WES analysis allowed to identify a pathogenic mutation in DSP gene (p.Q1297*) 
not previously detected by dHPLC in Family#3, and two putative TTN mutations 
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(p.R32573C and p.L32198M) that segregate in Family#4 and Family#5. In 
Family#5, a rare stop mutation in a candidate gene (CMYA5, p.K3597*) was also 
identified. 
In Family #6, a multi-step approach was applied. The availability of many affected 
and unaffected family members allowed to perform linkage analysis in an ‘affected 
only’ approach. The analysis pointed out the presence of two regions with positive 
pLOD score values on chromosome 19p13.3 and 11q21. The first corresponded to 
a 7cM region and was shared by all the affected subjects, but one. The 3cM region 
on chromosome 11q21 segregated in all the affected subjects exception made for 
two, who carried a PKP2 splice site variant (c.2578-3 T>C). WES performed in 4 
patients of the family failed to identified a possible shared pathogenic mutation 
neither inside the critical regions, nor in the whole exome. These results were 
confirmed with WGS performed in 2 affected and a healthy individual. Moreover 
WGS pointed out the presence of a huge amount of complex variants located in 
repetitive intronic or intragenic regions. 
Discussion. The identification of disease-causing mutations facilitates timely 
diagnosis, allows the prevention of complications and determines the potential risk 
in close relatives of a proband. For hereditary cardiomyopathies, as well as for 
most mendelian diseases, in the last ten years NGS technology improved this 
process allowing to parallel sequence a large amount of genes in a time and cost-
efficient manner. Since mutations in the most index cases sequenced by using a 
targeted gene panel have been detected, it resulted a valid approach not only for 
genetic testing but also to identify putative novel disease genes. In the present 
study, novel mutations in genes encoding for intercalated disc proteins (TJP1, 
CDH2) have been identified, confirming the idea that ACM has to be considered a 
‘junctional disease’ rather than only a ‘desmosomal disease’. 
Despite TGP remains the most commonly used approach for hereditary 
cardiomyopathies, WES, applied in familial ACM cases, allowed to identify novel 
variants in candidate genes that would be not detected with TGP and could have a 
possible pathogenic role or a modifier effect in the phenotypic expression. Finally, 
even though WGS didn’t allow to make a genotype-phenotype correlation in 
Family #6, the huge amount of data produced represent permanent data that could 
be re-analysed in the future with new insights and the discovery of novel disease 
genes. 
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RIASSUNTO 
 
Introduzione. La cardiomiopatia aritmogena (ACM) è una patologia ereditaria del 
muscolo cardiaco, caratterizzata da una progressiva sostituzione adiposa o 
fibroadiposa a carico prevalentemente del miocardio del ventricolo destro. Dal 
punto di vista clinico, è una patologia eterogenea con ampia variabilità clinica 
inter- ed intra- familiare; presenta infatti sia forme completamente asintomatiche 
sia forme molto gravi con rischio di morte improvvisa. Questa patologia,  
geneticamente eterogenea, è trasmessa come carattere autosomico dominante a 
penetranza incompleta ed espressività variabile. Ad oggi 15 loci e 13 geni sono 
stati associati alla malattia, di cui gran parte codificano per proteine desmosomali 
e proteine della cosiddetta area composita dei dischi intercalari. Poiché sono state 
identificate mutazioni causative in geni noti sono nel 60% dei casi, altri geni, non 
ancora identificati, potrebbero essere coinvolti nella comparsa del fenotipo 
patologico. 
Scopo della ricerca. Nello studio descritto nella presente tesi, il DNA di 59 casi 
indice è stato analizzato attraverso due diversi pannelli di geni tramite 
sequenziamento di nuova generazione (NGS). Inoltre, in quattro famiglie con 
ricorrenza di casi di ACM, in cui non sono state identificate mutazioni nei geni 
desmosomali, sono state integrate diverse tecniche allo scopo di identificare nuovi 
loci e geni malattia. 
Metodi. Nell’ambito del sequenziamento di nuova generazione (NGS) tre diversi 
approcci sono stati utilizzati: il sequenziamento di pannelli di geni target (TGP), il 
sequenziamento dell’intero esoma (WES) e il sequenziamento dell’intero genoma. 
Due sono i pannelli di geni considerati, uno comprendente 56 geni associati a 
diverse cardiomiopatie, l’altro comprendente 69 geni, tra cui i 13 geni associati alla 
cariomiopatia aritmogena e 56 geni candidati. L’analisi genetica è stata poi estesa 
ai familiari dei probandi, ove disponibili, per valutare la segregazione delle 
mutazioni identificate. L’intero esoma è stato poi sequenziato in 11 soggetti 
appartenenti a 4 diverse famiglie. Infine, in una di queste famiglie (Famiglia#6) è 
stata eseguita un’analisi di linkage ed è stato sequenziato l’intero genoma di tre 
soggetti. 
Risultati. L’utilizzo dei pannelli di geni target si è rivelato una buona strategia per 
lo screening di mutazioni in pazienti affetti da ACM: almeno una mutazione è stata 
trovata in 15 probandi su un totale di 19 analizzati con il pannello di geni associati 
a diverse cardiomiopatie; inoltre, è stata identificata una mutazione in uno dei geni 
candidati nel 40.6% dei probandi sequenziati con il secondo pannello e risultati 
negativi per mutazioni nei geni noti. Tra queste mutazioni, risultano di particolare 
interesse 2 nuove mutazioni missenso localizzate nel gene TJP1 (p.R265W, 
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p.Y669C), 2 mutazioni nel gene che codifica per l’N-caderina (CDH2, p.E493G, 
p.V491G) e una mutazione di stop nel gene TP63 (p.R266*). Entrambe le 
mutazioni di TJP1 riguardano aminoacidi altamente conservati, inoltre un’analisi in 
silico degli effetti della mutazione p.Y669C, che segrega all’interno della famiglia, 
evidenzia un riarrangiamento della struttura proteica della proteina che riporta la 
mutazione rispetto alla proteina wild-type.  
L’analisi dell’esoma nella Famiglia#3 ha permesso di identificare una mutazione 
patogena di stop nel gene DSP, che non era stato possibile individuare al 
precedente screening tramite dHPLC. Inoltre, tale approccio ha permesso di 
identificare due putative mutazioni nel gene TTN (p.R32573C and p.L32198M) che 
segregano nelle Famiglie #4 e #5, rispettivamente. Nella Famiglia #5 inoltre è 
stata identificata una rara mutazione di stop in un gene candidato (CMYA5, 
p.K3597*). Per lo studio della Famiglia#6, invece, sono stati utilizzati diversi 
approcci. Data la disponibilità di molti soggetti affetti e sani appartenenti alla 
famiglia, in seguito alla genotipizzazione degli stessi, è stata eseguita un’analisi di 
linkage. L’analisi ha evidenziato la presenza di due loci che riportano valori di lod 
score positivi a livello del cromosoma 19p13.3 e del cromosoma 11q21. Il primo 
locus corrisponde ad una regione di 7 cM ed è condiviso da tutti i soggetti affetti 
della famiglia, eccetto uno. La regione di 3cM nel cromosoma 11q21 invece 
segrega in tutti i soggetti affetti ad eccezione di due, che portano una mutazione in 
un sito di splicing del gene PKP2 (c.2578-3 T>C). Il sequenziamento dell’esoma in 
4 soggetti affetti della famiglia non ha permesso di identificare nuove mutazioni 
condivise né all’interno delle due regioni critiche, né all’interno dell’intero esoma. 
Tali risultati sono stati confermati dal sequenziamento del genoma effettuato in 
due affetti e un soggetto sano della famiglia. Il sequenziamento del genoma ha 
inoltre messo in luce la presenza di un’enorme quantità di varianti complesse 
localizzate in regioni introniche o intrageniche. 
Discussione. L’identificazione di mutazioni causative nella cardiomiopatia 
aritmogena facilita la diagnosi tempestiva, permette di prevenire eventuali 
complicazioni e determina il rischio di sviluppare la malattia nei familiari di un 
soggetto affetto. Per le cardiomiopatie ereditarie, come per la maggior parte delle 
malattie mendeliane, negli ultimi 10 anni le tecniche NGS hanno apportato grossi 
miglioramenti nel processo di identificazione di mutazioni, permettendo di 
sequenziare una grande quantità di geni parallelamente, in modo più rapido e 
meno costoso. In questo studio, dal momento che sono state identificate mutazioni 
nella maggior parte di probandi analizzati, l’utilizzo di pannelli di geni target si è 
dimostrato un valido approccio non solo per un test genetico ma anche per 
l’identificazione di nuovi geni malattia. Sono state infatti identificate nuove 
mutazioni in geni che codificano per proteine dei dischi intercalari dei cardiomiociti, 
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confermando l’idea che l’ACM deve essere considerata una ‘malattia delle 
giunzioni’ piuttosto che una ‘malattia dei desmosomi’. 
Nonostante l’utilizzo di pannelli di geni target rimanga l’approccio più 
comunemente usato nella ricerca di mutazioni nelle cardiomiopatie ereditarie, il 
sequenziamento dell’intero esoma, applicato in questo studio solo a casi familiari, 
ha permesso di identificare varianti in geni candidati non inclusi nei pannelli di geni 
e che potrebbero avere un ruolo nell’espressione del fenotipo patologico. Infine, 
nonostante il sequenziamento del genoma nella Famiglia#6 non abbia permesso 
al momento di stabilire una correlazione tra genotipo e fenotipo al momento, la 
mole di dati prodotti potrà essere rianalizzata in futuro alla luce di nuovi geni 
annotati e nuovi geni malattia identificati. 
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1. INTRODUCTION  
 
Cardiomyopathies are a heterogeneous group of myocardial disorders 
characterized by structural and functional abnormalities of the heart muscle, in the 
absence of coronary artery disease, hypertension, valvular disease and congenital 
heart disease sufficient to cause these anomalies (European Society of 
Cardiology, Maron et al., 2006). Cardiomyopathies were defined as primary if the 
heart is the sole or predominantly involved organ and secondary if those diseases 
in which myocardial dysfunction is part of a systemic disorder (Elliot et al., 2008). 
Most of the forms recognized as primary cardiomiopathies have a genetic origin 
and a familial presentation. Beyond channelopathies, the main described 
phenotypes are hypertrophic, restrictive, dilated and arrhythmogenic 
cardiomyopathies and isolated left ventricular non-compaction. 
Arrhythmogenic cardiomyopathy (ACM) is a heritable form of cardiomyopathy 
characterized by fibrofatty replacement which leads to right ventricular failure, 
arrhythmias, and sudden cardiac death (SCD) (Marcus et al., 1982, Nava et al., 
1988; Thiene et al., 1988). 
 
1.1 History and designation of the disease 
The first historical description of ACM date three centuries ago (1736), when 
Giovanni Maria Lancisi reported the recurrence of the disease in four generations 
of a family in the book entitled “De Motu Cordis et Aneurysmatibus”. However, the 
first comprehensive clinical description of the disease was reported in 1982 by 
Marcus and colleagues. They described 24 adults cases showing ventricular 
tachycardia of left bundle branch block (LBBB) morphology (Marcus et al., 1982). 
Two years later, the electrocardiographic features of the disease, including the 
characteristic epsilon wave were described (Fontaine et al., 1984). In 1988, Nava 
and colleagues reported that ACM is manifested at a young age with a 
polymorphic clinical and arrhythmic profile and the evidence of an autosomal 
dominant transmission pattern (Nava et al., 1988). Moreover, in the same year, 
Thiene and colleagues described several cases of sudden death in young people 
(≤35 years), who showed typical electrical ACM features, like inverted T waves in 
the right precordial leads and ventricular arrhythmias with LBBB, together with 
fibrofatty replacement in the right ventricular free wall (Thiene et al., 1988). Since 
then, ACM is consider one of the most important causes of sudden death among 
young people and athletes.  
In the beginning the term related to the disease was ‘arrhythmogenic right 
ventricular dysplasia (ARVD)’ for the histologic features of the myocardium and the 
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belief that ACM is a congenital heart defect. The name was then replaced with 
‘arrhythmogenic right ventricular cardiomyopathy (ARVC)’ due to acquired nature 
of myocardial atrophy, occurring after birth as a consequence of cumulative 
myocyte loss. Moreover, since the left ventricle of the myocardium seems to be 
involved in more than half of the cases (Corrado et al., 1997) and may precede the 
onset of significant right ventricular dysfunction, the adoption of the broader term 
‘arrhythmogenic cardiomyopathy (ACM)’ is supported (Sen-Chowdhry et al., 
2007).  
 
1.2 Epidemiology 
The estimated prevalence of ACM in the general population ranges from 1 in 2000 
to 1 in 5000 and it accounts for approximately 30% of cases of sudden cardiac 
death (SCD) in young and athletes (Nava et al., 1988). At least 50% are familial 
cases and it is typically transmitted with and autosomal dominant pattern of 
inheritance characterized by incomplete penetrance and variable expressivity. For 
these different manifestations, it should be consider an underestimation of the 
disease prevalence. Moreover, ACM affects men more frequent than woman, with 
an approximate ratio of 3:1, but it does not appear a priori to harbor adverse 
effects on long-term survival. Even if the cause remains unclear, important factors 
such as sexual hormones and physical activity could play a role (Bauce et al., 
2008). 
 
1.3 Clinical manifestations 
ACM usually arises from the second to the forth decade of life (Nava et al., 1988; 
Daliento et al., 1995), first symptoms during early childhood or beyond the age of 
60 years are in fact unusual.  
Traditionally the course of the disease is divided in four main phases based on the 
long-term follow-up of clinical data (Thiene et al., 1990): (i) an early subclinical 
phase in which functional and structural abnormalities are rare or absent  and 
sudden cardiac death can be the first manifestation of the disease; (ii) an overt 
‘electrical’ phase with right ventricular arrhythmias and both functional and 
structural abnormalities. This second phase is characterized by palpitations, 
syncope, and symptomatic ventricular arrhythmias of left bundle branch block 
(LBBB) morphology.(iii) A right ventricle (RV) dysfunctional phase with an 
extensive ad severe involvement of the RV in the absence of left ventricle (LV) 
dysfunction; (iv) an end-stage phase characterized by a biventricular failure 
mimicking dilated cardiomyopathy resulting in a more difficult differential diagnosis 
and sometimes requiring cardiac transplantation. By this stage, patients could 
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have endocardial mural thrombosis, and the risk of pulmonary and systemic 
thromboembolism become higher. 
In the last twenty years several studies demonstrated also the early involvement of 
the LV changing the conventional timing of the disease (Pinamonti et al., 1995; 
Lobo et al., 1999; Sen-Chowdhry et al., 2007) and proposing a general 
classification in 3 categories based on the patterns of the disease expression: 
classical pattern associated with right ventricular phenotype, left ventricular and 
biventricular forms. The three patterns are independent and coexist in the ACM 
population even within the same family. 
Although sudden cardiac death can be the first and final manifestation of ACM, the 
most common clinical presentation of ACM is symptomatic ventricular tachycardia 
(VT) with LBBB. Ventricular arrhythmias span from premature ventricular 
complexes to sustained VT or ventricular fibrillation (VF) leading to cardiac arrest 
(Basso et al., 2009). Associated symptoms range from palpitations and 
paroxysmal tachycardia to dizziness, syncope, and sudden cardiac arrest. Results 
of exercise stress testing and Holter monitoring revealed frequent premature 
ventricular beats, as well as effort-dependent ventricular couplets and unsustained 
VT (Corrado et al., 1990).   
   
 
Figure 1.1. 12 lead ECG recording of VT with left bundle branch block (LBBB) morphology. (Thiene 
et al., 2007). 
 
Furthermore, the presence of the disease is strongly suggested by distinctive ECG 
findings of inverted T waves in right precordial leads (V1 to V4) which reflect an 
inferior or superior QRS axis, depending on the origin of the arrhythmias (Figure 
1.1). Negative T waves in V1-V3 are observed in the majority of patients with 
some differences due to the RV dysfunction and the heterogeneous nature of 
ACM (Nasir et al., 2004; Dalal et al., 2005). Abnormalities of the QRS complex in 
the right precordial leads, which consist in the QRS duration >100 ms and 
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differences in QRS duration between right and left precordial leads >25 are typical 
ECG findings in ACM patients. Moreover, epsilon waves, described in ECG from 
patients (Fontaine et al., 1984), may represent delayed activation of the surviving 
myocytes interspersed with fatty and fibrous tissue in the RV. The same 
phenomenon is seen with the presence of late potentials in the signal average 
ECG (SAECG) (Figure 1.2). 
 
 
Figure 1.2. ECG recording: (a) post-excitation epsilon waves (arrows) in right precordial leads; (b) 
positive late potentials at signal-averaged electrocardiography (SAECG) (Thiene et al., 2007). 
 
The absence of a gold standard diagnostic test leads to the use of different non-
invasive techniques to determine ACM diagnosis, such as echocardiography, 
radionucleotide angiography and magnetic resonance imaging (MRI). 
Echocardiography is a good tool to assess RV size and function both in index 
cases and family members, because its availability, easy of performance and 
interpretation. Morphologic abnormalities consisting of wall motion abnormalities, 
trabecular derangement, and sacculations, as well as global RV dysfunction, can 
be detected by using this test (Yoerger et al., 2005). Among the imaging methods, 
MRI allows both qualitative and quantitative analysis of RV function with a high 
sensitivity and specificity (Tandri et al., 2008). MRI is able to detect 
intramyocardial fat infiltrations and RV dysfunction also in early and concealed 
cases of ACM in which other techniques can fail (Figure 1.3). Moreover, MRI with 
gadolinium enhancement can detect fibrosis in both RV and LV myocardium, a 
finding that can precede functional abnormalities (Tandri et al., 2005). 
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Figure 1.3. ACM fatty variant on cardiac MRI. Note the typical biventricular fatty replacement (bright 
white signal intensity) of the entire RV wall and of the LV lateral wall. From Perazzolo Marra et al., 
2015. 
 
Despite its invasiveness, angiography remains a powerful method to diagnose 
ACM. On angiography, RV end diastolic volume is increased and ejection fraction 
is reduced with widespread RV impairment (Nava et al., 1988). Moreover, three-
dimensional electroanatomical mapping can reveal low voltage areas 
corresponding to fibrofatty myocardial replacement, thus differentiating ACM from 
diseases that mimic ACM such as inflammatory cardiomyopathy and idiopathic 
right ventricular outflow tract tachycardia (Corrado et al., 2005). 
 
1.4 Pathological profile 
The typical pathological profile consists of the progressive replacement of the 
myocardium by fatty or fibro-fatty tissue, starting from epicardium or 
midmyocardium and then extending to become transmural. This infiltration may be 
diffuse or regional; typically located at the angles of the so-called “triangle of 
dysplasia”, including the inferior, apical, and infundibular walls (Figure 1.4). 
 
Figure 1.4. “Triangle of dysplasia”. RA=right atrium. RV=right ventricle. LV=left ventricle. Modified 
from Basso et al., 2009. 
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Only in the more severe forms of ARVC all the three areas are involved, while 
usually only one or two regions are affected in the minor cases (Thiene et al., 
2007). The ventricular septum seems to be involved in about 20% of the cases 
and LV in nearly half (Basso and Thiene, 2007). Parietal thinning, as well as 
endocardial thickening, is found in areas of transmural infiltration and aneurismal 
dilation providing a substrate for life-threatening arrhythmias (Romero et al., 2013). 
The fibro-fatty infiltration in fact interferes with electrical impulse conduction 
accounting for delay (late potentials, epsilon wave, parietal bundle branch block) 
and onset of re-entrant phenomena. 
Based on the prevalent type of tissue accompanying the myocytes loss, two 
histopathological variants have been defined, namely fatty or fibro-fatty ACM 
(Basso et al., 1996). The latter is characterized by severe atrophy and scarring of 
the myocardium, RV wall thickness may be reduced, and the wall becomes 
translucent and parchment-like, whereas when fatty replacement occurs, it is 
mainly localized in the anterior wall and infundibulum (Thiene et al., 1997). 
However, in these cases, a small amount of fibrous tissue is also present. Myocyte 
death, as well as myocardial substitution with fatty or fibro-fitty tissue are common 
features of both variants, indicating an injury and repair process (Basso and 
Thiene, 2007) (Figure 1.5). 
 
 
 
 
 
 
 
 
Figure 1.5. Ongoing myocyte death (a) and early fibro-fatty replacement infiltration (b). From 
Thiene et al., 2007. 
 
Some particular features appear to be related with a specific fatty or fibro-fatty 
pattern. Fibrofatty infiltration occurs during adolescence, and not after birth as in 
Uhl’s anomaly, a congenital heart defect in which the right ventricular myocardium 
does not develop during embryonic life (Uhl 1952). In the classical form of the 
disease the RV is earlier affected but the LV is involved in more than half of the 
cases (Figure 1.6).  
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Figure 1.6. Note the biventricular involvement at MRI (a), with transmural fibro-fatty replacement in 
the RV free wall (b) and focal subepicardial in the LV free wall (c). From Thiene et al., 2007. 
 
Usually in these cases the infiltration is confined to the posterolateral 
subepicardium and as it is observed in older patients with heavier hearts, it might 
occur at a later time. It is also well-known that fatty tissue is present in a large 
amount of normal heart, increasing with age and bodyweight and mainly localized 
in the subepicardial region. Subsequently the fatty infiltration alone in the right 
ventricle is not a sufficient hallmark of ACM, presence of fibro-fatty replacement 
and myocyte degenerative changes are essential to provide a clear-cut diagnosis 
(Basso and Thiene, 2005). 
Furthermore, fibro-fatty pattern shows a high incidence of RV aneurysms and focal 
myocarditis, consisting of patchy inflammatory infiltrates of lymphocytes 
associated with myocardial necrosis (Thiene et al., 1991; Basso et al., 1996). 
Whether the inflammatory response is a reaction to myocyte death or the 
consequence of infective or immune mechanisms remains not clear. Cardiotropic 
viruses have been detected in the myocardium of some ARVC patients indicating 
a possible rule in the disease pathogenesis (Calabrese et al., 2006). 
 
1.5 Diagnosis and Task Force Criteria 
In the early stages of ACM the diagnosis can also be difficult because of the non-
specific nature of the disease and the broad spectrum of the phenotypic 
expressions. Dilated cardiomyopathy, Brugada syndrome and myocarditis can 
mimic ACM and differential diagnosis can be very difficult in absence of classic 
ACM hallmarks, such as RV aneurysms. 
As previously mentioned, there is no gold standard diagnostic test for ACM, and 
the diagnosis relies on the combination of structural, functional, and 
electrocardiographic abnormalities caused by the underlying histological changes 
(McKenna et al., 1994). In 1994, the first International Task Force Criteria were 
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introduced as common guidelines and abnormalities were divided in major and 
minor criteria within six categories. A modification of these original criteria was 
introduced by Marcus and colleagues in 2010, in order to increase the diagnostic 
sensitivity including quantitative parameters particularly for the imaging studies 
(Marcus et al., 2010) (Table 1.1). 
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continued 
 
Table 1.1. International Task Force ACM diagnostic criteria. Original criteria are listed in the left 
column, the revised criteria in the right column. Modified from Marcus et al., 2010. 
 
In a first study of Cox and co-workers applying these new criteria to patients 
suspected of ACM, 64% of probable ACM patients and 11% of family members 
were additionally diagnosed, suggesting that revised Task Force Criteria could 
have a major impact in increasing diagnostic yield (Cox et al., 2010). The 
diagnosis of ACM is achieved in the presence of two major or one major plus two 
minor criteria or four minor criteria taken from different groups (Table 1.1). 
Moreover, a borderline condition is determined by the presence of one major and 
one minor, or three minor criteria from different groups, while a possible condition 
is held in the presence of one major or two minor criteria from different categories. 
The main application of these criteria remains in establishing a diagnosis of ACM 
in probands. Modifications of the Task Force guidelines have been proposed to 
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allow detection of ACM in first-degree relatives with mild or incomplete expression 
of the disease, during familial screening of index cases with confirmed ACM 
(Hamid et al., 2002). In these familial cases, diagnosis is made considering 
electrical, functional and structural aspects (Table 1.2). 
ARVC in first-degree relatives plus one of the following: 
I. ECG T-wave inversion in right precordial leads (V2 and V3) 
II. SAECG Late potentials seen on signal-averaged ECG 
III. Arrhythmia 
LBBB type VT on ECG, Holter monitoring or during exercise testing 
Extrasystoles >200 in 24 hours 
IV. Structural or functional abnormality of the 
RV 
Mild global RV dilatation and/or ejection fraction reduction with normal LV 
Mild segmental dilatation of the RV 
Regional RV hypokinesia 
Table 1.2 Proposed modification of Task Force Criteria for the diagnosis of familial ACM. From 
Hamid et al., 2002. 
 
1.6 Risk stratification and management 
Prevention of sudden death is the most important management strategy of ACM. 
Cardiac arrest, syncope, young age, malignant family history, participation in 
competitive sports, VT, severe right ventricular dysfunction, left ventricular 
involvement are considered as risk factors for ACM, even though the prognostic 
value of these single or combined risk factors has not been prospectively 
assessed. Turrini and colleagues in 2001 reported that QRS dispersion (≥40 ms) 
was the strongest independent predictor of sudden death in ACM and that risk 
stratification in these patients was refined by syncope, negative T-waves beyond 
V1 and QT dispersion >65 ms (Turrini et al., 2001). In a study of Hulot et al. a risk 
stratification scheme has been developed. Patients with clinical signs of right 
ventricular failure, left ventricular dysfunction and/or history of ventricular 
tachycardia are at high risk of cardiac events, while subjects without VT are at very 
low risk (Hulot et al., 2004). In case of high risk, patients should undergo a 
pharmacological therapy, beyond avoid competitive sport activities. Anti-
arrhythmic therapy, consisting of beta-blockers or class III antiarrhythmic drugs 
(sotalol and amiodarone) can be useful for controlling arrhythmia but they are not 
an equivalent alternative to implantable cardioverter defibrillator (ICD) therapy in 
patients with high risk of sudden death. Accepted indications for ICD implantation 
include secondary prevention after prior cardiac arrest and VT with hemodynamic 
compromise (Azaouagh et al., 2011). ICD implantation is imperative if an aborted 
sudden death is occurred but also indicated in case of sustained VT and/or 
syncope in presence of risk factors. It provides a life-saving protection by 
effectively terminating life-threatening ventricular arrhythmias with an estimated 
mortality reduction of 24–35% at 3-years follow-up (Corrado et al., 2003; Wichter 
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et al., 2004). Catheter ablation is indicated in subjects with ACM that show 
monomorphic and well-tolerated VT with localized forms of the disease and drug-
refractory or incessant VT or frequent ICD discharges. According to Zou and 
collegues catheter ablation would not be a long-term curative procedure (Zou et 
al., 2004). At last, only in the most severe cases of ACM with malignant intractable 
recurrent arrhythmias or refractory congestive heart failure, cardiac transplantation 
should be considered (Lacroix et al., 2005). 
 
1.7 Genetic basis of ACM 
ACM is a heritable cardiomyopathy characterized by incomplete penetrance and 
variable expressivity and usually transmitted as an autosomal dominant trait, even 
though recessive forms have been reported (Nava et al., 1988; McKoy et al., 2000; 
Norgett et al., 2000). Since 1994, when the first locus was described, 15 
independent loci and 13 disease genes have been identified (Table 1.3). One or 
more disease-causing mutations are detected in nearly half of the patients and 
most of them are located in genes encoding for desmosomal proteins at the 
intercalated discs.  
 
locus gene protein mutation prevalence 
mode of 
inheritance  
17q21 JUP plakoglobin rare AR/AD 
 
1q42-q43 RYR2 ryanodine receptor 2 rare AD 
 
 6p24 DSP desmoplakin 1% - 16% AD 
 
12p11 PKP2 plakophilin-2 7% - 70% AD 
 
14q23-q24 TGFB3 transforming growth factor β3 rare AD  
 18q12 DSG2 desmoglein-2 5% - 25% AD 
 
 18q12  DSC2  desmocollin-2 rare AD/AR 
 
3p25 TMEM43  transmembrane protein 43 (LUMA) rare AD  
2q35 DES  desmin rare AD 
 
 2q31 TTN titin rare AD 
 
1q21.2-q21.3 LMNA lamin A/C rare AD 
 
6q22.1  PLN phospholamban rare AD 
 
10q21 CTNNA3 αT-catenin rare AD 
 
Table 1.3. ACM known-genes. AD= autosomal dominant; AR= autosomal recessive. 
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Desmosomes are important intercellular junctions that maintain mechanical 
integrity of heart tissue providing strong adhesion between cells. Three separate 
families of protein assemble to form the desmosomes: cadherins (desmoglein and 
desmocollin), armadillo proteins (plakoglobin and plakophilin), and plakins 
(desmoplakin). The genes encoding for these five proteins represent the most 
mutated genes in ACM. 
 
1.7.1 Junctional components 
JUP 
The first ACM gene (JUP) was identified in a rare cardiocutaneous syndrome, 
characterized by arrhythmogenic right ventricular cardiomyopathy associated with 
palmoplantar keratoderma and peculiar woolly hair and showing an autosomal 
recessive pattern of inheritance (McKoy et al., 2000). This syndrome was called 
“Naxos syndrome”, because of its prevalence exceeds 1 in 1000 in the Greek 
island of Naxos. Despite the cutaneous phenotype appears early, cardiac 
abnormalities present later, during adolescence and young adulthood. In 2007, 
Asimaki and colleagues identified a dominant mutation in plakoglobin gene in a 
German family with ACM but no cutaneous abnormalities. The mutation was found 
to affect plakoglobin stability at the junctions (Asimaki et al., 2007). 
 
Figure 1.7. Desmosomal armadillo family members: plakoglobin and plakophilins. Structures and 
interaction with other desmosomal proteins. Modified from Delmar and McKenna, 2010. 
 
Plakoglobin (γ-catenin) together with plakophilin, belongs to the armadillo proteins, 
which are characterised by the presence of a central domain containing a variable 
number of imperfect 42 aa repeats. Plakoglobin has 12 arm repeats, in which both 
desmoglein and desmocollin proteins interact with distinct sites through their 
intracellular domains (Figure 1.7). Plakoglobin also interacts with the N-terminal 
plakin domain of desmoplakin which complete the link with desmin intermediate 
filaments (IF) through their C-termini (Garrod and Chidgey, 2008). The 
desmosome-IF complex is a network that maintains the integrity of tissues and 
gives mechanical strength to them. Moreover, it seems that C-terminal truncations 
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of plakoglobin alter desmosome morphology in cultured cells, while deletion of the 
N-terminus do not have a dramatic effect on the structure of desmosomes in these 
cells. This suggests that the presence of the C-terminus of plakoglobin limits the 
size of desmosomes, perhaps through regulating protein-protein interactions 
required for assembly of the desmosomal plaque (Palka and Green, 1997). In 
addition to its structural function and due to its high homology with β-catenin, 
plakoglobin has a role also in intracellular signal transduction. It is now well known 
that plakoglobin interacts and compete with β-catenin and  plays a unique role in 
Wnt signaling pathway, an ancient and evolutionarily conserved pathway that 
regulates crucial aspects of cell fate determination, migration, proliferation and 
apoptosis (Zhurinsky et al., 2000). 
The two catenins interact at multiple cellular levels with a net negative effect on 
the canonical Wnt/β-catenin signaling pathway through T cell/lymphoid-enhancing 
binding (Tcf/Lef) transcription factors (Ben Ze’ev et al., 1998; Klymkowsky et al., 
1999). Garcia-Gras and coworkers speculate that when plakoglobin is free from 
the desmosomes, it translocates into the nucleus and through competition with β-
catenin suppresses signaling through the canonical Wnt/β-catenin–Tcf/Lef 
pathway (Garcia-Gras et al., 2006). This is the case of ACM patients, when 
mutations in desmosomal genes compromise the integrity of these complexes. 
 
DSP 
Desmoplakin gene (DSP) was quickly associated with the classical autosomal 
dominant form of the disease (Rampazzo et al., 2002) even though recessive 
mutations in DSP have been earlier described in Carvajal syndrome, which 
consists of palmoplantar keratoderma, woolly hair, and biventricular dilated 
cardiomyopathy (Norgett et al., 2000). The first described autosomal dominant 
mutation is thought to disrupt a protein kinase C (PKC) phosphorylation site which 
is involved in plakoglobin binding and in clustering of desmosomal cadherin-
plakoglobin complexes. Other DSP mutations, both recessive and dominant, as 
well as different types of mutation in different domains of the protein and 
associated or not with cutaneous phenotype have been identified (Alcalai et al., 
2003; Jonkman et al., 2005; Whittock et al., 1999). 
Desmoplakin is an important constituent of the desmosomal plaque. It interacts 
with desmin intermediate filaments in cardiomyocytes, anchoring them to the 
plasma membrane and forming an essential scaffold for tissue integrity. 
Desmoplakin’s primary structure is divided in three parts: globular head or plakin 
domains, tail domains and a coiled-coil rod region. Alternative splicing of the gene 
generates two isoforms of desmoplakin (DPI and DPII), which differ only in the 
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length of the central rod domain. DPI is the only one expressed in cardiomyocytes 
(Angst et al., 1990) (Figure 1.8). 
 
 
Figure 1.8. Structure of desmoplakin. The two desmoplakin isoforms are shown. A, B and C are 
plakin repeat domains. Modified from Garrod and Chidgey, 2008. 
 
PKP2 
In 2004, Gerull and collegues screened a cohort of 120 ACM patients for all the 14 
exons of PKP2 gene and identified 25 different heterozygous mutations in 32 of 
them (Gerull et al., 2004). PKP2 gene encodes plakophilin-2, an essential protein 
of the cardiac desmosome which belong to the armadillo protein family (Figure 
1.7). Three plakophilins are known (PKP1-3) and show complex tissue specific 
patterns of expression. Plakophilin-2 is the only one isoform expressed in 
cardiomyocytes (Hatzfeld, 2006). Plakophilins are located in the outer dense 
plaque of desmosomes linking desmosomal cadherins with desmoplakin and the 
intermediate filament system, but it is also found in the nucleus, where they may 
have a role in transcriptional regulation (Mertens et al., 2001). Gerull et al. 
speculate that lack of plakophilin-2 or the presence of mutant plakophilin-2 into 
cardiac desmosomes impairs cell-cell contacts and, as a consequence, might 
disrupt adjacent cardiomyocytes, especially in response to mechanical stress or 
stretch (Gerull et al., 2004). In addition, a possible indirect role in Wnt signaling 
has been proposed following the evidence that PKP2 interacts with β-catenin 
through the N-terminal domain and expression of PKP2 in SW480 cells up-
regulates β-catenin/Tcf signalling in a β-catenin dependent fashion (Chen et al., 
2002). 
 
DSG2 
DSG2 together with DSP and PKP2, is one of the three most mutated genes, the 
so-called “three big genes”, with a mutation prevalence that span from 5% to 25% 
in different cohorts (Gerull et al., 2004; Dalal et al., 2006; van Tintelen et al., 2006; 
Lahtinen et al., 2008; den Haan et al., 2009; Fressart et al., 2010). In 2006, 
Pilichou and colleagues studied a cohort of 80 unrelated ACM cases, in which, for 
the first time, they detect heterozygous mutations exactly in 10% of probands 
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(Pilichou et al., 2006). In an independent study, Awad and collegues described 
four probands with DSG2 mutations and, among them one presented compound-
heterozygous mutations (Awad et al., 2006).   
Desmoglein-2 is one of the four desmogleins found in humans and this form is 
expressed in all tissues containing desmosomes. Together with desmocollin-2, 
desmoglein-2 belongs to the cadherin family and, through its cytoplasmic domains, 
mediates intercellular adhesion at the cardiac desmosomal plaque. Within the cell, 
both desmocollin and desmoglein have an intracellular cadherin-like sequence 
(ICS) domain which provide binding sites for other desmosomal constituents such 
as the armadillo proteins (Garrod and Chidgey, 2008). The cadherins are a 
superfamily of calcium-dependent adhesion molecules, in fact both DSCs and 
DSGs extracellular domains consist of four cadherin homology repeats (EC1-4) 
with a calcium binding motif and a membrane proximal extracellular anchor 
domain (Dusek et al., 2007) (Figure 1.9). 
 
 
Figure 1.9. Structure of desmosomal cadherins: desmoglein and desmocollin. Modified from 
Delmar and McKenna, 2010. 
 
All the 4 isoforms of desmoglein and the 3 of desmocollin are encoded by 
separate genes that are clustered together on opposite sides of a central region on 
chromosome 18q12.1, suggesting a shared control by a long-range master 
regulatory region. 
 
DSC2 
Belonging to the cadherin family together with DSG2, DSC2 presents similar 
structure and function at the intercalated discs and shortly became a good 
candidate gene for ACM. In 2006, Syrris et al. identified 4 mutations in DSC2: 2 
heterozygous variants, a deletion (1430delC) and an insertion (2687_2688insGA). 
Both result in frameshift and premature truncation of the DSC2 protein (Syrris et 
al., 2006). In some individuals with DSC2 mutations a premature and prominent 
left ventricular dysfunction was reported suggesting the involvement of both 
ventricles in the disease manifestation (Sen-Chowdhry et al., 2007). In another 
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study Beffagna et al. reported that two heterozygous mutations in the N-terminal 
domain of desmocollin-2 affect the normal cellular localization of the protein 
(Beffagna et al., 2007). Autosomal recessive ACM forms associated with 
homozygous DSC2 mutations were also described in combination with or without 
cutaneous manifestations (Simpson et al., 2009; Lorenzon et al., 2015). Hair or 
skin abnormalities have been associated only with homozygous mutations in 
DSC2, probably because in these tissue a gene dosage effect may exceed the 
ability of other DSC isoforms to compensate (Delmar and McKenna, 2010). 
 
TMEM43 
In 2008 Merner and co-workers identified a common region on chromosome 3p 
(locus ARVD5) in fifteen unrelated ACM families from Newfoundland. They found 
a missense mutation (S358L) in a highly conserved transmembrane domain of 
TMEM43 gene (transmembrane protein-43). They concluded that ACM at locus 
ARVD5 is a lethal, fully penetrant, sex-influenced morbid disorder (Merner et al., 
2008). The same mutation was reported also in a Danish families by Christensen 
et al. who identified another novel variant of unknown significance (c.705+7G>A) 
in one patient. In this study immunostaining experiments showed that the signal 
level of TMEM43 was reduced in cardiomyocytes from all the three TMEM43-
positive patients in addition to the reduction of plakoglobin (Christensen et al., 
2011). 
TMEM43 gene encodes for LUMA, which was initially considered to be a tetraspan 
transmembrane protein of the nuclear envelope. In a recent study, Franke and 
colleagues discovered that LUMA is a component of zonula adherens and 
punctum adherens plaques of diverse epithelia and epithelial cell cultures and is 
also located in the area composita at myocardiac intercalated discs (IDs). These 
findings allow the general conclusion that LUMA should be considered as an 
important component of (or associated with) cardiac IDs (Franke et al., 2014). 
Interestingly, two different missense mutations in TMEM43 gene were identified in 
patients affected by Emery-Dreifuss syndrome characterized by muscular 
dystrophy, joint contractures, and cardiomyopathy with conduction defects (Liang 
et al., 2011). This finding indicates that mutations located in different protein 
domains of transmembrane protein-43 may result in the expression of distinct 
phenotypes. 
 
CTNNA3 
Recently van Hengel and colleagues discovered a novel disease gene, CTNNA3 
gene, located on chromosome 10q21 and considered the fifth largest gene in the 
human genome (van Hengel et al., 2013). CTNNA3 gene encodes for αT-catenin, 
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a member of α-catenin proteins, which plays key functional roles in cadherin-
catenin cell-cell adhesion complexes and binds plakophilin-2 in the intercalated 
discs (Goossens et al., 2007). A heterozygous missense mutation (V94D) and a 
small deletion (del765L) were identified in two probands, both of them located in 
fundamental domains of αT-catenin. 
In order to characterize the functional effects of the CTNNA3 mutations, yeast two-
hybrid assays and cell transfection studies have been performed. The interaction 
between the p.V94D mutant protein and β-catenin was affected, whereas the 
p.del765L mutant protein showed a much stronger dimerization potential 
compared to wild-type protein (van Hengel et al., 2013). Moreover, in HEK293T 
cells, endogenous β-catenin was co-immunoprecipitated with exogenous GFP–αT-
catenin fusion protein, resulting in a diminished interaction between p.V94D 
proteins and full-length β-catenin. In contrast to p.V94D mutant protein, the 
stronger homodimerization potential of the p.del765L mutant protein could lead to 
a dominant negative or dominant positive effect and the formation of aggresomes 
in transfected HEK293T cells. 
 
1.7.2 Non-junctional components 
RYR2 
The first identified ACM gene in a dominant form was cardiac ryanodine receptor-2 
involved in ARVD2 (Tiso et al., 2001). RYR2 gene is one of the largest human 
genes (105 exons) and all the mutations described involve highly conserved amino 
acids in three critical domains: N-terminal domain, central and C-terminal domains. 
In myocardial cells, the RYR2 protein, a homo-tetrameric structure activated by 
Ca2+, induces the release of calcium from the sarcoplasmic reticulum into the 
cytosol (Missiaen et al., 2000; Stokes and Wagenknecht, 2000). 
Mutations affecting RYR2 gene are responsible of a form of ACM characterized by 
a less pronounced fibro-fatty substitution of the myocardial tissue and ventricular 
polymorphic arrhythmias, induced by effort. RYR2 mutations might be either gain 
and loss of function, thus suggesting a heterogeneity in functional consequences. 
Moreover, loss-of-function mutations have been also associated with 
catecholaminergic polymorphic ventricular tachycardia (CPVT), characterized by 
stress-induced, bidirectional ventricular tachycardia that may lead to cardiac arrest 
and sudden death in the absence of structural heart abnormalities (Priori et al., 
2001). Whether CPVT and ARVD2 are different diseases or different degrees of 
phenotypic expression of the same disease remains unsettled (d’Amati et al., 
2005). 
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TGFβ3 
TGFβ3 is a member of the transforming growth factor superfamily, a large group of 
regulatory proteins playing a pivotal role in development and tissue homeostasis. 
They inhibit proliferation in many cell types and induce apoptosis in epithelial cells. 
Two single nucleotide substitutions have been detected in 5’UTR and 3’UTR of 
TGFβ3 gene (c.-36G>A, c.1723C>T) in a large ACM family and in one proband 
respectively (Beffagna et al., 2005). Endomyocardial biopsy in the two probands 
carrying the UTR-TGFβ3 mutations revealed extensive replacement-type fibrosis 
and fatty infiltration, supporting the idea that TGFβ stimulates mesenchymal cells 
to proliferate and to produce extracellular matrix.  
Moreover, it has been demonstrated that TGFβs modulate expression of genes 
encoding desmosomal proteins in different cell types. Cardiac fibroblasts 
incubated in the presence or in the absence of exogenous TGFβs show increased 
expression of different genes, including plakoglobin (Kapoun et al., 2004). In 
another study, Yoshida et al. reported that TGFβ1 exposure of cultured airway 
epithelial cells increases the content of both the isoform I and II of desmoplakin 
(Yoshida et al., 1992). This suggests that TGFβs may play an important role into 
the regulation of cell–cell junctional complexes and mutations in UTR regions, that 
cause overexpression of TGFβ3, might affect cellular stability. 
 
DES 
Van Tintelen and colleagues in 2009 identified a p.S13F DES founder mutation 
associated with a severe cardiac phenotype with right ventricular predominance 
(van Tintelen et al., 2009). One year later, Klauke et al. reported a de novo 
missense mutation (N116S) in DES gene, in segment 1A of the desmin rod 
domain. The mutation leads to the aggresome formation in cardiac and skeletal 
muscle without signs of an overt clinical myopathy (Klauke et al., 2010). Other 
ACM-related DES mutations have been linked to clinically heterogeneous 
phenotype frequently associated with muscle alterations, the so-called desmin-
related myopathy (DRM) (Otten et al., 2010; van Spaendonck-Zwarts et al., 2012).  
In the skeletal and cardiac muscle cells, desmin forms a flexible 3-dimensional 
scaffold around the myofibrillar Z-discs. Desmin represents the cardiac 
intermediate filaments and connects myofibrils to the plasma membrane, nuclear 
lamina, mitochondria, and desmosomes. It plays key structural and signaling roles 
in myocytes and is critical for cytoskeletal organization and maintaining the 
cardiomyocyte structure (McLendon et al., 2011). 
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TTN 
Titin (TTN) is the largest described protein in mammals and constitutes the third 
most abundant type of filament, after myosin and actinin, both in cardiac and 
skeletal human muscle (Fürst et al.,1988). TTN is organized into four structurally 
and functionally distinct regions: the amino-terminal Z-line, the “TTN-anchor”; the I-
band, that behaves as “bidirectional springs” regulating the sarcomeric length; an 
inextensible A-band which binds myosin and myosin-binding protein and is thought 
to be critical for biomechanical sensing and signaling; and the carboxy-terminal M-
line extremity (Figure 1.10).  
 
Figure 1.10. TTN structure. Schematic representation of 4 TTN molecules (red) and their main 
domains, with their integration in the sarcomere. PEVK= TTN region rich in proline (P), glutamate 
(E), valine (V), and lysine (K). Modified from Chauveau, et al., 2014. 
 
TTN has multiple key roles in all striated muscle cells that span from structural and 
architectural roles to sensory and regulatory roles (Bennet et al., 2006). TTN gene 
encodes for 364 exons that undergo extensive alternative splicing to produce 
many isoforms, including two major full-length titin isoforms, N2BA and N2B, 
expressed both in cardiac and skeletal muscles. The N2BA variant has an 
additional element in the N2 region (segment N2A), which confers a higher level of 
elasticity (LeWinter and Granzier, 2010). TTN mutations have been associated 
with different phenotypes: the majority with a purely cardiac phenotype, 35 
mutations lead to a purely skeletal muscle phenotype, and nine mutations lead to 
overlap syndromes (Chauveau et al., 2014). Among the cardiac phenotypes 
associated with TTN mutations, dilated cardiomyopathy is the most widely 
represented, with 69 mutations identified (Itoh-Satoh et al., 2002; Gerull et al., 
2002; 2006). The first description of ACM patients carrying TTN mutations was 
published in a paper including 38 families, in which Taylor and colleagues 
identified 8 unique TTN variants, with a prevalence of the T2896I mutation (Taylor 
et al., 2011). This missense mutation is absent in all other tested controls and 
shows a complete segregation within the families, providing a strong genetic 
evidence that it is linked to the ACM phenotype. A recent study reported that TTN 
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variant carriers display distinct phenotypic characteristics including a greater risk 
for supraventricular arrhythmias and conduction disease but less severe clinical 
outcome compared to patients with mutations in desmosomal genes (Brun et al., 
2014). 
 
LMNA  
Lamin A/C is a nuclear envelope protein located on the nuclear surface of the 
inner nuclear membrane and it is involved in numerous signaling pathways 
including adipogenesis.  
It has been reported that genetic defects in distinct domains of lamin A/C 
selectively cause dilated cardiomyopathy with conduction system disease or 
autosomal dominant Emery–Dreifuss muscular dystrophy (Bonne et al., 1999; 
Fatkin et al., 1999), other than peripheral neuropathy, lipodystrophies and 
premature ageing syndromes. More recently, four novel missense variants in 
LMNA gene have been found in patients negative for desmosomal mutations and 
affected with a severe form of ACM (Quarta et al., 2012). It has been supposed 
that the effects caused by LMNA mutations observed in the laminopathies may 
arise from varying degrees of impaired nuclear mechanics and transcriptional 
activation, suggesting an involvement of this protein in cellular 
mechanotransduction (Lammerding et al., 2004). 
 
PLN 
PLN is a Ca2+-ATPase regulator, and together with other sarcoplasmatic Ca2+-
cycling proteins is a key regulator of cardiac contractility. PLN-R14del mutation 
was first identified in a large family with hereditary cardiomyopathy by the group of 
Haghighi, who performed functional studies using a transgenic mouse model 
overexpressing this mutation (Haghighi et al., 2006). These mice showed 
depressed cardiac function, histopathological abnormalities (fibrosis), and 
premature death. More recently, the same specific mutation was identified both in 
ACM and DCM cases, supporting the concept of ‘arrhythmogenic cardiomyopathy’ 
as an entity encompassing ACM, including left-dominant arrhythmogenic 
cardiomyopathy, and arrhythmogenic forms of DCM (van der Zwaag et al., 2012). 
 
1.8 From a ‘desmosomal disease’ to a ‘disease of the intercalated discs’ 
Cardiomyocytes are connected each other through complex entities, called 
intercalated discs (IDs), that provide mechanical and electrochemical coupling 
between cells. The original description of the IDs in vertebrates identified three 
separate structures: gap junctions (GJs), adherens junctions (AJs, also called 
fascia adherens in cardiac tissue), and desmosomes (Forbes and Sperelakis, 
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1985). Gap junctions represent the electric components of IDs, maintaining the 
electrical and chemical coupling by direct diffusion of small molecules and ions 
between cardiac myocytes (Saffiz, 2005). 
GJ channel is formed by two hemichannels, called connexons, resulting from 
assembly of six connexin (Cx) molecules that span across the extracellular space, 
forming a permeable pore (Delmar and Sorgen, 2009). In the myocardium the 
most abundant connexin isoform is connexin-43. 
Conversely, desmosomes and AJ are highly specialized anchoring structures, 
fundamental for the maintenance of the adhesion and integrity of a tissue such as 
the myocardium during exposure of mechanical stress. The molecular structure of 
the two components is similar, both of them are composed of intercellular 
adhesion molecules that bind in the extracellular space the adhesion proteins 
extending from the adjacent cells. Intracellularly, there are various adaptor 
proteins linked to the cytoskeleton or involved in signaling pathways (Rampazzo et 
al., 2014). For many years AJs and desmosomes have been considered as 
different entities. Different studies demonstrated that in the mature mammalian IDs 
the colocalization of different junctional proteins in both the structures lead to the 
idea that a unique and promiscuous complex exists, the so-called area composita 
(Borrmann et al., 2006; Pieperhoff and Franke, 2008) (Figure 1.11). 
 
 
Figure 1.11. Molecular organization of the IDs connecting cardiomyocytes. From Rampazzo et al., 
2014. 
 
Franke and colleagues proposed a novel molecular organization of the IDs in the 
heart, in which desmosomes and AJs proteins participate to the formation of the 
 28 
 
area composita, and it develops rather early in embryonic cardiac differentiation 
(Franke et al., 2006). These findings, together with the recent involvement of 
mutated αT-catenin, a protein found in the area composita (van Hengel et al., 
2013), suggest that ACM may be considered a disease of the IDs, rather than a 
purely desmosomal disease. 
 
1.9 Mutation frequency in ACM genes 
Genetic screening of the most mutated genes in different laboratories worldwide 
allowed to define the mutational spectrum of the disease-genes. As previously 
mentioned, most of mutations are located in one of the 3 big genes: PKP2, DSP, 
and DSG2, but respective frequencies can vary a lot with patients’ geographic 
origins. Both the groups of Dalal and van Tintelen reported a frequency of 43% of 
mutations in PKP2 gene, with a peak of 70% of the index Dutch patients with 
affected family members (Dalal et al., 2006; van Tintelen et al., 2006), whereas in 
other studies these frequencies are largely reduced to around 10% (Pilichou et al., 
2006; Sen-Chowdhry et al., 2007; Christensen et al., 2010). The varying mutation 
prevalence of PKP2 gene in different cohorts could be explained with a founder 
effect in certain populations, differences in patient selection, and geographical 
variations in genetic and nongenetic factors. In any case, the mutational trend is 
almost conserved and PKP2 remains the most mutated gene in ACM patients. 
The first described ACM gene, DSP, shows a mutation rate that span from 1% to 
16%, while heterozygous mutations in DSG2 have been identified in patients with 
ACM with a frequency range of 5% to 25% in different cohorts (Rampazzo et al., 
2014). Overall mutation screening of all the 13 known ACM genes can detect 
causative mutations in in ≈60% of probands (Groeneweg et al., 2015). Moreover, it 
is well known that in a significant proportion of cases, concomitant causes such as 
either a “second hit” in the same gene (compound heterozygosity) or in a different 
gene (digenic heterozygosity) is required for the overt clinical phenotype and it is 
often associated with a more severe phenotype in terms of LV and RV alterations 
(Bauce et al., 2010; Xu et al., 2010, Bhonsale et al., 2015). 
 
1.10 Pathogenetic mechanisms of ACM 
Significant progresses have been made in the genetics of ACM, which have led to 
identification of several causative mutations in junctional and non-junctional genes. 
Despite these findings, a consensus on the etiopathogenesis of ACM remains 
elusive, and the molecular processes underlying cardiomyocyte injury, fibro-fatty 
tissue repair, ventricular remodeling and arrhythmias are not completely clear. 
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At the beginning an inflammatory and an apoptotic theory (Valente et al., 1998) 
have been proposed based on histopathological findings. Inflammatory infiltrates 
are common in ventricular myocardium of ACM patients (Basso et al., 1996) and, 
they probably play a major part in triggering life-threatening arrhythmias (Thiene et 
al., 1991; Pinamonti et al., 1996). Therefore, cardiotropic viruses such as 
enteroviruses, cytomegalovirus, parvovirus, hepatitis C virus, and adenovirus, 
have been identified in some ACM patients (Bowles et al., 2002; Calabrese et al., 
2006). Nevertheless, this theory cannot explain all the ACM cases and the most 
reliable theory remains the desmosomal dysfunction.  
A desmosomal gene mutation may lead to unstable mechanical linkage between 
cells and disassociation at the intercalated discs which, in turn, can lead to 
myocyte injury, cell death either by apoptosis or necrosis, tissue remodeling and a 
clinical picture characterized by contractile dysfunction and cardiomyopathy. 
 
 
Figure 1.12. Paleness of desmosome internal plaques (arrows) in ACM (A) vs. control (B). From 
Basso et al., 2006.. 
 
An electron microscopy and morphometric analysis in a series of ACM patients 
provided evidence of highly convoluted nuclei, increased lipid droplets, decreased 
desmosome numbers and intercalated disc remodeling (Basso et al., 2006, Figure 
1.12).  
In 2009, Asimaki’s group demonstrated a significant reduction in immunoreactive 
signal levels for plakoglobin and variable patterns of altered distribution for the 
other desmosomal proteins at the intercalated discs (Asimaki et al., 2009; Figure 
1.13). The molecular mechanism responsible for this reduction remains unclear 
but it seems a consistent feature in patients with ACM and is not seen in other 
forms of heart-muscle disease. 
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Figure 1.13. Immunofluorescence signal of plakoglobin of left ventricular myocardium from two 
subjects with ACM (A1 and A2) and a control subject (C). Modified from Asimaki et al., 2009. 
 
Desmosomal dysfunction can also lead to gap junction remodeling because their 
strong associations with these structures and this could contribute to disease 
development (Delmar and McKenna, 2010). It does appear that reduced junctional 
expression of connexin-43 (Cx43), the major ventricular gap junction protein, 
occurs early in ACM, during the concealed phase (Kaplan et al., 2004; Asimaki et 
al., 2009). A significant decrease of Cx43, was observed also in N-cadherin–
depleted hearts of knockout mouse model (Kostetskii et al., 2005), demonstrating 
the hierarchical relationship of the structural components of the intercalated disc in 
the working myocardium. Moreover, Sato and colleagues demonstrated that loss 
of desmosomal integrity can affect sodium channel function, with deleterious 
consequences to the electrical stability of the heart (Sato et al., 2009, 2011). 
These findings were also supported by another study, in which a PKP2 
haploinsufficiency mouse model shows INa deficit that could contribute to 
generation and/or maintenance of arrhythmias in murine hearts (Cerrone et al., 
2012). The remodeling of gap junctions in ACM patients occurs diffusely in regions 
of the heart that show no apparent structural or functional alterations, suggesting 
that this process could cause conduction abnormalities that promote arrhythmias 
in ACM (Asimaki et al., 2009). Taken together, these findings demonstrate that 
desmosomes, gap junctions, and sodium channels act as a functional triad in 
which changes in the composition of one constituent can affect the function and 
integrity of the others. 
Together with the disruption of mechanical cell-cell junctions, various signaling 
pathways have been proposed to be involved in ACM pathogenesis, highlighting 
the dual function of junctional proteins as both components of intercellular 
adhesion structures and transcriptional regulators (Calore et al., 2015). 
The first described pathway involved in ACM pathogenesis was Wnt/β-catenin 
pathway, which is known to regulate adipogenesis, fibrogenesis and apoptosis 
(Ross et al., 2000) and is primarily involved in differentiation of cardiac progenitor 
C A A
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cells and embryonic development of the right ventricle and its outflow tract (Ai et 
al., 2007). Garcia-Gras and colleagues in 2006 demonstrated that suppression of 
desmoplakin expression leads to nuclear localization of plakoglobin and a 2-fold 
reduction in canonical Wnt/β-catenin signaling through Tcf/Lef1 transcription 
factors. This event leads to enhanced fibrogenesis, adipogenesis, myocyte 
apoptosis, and accumulation of fat droplets (Garcia-Gras et al., 2006). The 
involvement of Wnt-signaling in ACM pathogenesis was also found in a 
plakoglobin knockout mouse model, in which ablation of plakoglobin causes an 
increase of the dephosphorilated and active β-catenin form, which can lead to 
cardiac hypertrophy (Li J et al., 2011). In contrast, another group reported the 
main involvement of TGFβ-mediated signaling in JUP mutant cardiomyocytes at 
the early stage of cardiomyopathy, excluding an alteration of Wnt/β-catenin 
signaling (Li D et al., 2011). TGFβ signaling regulates myocyte cell death in 
addition to its important influence on cardiac fibrosis and hypertrophy.  
More recently, it has been postulated that an emerging signaling pathway, called 
Hippo/YAP pathway, seems to cross-talk with the canonical Wnt pathway and may 
have a role in its regulation and, in turn, in the pathogenesis of the disease. As β-
catenin for Wnt signaling, neurofibromin 2 (NF2) is an upstream molecule for the 
Hippo pathway and it is localized at IDs. Perturbed molecular changes at the IDs 
could affect both Wnt and Hippo pathways and, the activation of the latter may 
cause a suppression of the canonical Wnt pathway. After IDs perturbation in fact, 
the Hippo kinases downstream of NF2 are cascade-phoshorylated, which in turn, 
cause YAP phosphorylation (p-YAP) and its cytoplasmic retention (Chen et al. 
2014). p-YAP sequesters β-catenin and plakoglobin, resulting in a reduction of 
transcriptional activities in both pathways, followed by increased adipogenesis in 
ACM hearts (Figure 1.14). 
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Figure 1.14. Model of the molecular pathogenesis of ACM. Crosstalk between Hippo and Wnt/ β-
catenin pathways after mutations occurring on ID proteins. From Rampazzo et al., 2014. 
 
1.11 Animal models for ACM 
1.11.1 Spontaneous animal models 
ACM, as other forms of cardiovascular diseases, occurs commonly in pets, 
particularly in domestic cats and dogs. These are spontaneous animal models for 
ACM because they closely resemble the clinical and pathological features of 
human disease.  
Fox and co-workers, for the first time, described a spontaneously occurring ACM 
in 12 domestic cats, all of them showing pronounced RV lesions including marked 
myocardial injury (myocyte death and atrophy) and repair (fibrous and/or fatty 
replacement) (Fox et al., 2000). 
Similar to feline models, boxer dogs with ventricular tachycardia and fatty or 
fibrofatty replacement were described as a spontaneous model for ACM (Basso et 
al., 2004). The precise inheritance pattern in these cases is unsolved but 
transmission from one generation to another suggest the likelihood of dominant 
inheritance which, in turn, was reported by Meurs and colleagues, and consistent 
with that of the human disease (Meurs et al., 2007). 
Moreover a line of mice with inherited right ventricular dysplasia caused by a 
mutation of the gene laminin receptor 1 (LAMR1) is reported (Asano et al., 2004), 
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despite the fact that mutations in LAMR1 have never been identified in humans 
with ACM. 
These spontaneous animal models are considered a potentially important 
investigative tool that could enhance our understanding of the complex clinical and 
pathophysiological mechanisms responsible for sudden death and disease 
progression. 
 
1.11.2 Genetically-engineered models  
Plakophilin-2 mutant murine models 
The first mouse model with a disruption of the desmosomal protein plakophilin-2 
was created by the group of Grossmann in 2004. In the absence of plakophilin 2 
(PKP2-/-), mutant mice exhibited lethal alterations in heart morphogenesis and 
stability at mid-gestation (E10.5–E11) (Grossmann et al., 2004). In addition, 
disarrayed cytoskeleton and reduced trabeculations within the ventricles and atrial 
wall thinning was observed. Moreover, desmoplakin did not colocalize with 
junctional proteins at the intercalated disk but was dispersed over the cytoplasm, 
forming granular aggregates. In contrast to the myocardium, embryonic epithelia 
showed normal junctions. More recently, PKP2-heterozygous-null (PKP2-Hz) 
mutant mice have been created and studied (Cerrone et al., 2012). Ultrastructural 
but not histological or gross anatomical differences in PKP2-Hz hearts compared 
with wild-type (WT) were reported. On the other hand, decreased amplitude and a 
shift in gating and kinetics of the sodium current (INa) were observed in PKP2-Hz 
hearts as previously reported (Sato et al., 2009). 
Desmoplakin mutant murine models 
Desmoplakin targeted deletion mice DSP-/- die at embryonic stage due to 
desmosome instability and loss of tissue integrity (Gallicano et al., 1998; Garcia-
Gras et al., 2006). Partial rescue of desmoplakin expression in extra embryonic 
tissues promoted survival of embryos not beyond gastrulation, with major defects 
in heart muscle, neuroepithelium and skin epithelium (Gallicano et al., 2001). As 
these animals die before birth, they cannot be consider a proper model for ACM.  
Heterozygous DSP+/- mice developed normally but exhibited excess adipocytes 
and fibrosis in the myocardium, thin ventricular walls, increased myocyte 
apoptosis, cardiac dysfunction, and ventricular arrhythmias (Garcia-Gras et al., 
2006). In another study, DSP+/- mice showed normal echocardiograms but delayed 
conduction and inducible ventricular tachycardia associated with a delocalization 
and reduced expression of Cx43 (Gomes et al., 2012). Furthermore, transgenic 
(Tg) mice with cardiac-restricted overexpression of the C-terminal DSP mutant 
(R2834H) demonstrated histological evidence of cardiomyocyte apoptosis, cardiac 
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fibrosis, and lipid accumulation, along with ventricular enlargement and cardiac 
dysfunction of both right and left ventricles, confirmed by necroscopy (Yang et al., 
2006). Mutant mice also displayed interruption of DSP-desmin interaction and 
marked ultrastructural changes of the IDs. Recently, the same model was studied 
by Martherus and colleagues, who confirmed that Tg mice exhibit RV dilation and 
wall thinning compared to non-transgenic, when subjected to exercise. In these 
conditions AKT1 and GSK3-β signaling is perturbed in Tg mice, suggesting that 
endurance exercise causes progression of the ACM phenotype in these models 
(Martherus et al., 2016). 
Taken together, these results underline the role of desmoplakin in mantaining 
desmosomal stability and heart tissue integrity. 
Plakoglobin mutant murine models 
In 1996, targeted deletion of plakoglobin was described by two independent 
groups (Bierkamp et al., 1996; Ruiz et al., 1996). 
Homozygous JUP-/- mutant mice die between days 12-16 of embryogenesis due to 
severe defects in heart function; in addition, one of these models showed a 
blistering skin phenotype, with epidermolytic hyperkeratosis (Bierkamp et al., 
1996). Heterozygous JUP+/- mice appeared healthy and fertile. Ten-months-old 
animals had perturbed RV function and spontaneous ventricular ectopy, in the 
absence of left ventricular involvement. Histology did not identify right ventricular 
abnormalities and gap junctions localized correctly at the IDs (Kirchhof et al., 
2006). Two transgenic mouse models overexpressing respectively wild-type 
(PGWT) or truncated plakoglobin (PGTR) were created (Lombardi and Marian, 
2011). Both of them exhibited fibro-adiposis, cardiac dysfunction, and premature 
death; immunofluorescence experiments showed nuclear localization of PGWT and 
PGTR. A reduced binding with desmosome proteins DSP and DSG2 was uniquely 
found in PGTR mice. 
More recently, double knockout mice for both plakoglobin and β-catenin (DKO) 
were generated, to determine whether β-catenin is required to maintain cardiac 
conduction in the absence of plakoglobin (Swope et al., 2012). These mice 
showed reduced gap junctions at the IDs,  fibrous tissue replacement, and 
conduction abnormalities resulting in high percentage of SCD. 
Desmoglein-2 mutant murine models  
Transgenic mice with cardiac overexpression of the human homologue mutation 
p.N266S were generated (Tg-NS) (Pilichou et al., 2009). Contrary to homozygous 
DSG2-/- described earlier (Eshkind et al., 2002), Tg-NS did not manifest embryonic 
lethality, but they generally recapitulated human ACM phenotype, including 
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sudden death at young age, spontaneous ventricular arrhythmias, cardiac 
dysfunction, and biventricular dilatation and aneurysms. 
In another study, an homozygous DSG2 mutant mouse lacking two extracellular 
adhesion domains was considered and showed myocardial fibrosis and 
calcification (Krusche et al., 2011). These data suggest that desmoglein-2 is 
important in embryonic viability and loss of this protein compromises cell adhesion, 
but new findings demonstrated that the presence of DSG2 is not essential for late 
heart morphogenesis and for cardiac contractility to support postnatal life (Kant et 
al., 2016). 
Ryanodine receptor-2 murine models 
Knock-in mice with the human disease-associated RYR2 mutation R176Q 
(RYR2R176Q/+) were generated by Kannankeril and colleagues. Histological 
analysis revealed no evidence of fibrofatty infiltration or structural abnormalities, 
but it was reported that right ventricular end diastolic volume was decreased in 
RYR2R176Q/+ mice compared with controls. This model was inconclusive regarding 
the phenotype but demonstrated that R176Q mutation in RYR2 predisposes the 
heart to catecholamine-induced oscillatory calcium-release events that trigger a 
calcium-dependent ventricular arrhythmia, consistent with a CPVT phenotype 
(Kannankeril et al., 2006). 
Zebrafish models 
A zebrafish model system was used by Heuser and coworkers to investigate the 
physiological effects of a heterozygous splice-acceptor-site mutation in intron 5 
(c.631-2A>G) of DSC2 gene, which causes a creation of a premature stop codon 
(Heuser et al., 2006). Morpholino-induced knockdown of DSC2 gene resulted in a 
cardiac phenotype with dose-dependent bradycardia, chamber dilatation, 
abnormal cardiac contractility, and progressive pericardial oedema. Co-injection 
with wild-type human DSC2 mRNA, but not with mutant mRNA, rescued the 
morphant phenotype revealing the paramount role of DSC2 in the establishment of 
the normal myocardial structure and function in early cardiac morphogenesis. 
Knockdown of plakoglobin in zebrafish was also generated and resulted in 
decreased heart size, reduced heartbeat, cardiac oedema, valvular dysfunction 
leading to intrachamber reflux and a twisted tail (Martin et al., 2009). Moreover, 
morphant embryos showed an increased expression level of Wnt target genes, 
indicating that Wnt signaling was activated in absence of plakoglobin and β-
catenin cannot compensate this loss in desmosomes. 
Most recently, a zebrafish ACM model with the cardiomyocyte-specific expression 
of the human c.2057del2 JUP mutation was generated (Asimaki et al., 2014). The 
animals exhibited reductions in INa and IK1 current densities, heart enlargement 
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and peripheral oedema. Electron microscopy revealed also interruptions in cell-cell 
boundaries and structural disarray in mutant fishes. High-throughput drug 
screening has identified SB216763 as a molecule able to prevent or reverse the 
disease phenotype in these models, activating the canonical Wnt signaling 
pathway. The efficacy of SB216763 has been supported by additional experiments 
performed in two different cell lines: neonatal rat ventricular myocytes with the 
same JUP mutation and induced pluripotent stem cells from two ACM probands. 
Treatment with SB216763 restored the subcellular distribution of plakoglobin, 
connexin-43 and Nav1.5 in cardiomyocytes and of SAP97, a protein known to 
mediate the forward trafficking of Nav1.5 and Kir2.1, in both cell types. These 
findings were consistent with previous demonstrations of the involvement and 
dysregulation of Wnt/β-catenin signaling pathway in ACM pathogenesis. 
 
1.12 Induced Pluripotent Stem Cells (iPSCs) 
In the last few years, a new powerful tool to study ACM mechanism has been 
introduced and is represented by patient iPSC-derived cardiomyocytes (iPSC-
CMs). 
Up to now, all the published studies on iPSCs and ACM examined the effect of 
different PKP2 mutations on patients derived iPSCs.  
Kim and colleagues generated cardiomyocytes from fibroblasts of two patients, 
who carry a homozygous p.G828G and a heterozygous p.K672RfsX12 PKP2 
mutations respectively (Kim et al., 2013). Mutant iPSC-CMs demonstrated 
abnormal plakoglobin nuclear translocation and decreased β-catenin activity in 
cardiogenic conditions, but it was not sufficient to reproduce the pathological 
phenotype. The induction of an adult-like metabolism by culturing beating mutant 
embryoid bodies in a lipogenic milieu co-activated master peroxisome proliferator-
activated receptor (PPAR)-α-dependent metabolism and the PPAR-γ pathway and 
recapitulated the classical ACM features consisting in an exaggerated lipogenesis 
and apoptosis. In another study, Ma et al. reprogrammed iPSC from dermal 
fibroblasts of an ACM patient, harboring an heterozygous PKP2 mutation 
(p.L614P) (Ma et al., 2013). Gene expression levels of PKP2 and plakoglobin in 
these mutant cells were significantly lower compared with cardiomyocytes from 
control iPSCs, whereas no significant differences in the expression of 
desmoplakin, N-cadherin, and connexin 43 between the two groups was observed. 
Moreover, ACM–iPSC cardiomyocytes appeared larger and, darker lipid droplets 
were found. Clusters of lipid droplets were identified also in the ACM-iPSC 
cardiomyocytes from two other patients with two different frameshift PKP2 
mutations (Caspi et al., 2013). Immunostaining experiments revealed reduced 
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densities of PKP2, the associated desmosomal protein plakoglobin, and the gap-
junction protein connexin-43. Transmission electron microscopy identified widened 
and distorted desmosomes in the ACM-iPSC cardiomyocytes and it seemed to be 
correlated with the upregulation of pro-adipogenic PPAR-γ pathway. The effect of 
the adipogenic stimuli on the ACM-iPSC cardiomyocytes could be prevented by 
activation of the canonical Wnt pathway in these cells by a specific inhibitor of 
GSK-3β, suggesting the possible role of the canonical Wnt/β-catenin pathway in 
ACM pathogenesis. 
Despite the unique advantages of the iPSCs approach for modeling ACM, such as 
to overcome limitations arising from species differences in electrophysiological 
properties, this method still possesses some inherent limitations. It is unable to 
study pathological phenomena at the whole-organ and systemic levels and, up to 
now, only PKP2 mutant iPSC cardiomyocytes have been generated. 
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2. AIM OF THE STUDY 
 
Sudden death, ventricular arrhythmia and heart failure are common features in 
arrhythmogenic cardiomyopathy (ACM), an inheritable heart muscle disease, 
characterized by clinical and genetic heterogeneity. The typical pathological profile 
associated with the disease consists of the progressive replacement of the 
myocardium by fatty or fibro-fatty tissue. So far, 13 disease-genes have been 
identified, responsible for around 60% of all ACM cases, resulting in about 40% of 
patients genotype-negative with a strong clinical diagnosis. 
The role of the genetic analysis appears fundamental, not only to confirm a 
diagnosis and determine the potential risk in close relatives but also to research 
the genetic causes underlying the phenotypic expression. To this purpose, the 
introduction of the next generation sequencing (NGS) techniques made this 
process faster and cheaper, allowing to parallel sequence a large amount of 
genes. 
The objective of this study is twofold: to set up a custom targeted gene panel 
performing a comprehensive mutation screening in a cohort of affected subjects; 
and to identify putative novel ACM genes in both sporadic and familial cases by 
using three different NGS approaches (targeted gene panels, whole exome 
sequencing, whole genome sequencing). 
Identification of novel disease-genes is of paramount importance to understand 
the molecular pathogenesis of ACM, as well as to increase the power of genetic 
screening and develop successful targeted therapies. 
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3. MATERIAL AND METHODS 
 
3.1 Clinical evaluation 
The study population consisted of 63 unrelated index cases of Italian descent with 
a diagnosis of ACM.  Moreover, a total of 70 family members were subsequently 
clinically evaluated in the University of Padua Medical School-Azienda 
Ospedaliera.  
After written informed consent, blood for DNA extraction was obtained from all 
participating individuals, according to the pertinent Italian legislation. Clinical 
evaluation consisted of a detailed personal/family history, physical examination, 
12-lead electrocardiogram (ECG), signal-averaged ECG (SAECG), 24-hour Holter 
ECG, and 2-dimensional echocardiography (2D-echo). Invasive tests including 
angiography and right ventricular endomyocardial biopsy were performed in 
particular cases, when deemed necessary for the diagnosis. Clinical diagnosis of 
ACM was made according to the major and minor criteria established by the 
International Task Force of the European Society of Cardiology/International 
Society and Federation of Cardiology (Marcus et al., 2010). 
 
3.2 Salting-out DNA extraction 
Blood samples were stored at -20°C in EDTA vacutainer tubes and genomic DNA 
was extracted from peripheral blood leukocytes using a modification of the salting-
out procedure (Miller et al., 1988) at the Human Genetic Laboratory of University 
of Padua. To facilitate haemolysis of Red Blood Cells it is recommended to store a 
fresh sample for few hours in a freezer. After thawing, N-N solution (0,9%, NaCl 
0,1% Nonidet) was added to the blood and transferred into a Falcon tube, to a final 
volume of 40 mL. Two sequential sample centrifugations for 35 minutes at 6000 
rpm at 4°C followed. After centrifugation, supernatants were discarded and pellets 
were resuspended in 4 mL of TEN solution (TrisHCl 10mM; EDTA 2mM, pH 8; 
NaCl 400 mM) and well vortexed. After adding 300 μl of 20% SDS, the tubes were 
incubated at 80°C for 3 hours under mixing, to denature cellular proteins. After the 
incubation, 1 ml of saturated NaCl solution was added to the samples to induce 
protein precipitation and, after tubes spinning for 10 minutes at 6000 rpm at room 
temperature (RT), supernatant was poured off into a fresh tube, using a sterile 
Pasteur pipette. An isovolume of chloroform was added and the tubes were 
inverted for 10-15 times and centrifuged for 10 minutes at 6000 rpm at RT. After 
centrifugation, three different phases appeared: the upper containing nucleic 
acids, the second composed of proteins and cellular debris, and the third, 
consisting of chloroform. The upper aqueous phase was transferred into a clean 
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and sterile centrifuge tube (15 ml) and an equal volume of isopropanol was added; 
DNA was precipitated by gentle swirling of the tube and observed visually as a 
white thread. Samples were then centrifuged for 10 min at 6000 rpm at RT and 
supernatant was discarded. Pellets were washed twice with 1-2 ml of 70% ethanol 
and centrifuged for 10 minutes at 6000 rpm at RT. After the last centrifugation, 
pellets were dried from the excess of ethanol leaving the tubes open for 1 hour at 
RT or in a heater for less time, till the pellets appeared transparent. Finally, the 
dried pellets were resuspended in 300-500 μl TE buffer. 
 
3.3 DNA quantification 
DNA concentration was determined using NanoDrop ND-1000 UV-Vis 
Spectrophotometer (CELBIO). This instrument can measure DNA concentrations 
starting from 1 μL samples, also for highly concentrated samples without dilution, 
with high accuracy and reproducibility. Samples readings at 260 nm and at 280 nm 
provide directly DNA and proteins concentration in the sample, respectively. The 
ratio of these two values of absorbance was used to assess the purity of DNA, 
checking the presence of proteins or other contaminants that absorb near 280 nm. 
Pure DNA preparations have ratio values between 1.8 and 2.0. A ratio inferior than 
1.8 indicates that there may be proteins and/or ultraviolet (UV) absorbers in the 
sample, thus it is recommended to re-precipitate the DNA, whereas a ratio higher 
than 2.0 indicates that samples may be contaminated with chloroform or phenol. 
Moreover, the spectrophotometric analysis provided the absorbance ratio at 260 
and 230 nm, as secondary measure of DNA purity. Expected 260/230 values are 
commonly in the range of 2.0-2.2. If the ratio is appreciably lower than expected, it 
may indicate the presence of contaminants which absorb at 230 nm, such as 
phenolate ion, thiocyanates, and other organic compounds. 
The quantified DNA samples were diluted in sterile bidistilled water to a final 
concentration of 50 ng/μl and used for subsequent polymerase chain reactions 
(PCR). 
 
3.4 Genotyping and Linkage Analysis 
Linkage analysis was the primary tool used for the genetic mapping of Mendelian 
and complex traits with familial aggregation. It is still used to determine if there is 
significant evidence for co-segregation (linkage) of alleles at a marker locus and 
alleles at a hypothetical disease locus. The rate at which two alleles are 
transmitted together to the offspring is related to the probability of a crossing-over 
event between the loci and hence to their distance along the chromosome. 
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In the parametric linkage analysis the LOD score (logarithm of odds) value, is 
calculated to assesses the probability that a given pedigree, where the disease 
and the marker are co-segregating, is due to the existence of linkage or to chance 
(Morton, 1955). By convention, a LOD score greater than 3.0 is considered 
evidence for linkage, as it indicates 1000 to 1 odds that the linkage being observed 
did not occur by chance; conversely linkage hypothesis can be rejected if the LOD 
score is less than -2.0. Values of LOD score between -2 and +3 are inconclusive.  
Individual genotyping for 33 subjects belonging to the same family (Family #6) was 
carried out using the High-density SNP marker set Infinium HumanCNV370-Duo 
BeadChip (Illumina, San Diego, CA, USA), which includes 370,404 SNP markers 
with average spacing of 7.9 Kb. SNPs with high heterozygosity and uniform 
genome-wide distribution were selected to improve the probability to detect 
recombination events. 
For each family member, 200 ng of genomic DNA (gDNA) was analyzed with the 
SNP arrays on Illumina Iscan System according to the manufacturer's protocol 
(Figure 3.1). 
 
 
Figure 3.1. Illumina whole-genome genotyping on DNA arrays (www.illumina.com). Step 1. Whole-
genome amplification reaction amplifies the input gDNA by over 1000-2000X. This genome 
representation is fragmented to approximately 300 to 600 bp, precipitated, resuspended, and 
hybridized onto a BeadChip. Step 2. After capture of the target loci, the SNPs are scored using a 
single-base extension (SBE) reaction. SBE employs a single probe sequence 50 bp long (attached 
to the bead) designed to hybridize immediately adjacent to the SNP query site. The arrayed SNP 
locus-specific primers are extended with a single hapten-labeled dideoxynucleotide. Two different 
colored labeled terminators are used to discriminate the alleles. Finally, the haptens are detected in 
a multilayer immunohistochemical sandwich assay and genotype calls are generated by Illumina's 
software (Gunderson et al., 2005). 
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Genotyping raw data were processed by Plink software v1.07 (Purcell et al., 2007) 
to obtain a single file (*.snp) including all genotyping data of each family member, 
with markers sorted according to their physical map position. Quality control of 
genotypes was carried out with the program PLINK and SNPs not fulfilling the 
following criteria were excluded from analysis: minor allele frequency <1%; call 
rate <95% (defined as the percentage of successful genotype calls among 
subjects); Hardy-Weinberg equilibrium p<0.001. 
Moreover, SNPs in the same physical position or mapped on multiple loci were not 
included in the analysis. 
Linkage analysis was conducted by GeneHunter software version 2.1 (Kruglyak et 
al., 1996) through the graphical user interface EasyLinkage Plus v5.08 (Lindner 
and Hoffmann, 2005), using a parametric multipoint approach.  
An autosomal dominant inheritance with 0.0001 disease allele frequency and 0.02 
phenocopy rate was assumed, as well as equal allele frequencies for the markers 
tested. In order to avoid decrease of LOD score values due to low penetrance, an 
‘‘affected-only’’ approach was used, which classifies all individuals with no clinical 
manifestations as “unknown’’. For all regions showing positive LOD score values, 
haplotypes were constructed using Viterbi algorithm implemented in GeneHunter 
software and displayed by HaploPainter program (Thiele and Nurnberg, 2005). 
Haplotypes were subsequently checked on the basis of the minimal number of 
recombinations and both upper and lower borders of each critical interval were 
refined by GeneHunter, based on recombination events observed in affected 
individuals. 
 
Next Generation Sequencing Technology 
Background 
First described by Sanger in 1977, capillary electrophoresis (CE)-based 
sequencing of DNA allowed to sequence the full genome of any species in a 
reliable, reproducible manner (Sanger et al., 1977). After the first automated 
sequencer (AB370), the Genome Analyzer emerged in 2005 really revolutionized 
the sequencing capability, sequencing up to 1 Gb per run, thus introducing the 
“next generation” in genomic science. From that point forward, the data output of 
next generation sequencing (NGS) has outpaced Moore’s law (Figure 3.2). 
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Figure 3.2. Sequencing costs per basepair: after the introduction of NGS technology the cost are 
falling faster that Moore’s law.  
 
The concept behind NGS technology is similar to dideoxy-terminal method: DNA 
polymerase catalyzes the incorporation of fluorescently labeled dNTPs into a DNA 
template strand during sequential cycles of DNA synthesis. During each cycle, at 
the point of incorporation, the nucleotides are identified by fluorophore excitation. 
In contrast to Sanger sequencing, NGS extends this process across millions of 
fragments in a massively parallel fashion. 
Different NGS approaches share general processing steps, based on the Illumina 
sequencing by synthesis (SBS) chemistry. Illumina NGS workflows include 4 basic 
step (Figure 3.3): 
 
A. Library preparation: DNA is randomly fragmented and adapters are ligated 
at 5’ and 3’ ends. Adapter-ligated fragments are then PCR amplified and gel 
purified. 
B. Cluster generation: the library is loaded into a glass slide flow cell that 
displays oligonucleotides complementary to Illumina adapter sequences. 
Each fragment is then amplified into distinct, clonal clusters through bridge-
PCR (Figure 3.5). The clusters templates are ready for sequencing. 
C. Sequencing: in Illumina SBS technology, all 4 nucleotides are added 
simultaneously to the flow cell channels, along with DNA polymerase, for 
incorporation into the oligo-primed cluster fragments. The nucleotides carry 
a base unique fluorescent label and the 3’-OH group is chemically blocked, 
so that each incorporation is a unique event and natural competition 
minimizes incorporation bias. Subsequently, the 3’ blocking group is 
chemically removed to prepare each strand for the next incorporation. The 
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cycle is repeated, one base at a time, generating a series of images each 
representing a single base extension at a specific cluster. 
D. Data analysis: The newly identified sequence reads are then aligned to the 
human reference genome. Following alignment, many variations such as 
single nucleotide variants (SNVs) or insertions-deletions (InDels) are called. 
 
 
Figure 3.3. Illumina SBS chemistry workflow. 
Adapted from http://www.illumina.com/technology/next-generation-sequencing.html. 
 
3.5 Targeted gene panels 
The study involved a cohort of 59 unrelated index cases with diagnosis of ACM. In 
the majority of them (50 out of 59) the presence of mutations in the three most 
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mutated ACM genes (DSP, PKP2 and DSG2) was excluded by previous mutation 
screening with direct Sanger sequencing and dHPLC analysis. Only 9 samples 
sequenced with the ‘Cardiomyopathies gene panel’ (described below) were not 
previously investigated. Moreover, DNA from 4 patients were analyzed with both 
panels. 
Two different Targeted NGS gene panels have been generated in collaboration 
with BMR Genomics, a spin-off of University of Padua. 
The first panel, named ‘Cardiomyopathies gene panel’ comprises 56 genes (443 
kb), associated with different cardiomyopathies (Table 1, Appendix A). Specific 
exonic regions of 19 ACM probands were captured and sequenced on a MiSeq 
sequencer which provides a mean coverage depth of 200X. 
On the second panel, conventionally called ‘ACM known and candidate genes 
panel’, 44 samples were sequenced by using a NextSeq500 platform. The exonic 
and intronic flanking regions of 69 genes were sequenced at a mean coverage 
depth of 267X. The genes included in this panel have been selected because their 
previous association with ACM phenotype or as candidate genes. A gene is 
considered ‘candidate’ if encodes for a protein which functions and/or localization 
can be associated with the disease pathogenic mechanism (Table 2, Appendix A).  
In both panel strategies the preliminary enrichment step has been performed with 
Haloplex Target Enrichment System as described below. 
 
a. Samples precipitation 
Prior to capture, DNA samples must be resuspended in nuclease-free water to a 
final concentration of 200 ng/µl and a minimum quantity of 4 µg. Since all the 
samples have been already diluted in TE buffer after DNA extraction (paragraph 
3.2), they must be precipitated. 
A volume of sodium acetate 3M (pH=5.2) equal to 1/10 of the total DNA volume in 
addition to a 2.5X volume of absolute ethanol were added to the samples. After 
mixing, the samples were incubated overnight at -20°C and then centrifuged for 
one hour at 4 °C. Supernatants were discarded and two washes with cold 70% 
ethanol followed. After a short centrifugation (5-10 min), supernatants were 
eliminated and pellets were dried at RT or in a heater (37°C). Finally, the dried 
pellets were resuspended in a volume of bidistilled water to reach the theoretical 
requested concentration (200 ng/µl). 
 
b. Haloplex Target Enrichment System 
Haloplex workflow is optimized for a total of 225 ng of genomic DNA (gDNA) and 
comprises the following steps (Figure 3.4). 
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Figure 3.4. Haloplex workflow. From HaloPlex Target Enrichment System Automation Protocol for 
Illumina Sequencing (http://www.chem.agilent.com/library/usermanuals/Public/G9900-90020.pdf).  
  
1. Digest genomic DNA with restriction enzymes. In this step, gDNA samples 
are digested by 16 different restriction enzymes to create a library. The 
gDNA is digested in 8 different restriction reactions, each containing 2 
enzymes.  
2. Hybridize digested DNA to HaloPlex probes for target enrichment and 
sample indexing. In this step, the restriction fragments are hybridized to the 
HaloPlex probe capture library. HaloPlex probes are designed to hybridize 
selectively to fragments originating from target regions of the genome and 
to direct circularization of the targeted DNA fragments. During the 
hybridization process, Illumina sequencing motifs including index 
sequences are incorporated into the targeted fragments. 
3. Capture, amplify and purify the target DNA. The circularized target DNA-
HaloPlex probe hybrids, containing biotin, are captured on streptavidin 
beads. After capture, DNA ligase is added to seal nicks, then target DNA is 
eluted and PCR-amplified. The amplified target DNA samples are purified 
using AMPure XP beads. 
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4. Validate enrichment and quantify enriched target DNA. Prior to sample 
pooling and sequencing sample preparation, enriched target DNA in each 
library sample is validated and quantified by microfluidics analysis using the 
2100 Bioanalyzer. Enriched library samples may also be qualitatively 
analyzed using gel electrophoresis. Each amplicon in the prepared library 
includes 50 to 500 bp of target DNA insert and 125 bp of sequencing motifs. 
5. Pool samples with different indexes for multiplexed sequencing. 
Bioanalyzer-measured concentration of 175-625 bp products in each 
sample are used to pool equimolar amounts of differentially indexed 
samples in order to optimize the use of sequencing capacity. The final 
enrichment pool is ready for direct sequencing using Illumina paired-end 
primers and chemistry on the Illumina MiSeq or NextSeq500. 
 
c. Sequencing 
Sequencing of the enriched libraries was done on MiSeq or NextSeq500 platform 
(Illumina) which produce 150 bp paired-end (PE) reads. PE sequencing involves 
sequencing both ends of the DNA fragments, and aligning the forward and reverse 
reads as read pairs. As previously described Illumina technology relies on solid-
phase bridge PCR (Adessi et al., 2000; Fedurco et al., 2006) to amplify each DNA 
template (Figure 3.5) and reversible terminator chemistry to sequence the 
amplified libraries. 
 
 
 
 
 
 
 
 
Figure 3.5. Bridge-PCR. The flow cell surface is coated with two different populations of 
oligonucleotides 5'-attached by a flexible linker and complementary to the adapters of the library 
DNA fragments. Single-stranded library molecules are annealed to the immobilized 
oligonucleotides and a new strand is synthesized from the original template which is then removed 
by denaturation. The copied strand bends over and the adapter sequence at the 3' end hybridizes 
to another complementary oligonucleotide, forming a bridge and allowing the synthesis of a second 
covalently bound strand. At the conclusion of the PCR, each clonal cluster contains about 1,000 
copies of a single member of the template library. Modified from Shendure and Ji, 2008. 
 
d. Bioinformatic analysis 
Sequence reads were mapped to the UCSC reference human genome (hg 19, 
NCBI build 37.1) (http://genome.ucsc.edu) and Binary Alignment Map files (.bam) 
have been generated. These files can be loaded to genomic public browsers as 
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Integrative Genomic Viewer (IGV, Broad Institute, Cambridge, MA, USA) and 
represent the bases for the variant calling process. Different variant callers such 
as VarScan and FreeBayes were used to detect any difference between the 
sequencing product and the reference genome, generating a Variant Call Format 
(.vcf) file. The annotation step performed by BMR Genomics was done using 
ANNOVAR (Wang et al., 2010; http://www.openbioinformatics.org/annovar/), 
which integrates several information to the .vcf file about the coordinates, the 
frequencies and the predictions of the identified variants. To facilitate variants 
annotation and data analysis, BMR Genomics created also an on-line tool, called 
SNP-shot (paragraph 3.11). 
 
e. Mutation validation 
Direct Sanger sequencing of PCR products from genomic DNA was performed to 
confirm the presence of the detected variants and to study the segregation within 
the family members, where possible. 
All PCR primers were designed by Primer3 web version 4.0.0 software 
(http://primer3.ut.ee/), based on the sequence data in GenBank. PCR reactions 
were carried out using a standard or touch-down protocol. 
 
3.6 DNA amplification by PCR 
All the uncovered exons of the known-disease genes in the 19 probands screened 
with the ‘Cardiomyopathies gene panel’ other than exons containing a detected 
variant were amplified by Polymerase Chain Reaction (PCR) assay and 
sequenced by direct Sanger sequencing. 
PCR reactions were carried out in a total volume of 25 μl containing 50 ng of DNA, 
10 pmoles of each primer (10 pmol/μl), 100 μM deoxinucleotide triphosphate 
(dNTPs 1mM, Invitrogen), 1X PCR Buffer (Promega), 5U/μl of GoTaq DNA 
polymerase (Promega), and bidistilled water to reach the final volume. 
DNA amplification was performed in a Peltier PTC-200 thermal cycler (MJ 
Research) using standard or touch-down protocols. 
After activation of the enzyme at 95°C, the cycling conditions (denaturation at 
95°C for 30 sec, annealing at the working temperature for 30 sec, extension at 
72°C for 30 sec) were repeated 35 times in a standard PCR protocol. For a touch-
down (TD) protocol the thermal cycler was programmed to perform runs in which 
the annealing temperature is lowered incrementally during the PCR cycling from 
an initial value above the expected Tm to a value below the Tm. TD-PCR should 
increase the specificity of a PCR reaction, discouraging the formation of spurious 
products. 
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An aliquot of PCR product was loaded onto a 2% w/v agarose gel stained by Gel 
Red (Biotinum), in order to check the amplification reaction. Amplicons were then 
visualized under ultraviolet trans-illumination and identified by comparing with a 
known molecular-weight marker. 
 
3.7 Sanger sequencing 
Before the sequencing step, PCR amplicons had to be purified to eliminate 
possible dNTPs and primers not used in the amplification that could interfere with 
the sequencing reaction. Purification was performed with a mix of two enzymes 
(ExoSAP, Affymetrix): SAP, an alkaline phosphatase, that removes exceeding 
nucleotides, and EXOI, an exonuclease that removes single strand filaments and 
primers. A volume of 2.5 μl of ExoSAP solution was add to 5 μl of PCR product. 
The mixture was then incubated in a thermal cycler at 37°C for 15 minutes and 
then at 80°C for other 15 minutes to inactivate the enzymes. The purified PCR 
products together with 1 μl of primer (forward or reverse) were sequenced at the 
BMR Genomics (Padua, Italy) by ABI Prism 3730XL DNA sequencer (Applied 
Biosystems), with the BIG DYE dideoxy-terminator chemistry (Applied 
Biosystems). Sequencing results were visualized as electropherograms and 
analyzed by using Seqman II software (DNASTAR). It allows to align and compare 
the obtained sequence with the consensus sequence and eventually detect single 
nucleotide variants (SNVs), small insertions and deletions (InDels). 
 
3.8 In silico analysis of TJP1 gene variants  
Two different mutations (p.R265W, p.Y669C) affecting the human tight junction 
protein ZO-1 (TJP1) were identified in two probands with the ‘ACM known and 
candidate genes panel’. To predict the effect of these variations, a conservation 
analysis was performed in collaboration with Dr. Giovanni Minervini and Prof. 
Silvio Tosatto, Department of Biomedical Sciences, University of Padua. 
The TJP1 sequence (accession code: Q07157) was downloaded from the Uniprot 
database. Homologous sequences were retrieved from the OMA browser 
database using standard parameters and then realigned with Clustal Omega using 
a gap opening penalty 3.0 and gap extension penalty 1.8. The final alignment has 
been refined using Jalview (i.e. removing macroscopic misalignment and used in 
the subsequent analysis). Search into PFAM database was used to identify 
conserved domains, whereas search into MobiDB was used to investigate the 
presence of intrinsically disordered regions. For the second mutation (p.Y669C), 
which affects the guanylate kinase-like domain of TJP1, a modular dynamics 
simulation was performed. The mutation was modeled with Modeller using the wild 
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type crystal structure of SH3-Guanylate kinase core domain (PDB code 3LH5) as 
template. The resulting model was used to perform molecular dynamics simulation 
in order to highlight the structural impact of amino acid substitution. The overall 
fold stability was studied by performing 40 ns of molecular dynamics (MD) 
simulation with Gromacs 4.6 using the CHARMM 27 force field. Finally, networks 
of interacting amino acids affected by mutations were calculated with RING. 
 
3.9 Whole Exome Sequencing (WES) 
Whole exome sequencing was performed in 11 total affected subjects at the 
Beijing Genomics Institute (BGI, http://www.genomics.cn/en/index): 4 subjects of 
Family #6 (IV-5, IV-8, IV- 9, IV-12), 3 subjects of Family #5 (I-1, II-2, II-4), and 2 
subjects belonging to Family #3 (II-4, II-7) and Family #4 (II-4, III-5), respectively. 
 
a. SureSelect Target Enrichment and sequencing 
For each sample, individual library preparations, hybridizations, and captures were 
performed, following the manufacturer's protocols. 
The qualified gDNA sample was randomly fragmented by Covaris and paired-end 
sequencing adapters were ligated to both ends of 150-200 bp DNA fragments. The 
adapter-ligated templates were purified by the Agencourt AMPure SPRI beads 
(Beckman Coulter Genomics) and fragments with insert size about 176 bp were 
excised. Extracted DNA was amplified by ligation-mediated PCR (LM-PCR), 
purified, and hybridized to the SureSelect Biotinylated RNA Library (BAITS) for 
enrichment with the Agilent SureSelect All Exon Kit (Figure 3.6). Hybridized 
fragments were bound to the strepavidin coated magnetic beads and, after 
washing non-hybridized fragments and RNA digestion, captured products were 
amplified by PCR. Captured LM-PCR products were subjected to Agilent 2100 
Bioanalyzer to estimate the magnitude of enrichment. Each captured library was 
then loaded on Illumina Hiseq2000 platform, and high-throughput sequencing 
were performed as described in paragraph 3.5 c.  
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Sequencing-derived raw image files were processed by Illumina base-calling 
Software 1.7 for base-calling with default parameters and the sequence data of 
each individual was generated as paired-end reads, which was defined as "raw 
data" and stored in FASTQ format. 
 
b. Bioinformatic analysis 
Starting from the raw data produced by the Illumina sequencer, the “clean data” 
were generated through a filtering step. Data filtering included: i) Removing reads 
containing sequencing adapter; ii) Removing reads whose low-quality base ratio 
(base quality less than or equal to 5) is more than 50%; iii) Removing reads whose 
unknown base ('N' base) ratio is more than 10%. All “clean data” of each sample 
were mapped to the human reference genome (GRCh37/hg19) using Burrows-
Wheeler Aligner (BWA V0.7.12) software. Considering that the same DNA 
molecules can be sequenced several times during the sequencing process and 
that the resulting duplicate reads are not informative, Picard tools (v1.118) was 
used to mark and remove these duplicates. Local realignment around InDels and 
base quality score recalibration were performed using Genome Analysis Toolkit 
(GATK). The sequencing depth and coverage for each individual were calculated 
based on the alignments. In WES, the variant calling is restricted to the exonic 
Figure 3.6. SureSelect Target 
Enrichment workflow. 
1. Starting from gDNA, a shearing 
step produces small fragments. 
2. Prepare library with sequencer 
specific adaptors and indexes. 
3. Hybridize sample with biotinylated 
RNA library baits (120mer). 
4. Select targeted regions using 
magnetic streptavidin beads. 
5. Amplify and load on the 
sequencer. 
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target regions and their flanking regions (extending 200bp towards both sides of 
each target region). The HaplotypeCaller of GATK(v3.3.0) was used to call both 
SNVs and InDels simultaneously via local de novo assembly of haplotypes. The 
raw variation set containing all potential variants was outputted into a .vcf file and, 
after that, an hard-filtering method was applied to get high-confident variant calls. 
The AnnoDB tool developed by BGI was applied to perform: i) Gene-based 
annotation: identify whether SNVs or InDels cause protein coding changes and 
which amino acid is affected; ii) filter-based annotation: identify variants that are 
reported in SNPs databases (1000 Genomes Project database, ftp://ftp-
trace.ncbi.nih.gov/1000genomes/ftp/release; dbSNP141, 
http://www.ncbi.nlm.nih.gov/snp) or identify the pathogenicity score given to the 
subset of coding non-synonymous variants by Sorting Intolerant From Tolerant 
(SIFT, http://sift.jcvi.org/) or Polymorphism Phenotyping v2 (PolyPhen2, 
http://genetics.bwh.harvard.edu/pph2/).  
Each putative pathogenic variant identified was validated with Sanger sequencing 
and the analysis of the co-segregation with ACM phenotype within the families 
was carried on, as described in paragraphs 3.6 and 3.7. 
 
3.10 Whole Genome Sequencing (WGS) 
Unlike focused approaches such as targeted sequencing or WES, which analyze a 
limited portion of the genome, WGS delivers a comprehensive view of the 3.2 
billion bases of the human genome. 
The whole genome of subjects IV-3, IV-10 and IV-12 belonging to Family #6 was 
sequenced at Novogene (http://en.novogene.com/). A total amount of 1 µg DNA 
per sample was used to libraries preparation. Sequencing libraries were generated 
using Truseq Nano DNA HT Sample preparation Kit (Illumina) following 
manufacturer’s recommendations and index codes were added to attribute 
sequences to each sample. The genomic DNA were then polished, A-tailed, and 
ligated with the full-length adapter for Illumina sequencing with further PCR 
amplification. At last, PCR products were purified (AMPure XP system) and 
libraries were analyzed for size distribution by Agilent2100 Bioanalyzer and 
quantified using real time PCR (Figure 3.7). 
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Figure 3.7. WGS workflow. Modified from preliminary report from Novogene. 
 
After cluster generation with Hiseq X HD PE Cluster Kit (Illumina) according to the 
manufacturer’s protocols, the library preparations were sequenced on the HiSeq X 
Ten Illumina platform and paired-end reads were generated. Raw data obtained 
from sequencing contains adapter contamination and low-quality reads, that were 
removed. Two parameters were considered to establish the sequencing quality: 
the error rate (e) and the base quality Phred score expressed as Qphred. They are 
linked by the following equation: Qphred= -10log10(e) 
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The sequencing error rate was obtained from the base calling process and the 
corresponding relation is listed as below: 
 
Phred score 
sequencing 
error rate 
correct 
sequencing 
rate 
Q-sorce 
10 01/10 90% Q10 
20 1/100 99% Q20 
30 1/1000 99.9% Q30 
40 1/10000 99.99% Q40 
Table 3.1. Relation between Qphred and sequencing error rate. 
 
Error rate is increasing with sequencing reads extension due to the consumption 
of chemical reagents and is higher in the first six bases of a read. Generally, each 
bases sequencing error rate should be smaller than 1% and most base quality is 
required to be greater than Q20. 
Reads alignment and duplicated reads removal have been performed as 
described for WES. To detect genomic variations different software were used: 
SAMtools 1.0 (http://samtools.sourceforge.net/) to identify SNVs and InDels, 
BreakDancer 1.4.4 (Chen et al., 2009; http://breakdancer.sourceforge.net/) for 
structural variants, and control-FREEC v6.7 (http://bioinfo-
out.curie.fr/projects/freec/) for copy number variations (CNVs). SNVs and InDels 
were then annotated by using ANNOVAR. 
Moreover, exomes were extracted from the genomes and re-annotated using the 
in-house pipeline at the Human Genetics Department of the Radboud University 
medical center (Nijmegen) in collaboration with Dr. Christian Gilissen and Prof. 
Joris Veltman. Data from about 5000 WES projects were integrated and used to 
filter for the allele frequency. 
 
3.11 Bioinformatic tools 
UCSC Human Genome Browser (http://genome.ucsc.edu) 
It’s a browser that contains the reference sequence and working draft assemblies 
for a large collection of genomes. It comprises many useful tools and links for 
genomic analysis. The Browser zooms and scrolls over chromosomes, showing 
the work of annotators worldwide. Gene Sorter shows expression, homology and 
other informations on groups of genes. Moreover, graphical representation of the 
fragments making up a region of draft genome can be displayed, showing the 
relative size and overlaps of each fragment and also whether any gap between 
fragments are bridged by mRNAs or paired BAC end sequences. There is an 
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increasing amount of data becoming available from large-scale gene expression 
studies. More recently genomes from many different species are available on the 
browser. 
 
Primer3 (http://primer3.ut.ee) 
Primer3 is a free online tool to design and analyze primers for PCR and real time 
PCR experiments developed and supported from WI/MIT. Primer3 can also select 
single primers for sequencing reactions and can design oligonucleotide 
hybridization probes.  
 
SeqManII (DNASTAR) 
SeqManII is a software used to assemble from two to tens of thousands of 
electropherograms into contigs. Prior to assembly, SeqManII evaluates the quality 
of the underlying trace data to eliminate contaminating and poor quality data from 
the projects, thus generating the most accurate consensus sequence possible. 
This software is useful to detect nucleotides that differ from the consensus 
sequence and that could be a pathogenic mutation. 
 
IGV (Integrative Genomic Browser) 
The Integrative Genomics Viewer (IGV) is a high-performance visualization tool for 
interactive exploration of many different types of large genomic datasets. It is 
freely available for download from http://www.broadinstitute.org/igv. IGV includes a 
large number of specialized features for exploring next generation sequencing 
read alignments (.bam files), including features for sequencing coverage and 
variant visualization (.vcf files) (Figure 3.8).  
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         Figure 3.8. IGV application window. From Thorvaldsdóttir et al., 2013. 
 
SNP-shot tool (http://www.bmr-genomics.it/SNP-Shot) 
It is an on-line tool, created by BMR Genomics to facilitate the analysis of the next 
generation sequencing data. SNP-shot integrates several information such as the 
genomic position of a variant, the resulting effect on the protein, the allele 
frequencies (1000 Genomes, EVS, ExAC), the predicted mutation effects 
(PolyPhen2, SIFT) and, when possible, the association with a particular 
phenotype. It considers all the mutations previously reported in a Locus Specific 
Database (LSDB) such as HGMD, ClinVar, ARVD/C Genetic Variants Database 
and LOVD. It allows to select and analyze all the variants in a subgroup of genes 
and make a comparison with two samples. 
 
Variation public databases 
1000 GENOMES (http://www.1000genomes.org) 
1000 Genomes Project started in 2008 and was the first project to sequence the 
genomes of a large number of people, to provide genetic variants present in the 
population studied. The genomes of about 2500 unidentified people from about 25 
populations around the world have been sequenced using NGS technologies. 
Data obtained are available to the worldwide scientific community through freely 
accessible public databases. 
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dbSNP (Single Nucleotide Polymorphism Database)  
(http://www.ncbi.nlm.nih.gov/projects/SNP) 
The Single Nucleotide Polymorphism Database (dbSNP) is a free public archive 
for genetic variations within and across different species developed and hosted by 
the NCBI. Other than single nucleotide polymorphisms (SNPs), it contains a range 
of molecular variations such as short deletion and insertion polymorphisms 
(InDels). In February 2010, dbSNP contained more than 184 million submissions 
representing more than 64 million distinct variants for 55 organisms. Each sub-
mitted variation can be identified with an unique identification number and a 
reference SNP ID number (“rs#”), that gives the basic information. 
EVS (Exome Variant Server) (http://evs.gs.washington.edu/EVS)  
The NHLBI Exome Sequencing Project (ESP) is focused on understanding the 
contribution of rare genetic variation to heart, lung and blood disorders through the 
sequencing of well-phenotyped populations. Variant count data are available on 
the Exome Variant Server (EVS), which currently contains NGS data on 6503 
individuals, and allele frequencies are provided for African-Americans and 
European-Americans. 
ExAC (Exome Aggregation Consortium) (http://exac.broadinstitute.org) 
The data set provided by the Exome Aggregation Consortium (ExAC) span 60,706 
unrelated individuals sequenced as part of various disease-specific and population 
genetic studies. All the sequencing data divided in specific population groups 
(Latino, European, European (Finnish), East Asian, South Asian, African and 
‘others’) are available and freely downloaded for the benefit of the wider 
biomedical community. 
ARVD/C Genetic Variants Database (http://www.arvcdatabase.info) 
It contains information from clinical research and other types of data on variants in 
genes causing Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy 
(ARVD/C). When the project started, in 2009, it contained 481 variants in eight 
genes. A total of 144 variants were considered pathogenic, 73 were 
unknown/unclassified, and 264 had no known pathogenicity (van der Zwaag et al., 
2009). The database was converted into the Leiden Open Variation Database 
(LOVD) format, a gene-centered collection of DNA variations. 
 
Genetic diseases databases 
OMIM (Online Mendelian Inheritance in Man) (http://www.ncbi.nlm.nih.gov/OMIM) 
It is an online catalog of Human Genes and Genetic Disorders, focusing on the 
relationship between phenotype and genotype. It is freely available and daily 
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updated and contains information on all known mendelian disorders and over 
15,000 genes. This database was initiated in the early 1960s by Dr. Victor A. 
McKusick as a catalog of mendelian traits and disorders, entitled Mendelian 
Inheritance in Man (MIM). The online version, OMIM, was created in 1985 by a 
collaboration between the National Library of Medicine and the William H. Welch 
Medical Library at Johns Hopkins. In 1995, it was developed for the World Wide 
Web by NCBI, the National Center for Biotechnology Information. 
ClinVar (http://www.ncbi.nlm.nih.gov/clinvar) 
The National Center for Biotechnology Information has also a public archive of 
reports of the relationships among human variations and phenotypes, named 
ClinVar. ClinVar is freely accessible and processes submissions reporting variants 
found in patient samples, assertions made regarding their clinical significance, 
information about the submitter, and other supporting data. A major goal is to 
support computational (re)evaluation, both of genotypes and assertions, and to 
enable the ongoing evolution and development of knowledge regarding variations 
and associated phenotypes. Novel variants submitted to ClinVar are in turn 
submitted to dbSNP or dbVar, as appropriate, for accessioning. 
HGMD (The Human Gene Mutation Database) 
(http://www.hgmd.cf.ac.uk/ac/index.php) 
The Human Gene Mutation Database (HGMD) represents an attempt to collate 
known (published) gene variants responsible for human inherited disease. Other 
than various types of mutations associated with human inherited disease, HGMD 
contains disease-associated/functional polymorphisms reported in the literature. It 
may also include additional reports for certain mutations if these reports serve to 
enhance the original entry (e.g. functional studies). There are two versions of the 
database: a public freely-available and less up-to date HGMD and a weekly-
update version (HGMD Professional), for which a license is required. 
 
Mutation prediction tools 
PolyPhen2 (Polymorphism Phenotyping v2)  
(http://genetics.bwh.harvard.edu/pph2) 
It’s a software tool which predicts a possible impact of amino acid substitutions on 
the structure and function of human proteins using straightforward physical and 
evolutionary comparative considerations. PolyPhen2 makes functional predictions 
based on a number of features comprising the sequence, phylogenic and 
structural information characterizing the substitution. This analysis classifies 
mutations as benign and possibly or probably damaging. 
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SIFT (Sorting Intolerant From Tolerant) (http://sift.jcvi.org) 
SIFT is a sequence homology-based tool that sorts intolerant from tolerant amino 
acid substitutions and whether an amino acid substitution affects protein function. 
SIFT prediction is based on the degree of conservation of amino acid residues in 
sequence alignments derived from closely related sequences, collected through 
PSI-BLAST. SIFT can be applied to naturally occurring nonsynonymous 
polymorphisms or laboratory-induced missense mutations. 
Mutation Taster (http://www.mutationtaster.org) 
It is a free, web-based application for rapid evaluation of the disease-causing 
potential of DNA sequence alterations. Mutation Taster integrates information from 
different biomedical databases and uses established analysis tools such as 1000 
Genomes database, ExAC browser and protein prediction tools. Analyses 
comprise evolutionary conservation, splice-site changes, loss of protein features 
and changes that might affect the amount of mRNA. Test results are then 
evaluated by a naive Bayes classifier2, which predicts the disease potential. A 
typical query is completed in less than 0.3 seconds. 
 
PhyloP (phylogenetic P-values) 
PhyloP is a program freely available (Pollard et al., 2010) that compares 
probability of observed substitutions under hypothesis of neutral evolutionary rate. 
The scores generated reflect either conservation (positive scores) among 44 
vertebrate species or selection (negative scores). The scores generated range 
from -7 to +7, and a position is considered highly conserved for phyloP scores 
≥2.5. 
 
RVIS (Residual Variation Intolerance Score) (http://genic-intolerance.org) 
RVIS is a gene-based score intended to help in the interpretation of human 
sequence data. The intolerance score in its current form is based upon allele 
frequency data as represented in whole exome sequence data from the NHLBI-
ESP6500 data set. The score is designed to rank genes in terms of whether they 
have more or less common functional genetic variation relative to the genome 
wide expectation given the amount of apparently neutral variation the gene has. A 
gene with a positive score has more common functional variation, and a gene with 
a negative score has less and is referred to as "intolerant".  
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4. RESULTS 
 
4.1 Targeted gene panels: ‘Cardiomyopathies gene panel’ 
  
4.1.1 Coverage 
Target regions of 19 DNA from ACM probands have been captured with HaloPlex 
kit (Agilent) and sequenced using 150 bp paired-end reads on a MiSeq sequencer 
(Illumina). This kit is able to capture target genomes with size <500 kb and 
consists of 20.000 probes, providing a mean theoretical coverage of 200X. This 
value does not correspond to the effective coverage and therefore it is necessary 
to establish a cutoff value, below which the base called in that position is not 
informative. There is no ideal coverage threshold, but 20X has been adopted by 
many research groups as a good cutoff point. 
Overall, coverage >20X was obtained for 91.95% of 1.416.998 nucleotides 
analyzed and for 90.93% of the 13 ACM genes. In particular, DSG2 and DSC2 
ACM genes resulted to be the most poorly covered genes, with 84.07% and 
68.08% of target nucleotides covered >20X, respectively (Table 4.1). 
 
ACM genes % bases >20X 
PKP2 90.51 
DSP 97.91 
DSG2 84.07 
DSC2 68.08 
CTNNA3 95.16 
DES 99.92 
JUP 98.18 
LMNA 95.63 
TMEM43 93.91 
PLN 78.27 
RYR2 89.14 
TTN 92.51 
TGFβ3 98.81 
Mean for all ACM genes 90.93 
Table 4.1. Percentage of bases with coverage >20X in ACM disease genes. 
 
All the uncovered exons of the most mutated desmosomal genes in ACM (PKP2, 
DSP, DSG2, DSC2 and JUP) were re-sequenced with traditional Sanger method, 
but only common polymorphisms have been detected in these regions.  
 
4.1.2 Previously detected variants 
Among the 19 probands analyzed by using this panel, 10 were previously 
investigated for mutations in the ‘three big ACM genes’ (PKP2, DSP and DSG2) 
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with Sanger sequencing. Three mutations and a rare variant were identified in four 
different subjects in addition to 23 total polymorphisms (Table 4.2, Table 4.3). 
 
Gene Nucleotidic variant Aminoacidic variant MAF #proband 
Mutations 
PKP2 c.1216delG p.V406FfsX13 - 3a 
DSP c.3912G>C p.E1304D - 6a 
PKP2 c.148_151delCAGA p.T50SfsX60 - 7a 
Rare variant 
DSG2 c.1003A>G p.T335A G: 0.02% 12a 
Table 4.2. Mutations and a rare variant previously identified with Sanger sequencing. PKP2 
c.148_151delCAGA and DSP c.1003A>G variants are classified as pathogenic in ARVC/D Genetic 
Database. 
 
Gene SNP ID Nucleotidic 
variant 
Aminoacidic 
variant MAF #proband 
Polymorphisms 
DSG2 
rs2230233* c.861T>C p.N287N C: 47.34% 3a, 4a, 14a 
rs1042769 c.2505A>G p.T835T G: 19.75% 3a, 4a 
rs1791235 c.3321C>T p.V1107V T: 45.71% 3a, 4a, 14a 
rs2230234 c.877A>G p.I293V G: 3.23% 6a 
rs3737378 c.828+16C>A - A: 21.15% 14a 
rs62095194 c.1014+27G>A - A: 21.63% 14a 
rs79241126 c.2137G>A p.E713K A: 2.6% 14a 
rs2278792 c.2318G>A p.R773K A: 24% 14a 
PKP2 
rs10772008 c.2145+45A>G - G: 40.83% 5a, 6a, 14a 
rs77991187 c.2489+73T>A - NA 5a 
rs6488091 c.2490-56C>A - A: 45.03% 5a 
rs6488092 c.2490-104C>G - G: 46.69% 5a 
rs7956824 c.2578-69G>A - A: 45.05% 5a 
rs61927769 c.2489+72G>A - A: 24.94% 14a 
rs71447623 c.2489+73delT - –: 24.94% 14a, 5a 
DSP 
rs10484326 c.274-31T>C - C: 15.62% 6a 
rs2806234 c.741G>T p.A247A T: 0% 6a 
rs2076296 c.1141-44T>C - C: 22.72% 6a 
rs2076304 c.2091G>A p.G697G A: 22.56% 6a 
rs2064217 c.2862C>T p.C954C T: 27.52% 6a 
rs2064218 c.2877+79A>C - C: 30.61% 6a 
rs2076300 c.7122C>T p.T2374T T: 21.17% 6a 
rs2744380 c.8472C>G p.G2824G G: 29.05% 6a 
Table 4.3. Polymorphisms previously detected with Sanger sequencing. Asterisk indicates the 
polymorphism not detected with NGS analysis. MAF: Minor Frequency Allele from dbSNP 
database; NA= data not available. 
 
Targeted NGS approach allowed to identify 96% of the variants previously 
detected by Sanger: all the 3 mutations, the rare variant and 22 out of 23 
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polymorphisms. The SNP c.861T>C in DSG2 gene (rs2230233) has been 
detected in probands n° 4a and 14a but not in patient n° 3a. Looking at the aligned 
reads with IGV software, it appeared evident that the region where the SNP is 
located is poorly covered (coverage=4X) for this sample. 
 
4.1.3 Detection of variants with Targeted ‘Cardiomyopathies gene panel’ 
All the variants detected by at least one variant caller were annotated and 
analyzed by using SNP-Shot tool, which allowed to filter the variants for different 
parameters, such as the frequency in the population, the genomic region involved, 
and the type of variant (SNV synonymous, missense, non-sense or InDel). All the 
missense/non-sense variants with a MAF ≤1% and located both in ACM known-
disease genes (with exclusion of TTN gene) and in genes associated with other 
cardiomyopathies were considered.  
For each annotated variant the sequencing alignments were analyzed with IGV to 
determine: i) the real coverage at this position; ii) the balance between the 
reference and the alternative alleles; iii) the position of the variant in the read. 
These information are useful to recognize false positives from real variants. 
Overall, applying the filters described above, 34 variants were identified, including 
the 3 mutations and the rare variant previously detected. Among the 30 novel 
variants, 28 were subsequently confirmed with Sanger sequencing (Table 4.4) 
resulting in two false positives detected in patient n°1a in MYH7 gene (c.3382G>A, 
p.A1128T) and in patient n°14a in gene encoding for DMD (c.1633A>G, p.R545G). 
In both cases the two variants were called only by one variant caller and the 
alleles resulted unbalanced. 
 
 
#proband gene variant frequences predictions 
1a ANK2     c.2075T>G p.I692S   
PolyPhen2: 
p.damaging          
SIFT: deleterious 
2a - - 
  
3a PKP2 c.1216delG p.V406FfsX13     
4a MYBPC3 
rs373164247 
c.148A>G          
p.S50G 
EVS:0.0077%  
ExAC:0.0038% 
PolyPhen2: benign      
SIFT: tolerated 
5a 
JUP c.1355C>T p.T452M ExAC:0.0074% 
PolyPhen2: 
p.damaging           
SIFT: deleterious 
DSC2 c.577_624del48 p.G193_F208del16   
6a DSP c.3912G>C p.E1304D 
  
7a PKP2 c.148_151delCAGA p.T50SfsX60     
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#proband gene variant frequences predictions 
8a 
DES rs62636490 c.322G>A   p.E108K       
PolyPhen2: 
p.damaging           
SIFT: deleterious 
DSC2 rs61731920 
c.2616C>T p.C872C   
dbSNP:0.16%   
EVS:0.23%  
ExAC:0.06% 
  
GPD1L rs72552293 c.370A>G p.I124V      
dbSNP:0.08% 
EVS:0.1%  
ExAC:0.2% 
  
SCN5A rs41276525 c.647C>T p.S216L 
dbSNP:0.08% 
EVS:0.09% 
ExAC:0.1% 
  
9a 
ABCC9 c.1274T>C p.M425T ExAC:0.0008% 
PolyPhen2: possibly 
damaging             
SIFT: deleterious 
SCN1B c.794G>A p.R265Q   PolyPhen2: - SIFT:deleterious 
ANK2 rs66785829 
c.4619T>A p.V1540D 
dbSNP:0.2% 
EVS:0.23% 
ExAC:0.27% 
  
10a KCND3 rs142744204 
c.641A>G  p.K214R 
dbSNP:0.02%   
EVS:0.03% 
ExAC:0.023% 
  
11a 
PKP2 c.2043delT p.I681MfsX3     
VLC rs146278697 
c.1237G>A p.A413T 
dbSNP:0.02% 
EVS:0.023%      
ExAC:0.024% 
  
CACNA2D1 rs35131433 
c.3134A>C p.D1045A  
dbSNP:0.18%   
EVS:0.5% 
ExAC:0.28% 
  
12a DSG2 rs191564916 
c.1003A>G p.T335A  
dbSNP:0.02% 
EVS:0. 4%     
ExAC:0.055% 
  
13a 
TNNI3 c.232C>T p.T78S   PolyPhen2: benign      SIFT: deleterious 
DSP rs121912998 c.88G>A   p.V30M 
 dbSNP:0.22% 
EVS:0.12%   
ExAC:0.3%   
  
14a 
DSP c.944G>C             p.R315P   
PolyPhen2: 
p.damaging           
SIFT: deleterious 
JUP rs143043662 
c.1942G>A p.V648I 
dbSNP:0.26% 
EVS:0.67% 
ExAC:0.7% 
  
15a 
PKP2 c.1643delG p.G548VfsX15 -   
DES c.1282T>G          p.F428V ExAc:0.0008% 
PolyPhen2: benign 
SIFT: tolerated 
16a TMEM43 rs145619906 
c.424G>A p.E142K 
dbSNP:0.08% 
EVS:0.13% 
ExAC:0.048%  
17a MYL2 c.34G>T              p.G12C ExAC:0.0008% 
PolyPhen2:unknown 
SIFT:tolerated 
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#proband gene variant frequences predictions 
18a 
LMNA c.1835C>T p.S612F 
 
PolyPhen2:probably 
damaging   
SIFT:deleterious 
PSEN2 rs143501870 
c.149A>G p.Q50R EVS:0.0077% 
PolyPhen2: benign 
SIFT: tolerated 
TPM1 rs397516389 
c.775G>A p.E259K  
PolyPhen2: benign 
SIFT: tolerated 
19a 
PKP2 c.39C>G              p.I13M  
PolyPhen2: 
p.damaging          
SIFT: deleterious 
DSP c.1067C>T         p.T356M  
PolyPhen2: 
p.damaging         
SIFT:tolerated 
Table 4.4. Variants detected with Targeted NGS and confirmed with Sanger sequencing. The SNP-
Shot annotation includes frequency data from dbSNP, Exome Variant Server (EVS) and ExAC 
Browser and pathogenicity predictions from PolyPhen2 and SIFT. 
 
Among the 32 variants reported, 5 were deletions, 4 of which affecting PKP2 gene 
and a homozygous deletion of 48 bp in DSC2 gene identified in patient n° 8a 
(Figure 4.1). 
 
 
Figure 4.1 . IGV view: sequencing alignments of DSC exon 5 for patient n°8. 
 
Taking into account that the allele frequency of ACM in the general population 
span from 0.01% and 0.025%, a genetic variant should be considered as a 
‘mutation’ if its minor allele frequency (MAF) is ≤ 0.01%, as a ‘rare variant’ if 
reported with 0.01%≤ MAF≤ 0.5% and as a ‘low frequency variant’ with 0.5%≤ 
MAF≤ 1%.  
Considering this classification, 15 out of 19 probands analysed reported one or 
more mutations in a known-ACM gene (patients n° 3a, 5a, 6a, 7a, 8a, 11a, 14a, 
15a, 18a, 19a) or in a gene associated with other cardiomyopathies (patients n° 
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1a, 4a, 9a, 13a, 17a). Several rare or low frequency variants were also detected in 
all the samples (Table 4.4). Among these, the rare variant in DSP gene (p.V30M) 
found in patient n° 13a and the missense variant in GPD1L gene (p.I124V) in 
patient n° 8a are reported in ClinVar database and associated with ACM and 
Brugada syndrome, respectively. Moreover, the missense variant in ANK2 gene 
(p.V1540D) identified in patient n° 9a has been associated with cardiac arrhythmia 
in HGMD database. 
In some familial cases, described below, it was possible to study the segregation 
of the detected variants within the families. 
 
Proband #14a 
The patient resulted to carry 2 variants in 2 ACM genes: a novel missense variant 
in DSP gene (p.R315P), predicted damaging by the two prediction tools, and a low 
frequency variant (ExAC MAF: 0.7%) in JUP gene (p.V648I) classified as 
“unknown variant” in the ARVD/C Genetic Variants database. The presence of 
both variants was assessed in subjects II-2, III-4 and III-5 (Figure 4.2). 
 
 
Figure 4.2. Family’s pedigree of patient n°14a (pointed with the arrow). 
None of the healthy family members present the DSP mutation, whereas two of 
them (II-2, III-5) reported the variant in JUP gene. 
 
Proband #15a 
The patient reported a frameshift PKP2 mutation (p.G548VfsX15) and a missense 
mutation in DES gene (p.F428V), predicted to be tolerated by SIFT and 
PolyPhen2. Genomic DNA of 4 family members (III-2, III-3, III-4, III-5) was 
available and analyzed for the two variants identified in the proband (II-3) (Figure 
4.3). 
+ DSP p.R315P 
- negative for DSP p.R315P 
+ JUP p.V648I 
- negative for JUP p.V648I  
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Figure 4.3. Family’s pedigree of patient n°15a (pointed with the arrow). 
All the affected family members resulted positive for PKP2 frameshift mutation, 
which is not present in the DNA of the healthy subject III-3. The missense DES 
variant is present in 2 out of 4 individuals (III-3 and III-5) beyond the proband. 
 
4.1.4 TTN variants 
First analysis of the sequencing data excluded all the variants found in TTN gene, 
because of the size of this gene and the difficulty to interpret the frequent 
missense variants identified also in individuals from control populations. However, 
among the huge amount of TTN variants identified in our cohort of patients, all the 
variants called in 10 or more samples were ignored as possible sequencing errors, 
whereas the others were divided in two groups: the ‘private variants’, present in 
only one proband, and the ‘common variants’ present at least in 2 samples. 
Excluding the synonymous TTN variants, 32 ‘private variants’ (Table 1, Appendix 
C) have been found, resulting in a mean of 1.68 TTN missense variants for each 
subject. The only one mutation reported at least in one database is the 
c.30274C>T (p.H10092Y) variant (rs72650011) identified in proband n° 15a, which 
is present both in ClinVar and HGMD databases and classified as ‘pathogenic’ in 
ARVD/C Genetic Variants database. Moreover, other 8 missense variants present 
in more probands have been found (Table 4.5). For all these variants the 
frequency data in the general population is not reported in the databases.  
 
 
 
 
+ PKP2 p.G548VfsX15 
- negative for PKP2 p.G548VfsX15 
+ DES p.F428V 
- negative for DES p.F428V 
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TTN variant frequences predictions #probands 
c.85136C>A p.A28379E - PolyPhen2: p.damaging         SIFT: deleterious 2a, 3a 
c.47860G>T p.A15954S - PolyPhen2: p.damaging         SIFT: deleterious 
3a, 5a, 6a, 8a, 12a, 14a, 
16a 
c.84562G>A p.G28188S - PolyPhen2: p.damaging         SIFT: deleterious 8a, 9a, 12a 
rs55634791            
c.82691C>T p.A27564V - 
PolyPhen2: possibly damaging    
SIFT: deleterious 9a, 11a, 16a, 18a 
rs201675016          
c.53062A>G p.K17688E - 
PolyPhen2: benign        SIFT: 
deleterious 9a, 11a 
c.10831C>A   p.Q3611K - PolyPhen2: benign        SIFT: deleterious 
9a, 10a, 11a, 12a, 16a, 
17a, 18a, 19a 
c.55784C>T p.T18595I - PolyPhen2: p.damaging         SIFT: deleterious 10a, 19a 
c.49814T>G p.V16605G - PolyPhen2: p.damaging         SIFT: deleterious 14a, 15a, 16a 
Table 4.5. TTN ‘common variants’ detected in 19 ACM probands. 
 
4.2 Targeted gene panels: ‘ACM known and candidate genes panel’ 
 
4.2.1 Coverage 
Four subjects previously analyzed with the ‘Cardiomyopathies gene panel’ (2a, 4a, 
16a, 17a) together with other 40 ACM probands were screened using a panel that 
includes a total of 69 genes, 13 known-disease genes and 56 ACM candidate 
genes. All the patients included in this study were diagnosed affected based on 
the Revised Task Force Criteria (Marcus et al., 2010) and resulted negative for 
mutation screening of the ‘three big ACM genes’ (PKP2, DSP and DSG2). 
Overall, coverage >20X was obtained for 92.45% of sequenced nucleotides and 
for 91% considering only the 13 ACM genes (Table 4.6). On average, 445 variants 
per sample have been detected, of them 409 are SNPs and 36 InDels. 
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ACM genes % bases >20X 
PKP2 89.1 
DSP 96.8 
DSG2 90.6 
DSC2 84.3 
CTNNA3 95.2 
DES 97.7 
JUP 96.8 
LMNA 95.3 
TMEM43 94.2 
PLN 76.6 
RYR2 89.5 
TTN 82.6 
TGFβ3 94.8 
Mean for all ACM genes 91.0 
Table 4.6. Percentage of bases with coverage >20X in ACM disease genes. 
 
4.2.2 Detection of variants with Targeted ‘ACM known and candidate genes 
panel’ 
After the variant calling process performed with FreeBayes and VarScan, the 
annotation step was carried out by using SNP-Shot tool, as previously described. 
SNP-Shot interface reported also a specific parameter called ‘class’, indicating the 
presence and the classification of the variant in mutation databases (ClinVar, 
HGMD). All the missense/non-sense variants with a MAF ≤1% were considered, 
located both in ACM known or candidate genes (with exclusion of TTN gene). 
The number of probands carrying mutations (MAF ≤0.01%) in known or candidate 
genes is listed in Table 4.7. 
 
TOT n° of probands  
 
N° probands with 
mutations  
in candidate genes 
N° probands 
carrying 
mutations in 
known-disease 
genes 
In ACM genes 6 (13.6%) 3 (50%) out of 6  
In other 
cardiomyopathies 
genes 
6 (13.6%) 2 (33.3%) out of 6  
none 32 (72.7%) 13 (40.6%) out of 32  
 TOT 44 18 (40.9%) out of 44  
Table 4.7. N° of probands in whom mutations have been identified in known disease genes divided 
in ACM known genes and in genes associated with other cardiomyopathies (on the left) and in 
candidate genes (column on the right). 
 
a. Mutations in ACM genes 
In 6 out of 44 probands (Table 4.7), one or more mutations (MAF ≤0.01%) in ACM-
known disease genes have been identified and confirmed with Sanger sequencing 
(Table 4.8).  
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#proband gene variant frequences predictions class 
6b 
DSP rs121912997 c.3799C>T p.R1267*      I 
PKP2 rs146102241 c.1759G>A p.V587I   PolyPhen2: p.damaging SIFT: tolerated   I 
MYZAP rs141271435 c.209G>C p.G70A  ExAC: 0.008% PolyPhen2: p.damaging SIFT: tolerated    
FAT1 rs180820128 c.2563G>A p.G855R 
EVS:0.2%  
ExAC:0.2%     
XIRP1 rs199632343 c.2066C>T p.P689L ExAC: 0.04%     
12b 
DSP  c.1267-2A>G       
TJP1 rs2229517 c.1412A>G p.N471S  
dbSNP:0.7%  
EVS:1%  
ExAC:0.9% 
    
KCNJ11 c.820G>A p.D274N ExAC: 0.006% PolyPhen2: benign SIFT: deleterious   
FAT1 rs116784674 c.7700G>A p.R2567H 
dbSNP:0.5%  
EVS:1%  
ExAC:0.9% 
    
14b PKP2 c.1063C>T p.R355*       I 
25b 
DSG2 c.1557C>A p.D519E    PolyPhen2: p.damaging           
 SIFT: deleterious   
DSG2 rs2230232 c.266A>G p.Y89C  dbSNP:0.2%  ExAC:0.1%   IX 
DSG2 rs191143292 c.473T>G p.V158G 
dbSNP:0.2%  
ExAC:0.5%   III 
27b 
JUP c.1355C>T p.T452M  ExAC:0.007% PolyPhen2: p.damaging           
 SIFT: deleterious   
DSP rs41302885 c.6208G>A p.D2070N  
dbSNP:0.2%  
EVS:0.3%  
ExAC:0.4% 
  IX 
33b 
JUP c.1359G>T p.E453D  ExAC:0.006% PolyPhen2: p.damaging            SIFT: deleterious IV 
FAT1  c.8938G>T p.V2980L ExAc:0.0008% PolyPhen2: benign SIFT:deleterious   
AXIN1  rs146947903 c.1485C>G p.D495E 
dbSNP:0.4%  
EVS:0.6%  
ExAC:0.6% 
    
DCHS1 rs117368891 c.1245C>A p.S415R  
dbSNP:0.6%  
EVS:0.8%  
ExAC:0.6% 
    
Table 4.8. Probands reporting one or more mutations in ACM-known disease genes. Class I: 
Pathogenic, variants reported in LSDB (Locus Specific Databases) and/or HGMD professional as 
pathogenic for a given phenotype; class III: Uncertain Pathogenicity, variants reported in LSDB and 
for which the evidence for pathogenicity for a given phenotype may be dubious; class IV: 
Unclassified, variants reported in LSDB as unclassified; class IX: Not Pathogenic; variants reported 
in LSDB as likely not pathogenic. In bold type are the mutations in the known-disease genes. 
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For patients n° 6b, 12b, 14b and 25b the mutation screening previously performed 
with dHPLC or Sanger sequencing failed to identify the stop-mutations in DSP 
gene (p.Arg1267*) and PKP2 gene (p.Arg355*), the missense mutation in DSG2 
gene (p.Asp519Glu) and the variant affecting a DSP splice-site (c.1267-2A>G). 
 
b. Mutations in genes not previously associated with ACM 
As observed in the 19 probands screened with the ‘Cardiomyopathies gene panel’, 
also in this cohort of ACM patients there is a fraction of subjects (Table 4.7) 
carrying one or more mutations in genes associated with other cardiomyopathies 
(Table 4.9). All the putative pathogenic mutations have been subsequently 
validated by Sanger sequencing. 
 
#proband gene variant frequences predictions class 
4b 
LMNA rs267607571 c.569G>A p.R190Q     PolyPhen2: p.damaging SIFT: deleterious  I/IV 
XIRP1 rs146284335 
c.5352G>A p.M1784I 
dbSNP:0.5%  
EVS:1%  
ExAC:0.7% 
    
11b 
SCN5A c.3763C>A p.L1255M 
ExAC: 
0.0008% PolyPhen2: p.damaging SIFT: deleterious   
PKP4 rs146222858 
c.2764G>A p.G923S ExAC:0.1% PolyPhen2: possibly damaging SIFT: tolerated   
FAT1 
rs77280820 
c.3446T>C 
p.M1149T  
dbSNP:0.3%  
EVS:0.5%  
ExAC:0.3% 
    
CTNNA1  rs28363394 
c.536C>T p.A179V  
EVS:0.2%  
ExAC:0.1%     
TJP2  rs140340673 
c.985G>A p.V329I  ExAC: 0.008% PolyPhen2: benign SIFT: tolerated   
15b TNNC1 rs267607124 
c.435C>A p.D145E  ExAC: 0.02% PolyPhen2: possibly damaging SIFT: deleterious  I 
32b 
TNNC1 c.208G>A     p.G70S  ExAC:0.0016%  PolyPhen2: p.damaging SIFT: deleterious   
XIRP1 rs146284335 
c.5352G>A p.M1784I 
dbSNP:0.5%  
EVS:1%  
ExAC:0.7% 
    
36b 
TPM1 c.803A>G p.L268R    PolyPhen2: benign SIFT: tolerated    
DCHS1 rs377088444 
c.1669C>T p.P557S  ExAC:0.0024% PolyPhen2: benign SIFT: tolerated   
TJP1 
rs201943761 
c.3505G>T 
p.G1169C  
EVS:0.1%  
ExAC:0.1%     
FAT1 c.13621G>A p.A4541T     PolyPhen2: benign SIFT: tolerated    
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#proband gene variant frequences predictions class 
44b(17a) MYL2 c.34G>T p.G12C  ExAC:0.0008% PolyPhen2:unknown SIFT:tolerated 
  
Table 4.9. Probands reporting one or more mutations in genes not previously associated with ACM. 
Class I: Pathogenic, variants reported in LSDB and/or HGMD professional as pathogenic for a 
given phenotype; class IV: Unclassified, variants reported in LSDB as unclassified. In bold type are 
the mutations in genes associated with other diseases. 
 
Despite the fact that LMNA is a gene already associated with ACM, in the 
literature the mutation p.Arg190Gln has been reported in a patient affected with 
Emery-Dreifuss syndrome (ClinVar). Two probands (15b and 32b) showed 
missense variants in TNNC1 gene, and one of these (p.Asp145Glu) has been 
already identified both in patients affected with HCM and DCM. Patient n° 44b was 
previously screened with the ‘Cardiomyopathies gene panel’ (proband n° 17a), but 
in both cases only p.Gly12Cys mutation in MYL2, a gene associated with HCM, 
has been identified.  
 
c. Mutations in candidate ACM genes 
The application of this Targeted gene panel allowed to identify missense and non-
sense mutations in candidate genes in 40.6% of the index cases negative for 
mutations in known-disease genes (Table 4.7). Among the 56 candidate genes 
included in the panel, 13 reported very rare coding variants (MAF ≤0.01%) and in 
4 of them more than one different missense mutation was found (Table 4.10). 
 
#proband gene variant frequences predictions class 
8b 
TP63  c.796C>T p.R266*        
TLN1 c.3707A>G p.Q1236R    PolyPhen2: possibly damaging           SIFT: tolerated   
16b FAT1 c.2755G>A p.D919N    PolyPhen2: p.damaging SIFT: deleterious   
17b AXIN rs140190126 
c.1532C>T p.S511L  ExAC:0.007% PolyPhen2: benign SIFT: tolerated  
19b 
XIRP1  c.223G>A  p.E75K  ExAC: 0.016%     
CASQ2 c.1147_1149delGAT p.D383del        
24b DCHS1 c.6803T>C p.I2268T  ExAC:0.0016% PolyPhen2: benign SIFT: tolerated  
  
26b(2a) DCHS1 c.259G>A p.G87S ExAC: 0.0008% PolyPhen2: p.damaging SIFT: tolerated    
30b DCHS1 c.3206T>A p.I1069K  ExAc:0.006% PolyPhen2: benign SIFT: tolerated   
31b AXIN1 rs140190126 
c.1532C>T p.S511L ExAC:0.007% PolyPhen2: benign SIFT: tolerated 
 
35b ANK3 c.2309C>A p.T770K 
   
37b TJP1 c.793C>T p.R265W  ExAC:0.0008% PolyPhen2: p.damaging SIFT: deleterious   
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#proband gene variant frequences predictions class 
38b KAZN  c.2242G>T p.E748*        
40b 
CDH2 c.1478A>G p.E493G    PolyPhen2: p.damaging SIFT: deleterious    
CDH2 c.1472T>G p.V491G    PolyPhen2: possibly damaging           SIFT: deleterious   
FAT1 rs201352448 
c.7138G>A p.V2380I ExAC:0.003% PolyPhen2: benign SIFT: tolerated   
41b TJP1  c.2006A>G p.T669C    PolyPhen2: p.damaging              
Table 4.10. Probands reporting one or more mutations in candidate ACM genes.  
 
Other than the patients reported in Table 4.10, who carried only mutations in one 
or more candidates genes, other probands resulted positive for mutations in these 
genes together with mutations in ACM known-disease genes (proband n° 6b, 12b 
and 33b, Table 4.8), or in genes associated with other cardiomyopathies (proband 
n° 11b and n° 36b, Table 4.9) (Table 4.7). 
The most mutated genes resulted FAT1 and DCHS1, both encoding for members 
of the cadherin superfamily. Mutations in FAT1 gene were found in 4 subjects 
(16b, 33b, 36b and 40b), whereas 4 probands showed mutations in DCHS1 gene 
(24b, 26b, 30b and 36b). In most of the cases, these missense mutations were 
predicted ‘tolerated’ from prediction tools. Moreover many rare or low-frequency 
variants in these two genes were also found in our cohort of patients. 
Among these 13 candidate mutated genes, 2 showed single nucleotide variants 
which cause the formation of a stop codon. The c.2242G>T (p.E748*) mutation 
located in gene encoding for kazrin (KAZN, proband n° 38b), resulted in a stop-
gain variant affecting only one out of 5 isoforms considered for this gene 
(NM_201628), whereas the same variant is located in an intergenic region for 
other isoforms. The other stop mutation identified in TP63 gene (p.R266*) in 
proband n° 8b will be described below (Family #1).  
CDH2 gene 
Proband n° 40b showed 2 single nucleotide variants, one 6 bp far from the other in 
exon 10 of CDH2 gene (c.1478A>G p.E493G, c.1472T>G p.V491G). Both 
mutations were validated with Sanger sequencing, which highlighted also the 
presence of a homozygous SNP (c.1377C>G, rs1628684) with a MAF= 0.18% for 
the G allele. 
CDH2 gene (NM_001792) encodes for a calcium dependent cell-cell adhesion 
glycoprotein. It belongs to the cadherin superfamily and is composed by five 
extracellular cadherin repeats, a transmembrane region and a highly conserved 
cytoplasmic tail. N-cadherin is highly expressed by the developing and mature 
myocardium, where it is found predominantly in the fascia adherens of the 
transverse region of intercalated discs (IDs) and in the regions of close lateral 
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contact between neighboring cardiomyocytes. Both the variants are absent in all 
SNP databases and affected two highly conserved amino acids (phyloP=4.9 for 
p.E493G mutation, phyloP=3.3 for p.V491G mutation), localized into the 
extracellular protein domain. Moreover, both the amino acid substitutions have 
been predicted to be deleterious by SIFT tool and probably or possibly damaging 
by PolyPhen2 tool. 
In two familial cases the analysis was extended to the available family members. 
 
Family #1 
Proband n°8b showed first signs of the disease at the age of 14. He reported 
infundibular arrhythmias and late potentials. The proband’s mother was also 
diagnosed affected with ACM. The proband underwent to traditional screening for 
the 5 most mutated genes in ACM, but no putative causative mutation was found. 
Analysis of the data obtained by Targeted gene panel highlighted the presence of 
two novel mutations: a missense variant in TLN1 gene (c.3707A>G, p.Q1236R) 
and a stop mutation in TP63 gene (c.796C>T, p.R266*). The latter was called only 
by FreeBayes variant caller and not by VarScan, but Sanger sequencing allowed 
to confirm both variants.   
TP63 stop mutation was carried also by the mother (II-2), but was not found in 
subject (II-3) for whom clinical data are not available. Conversely, the missense 
mutation in TLN1 gene was detected only in the proband, but not in subjects II-2 
and II-3 (Figure 4.4). 
 
 
Figure 4.4. Family’s pedigree of patient n° 8b (pointed with the arrow). Black and white symbols 
represent clinically affected and unaffected individuals, respectively. 
+ TP63 c.796C>T p.R266* 
- negative for TP63 c.796C>T p.R266* 
• TLN1 c.3707A>G p.Q1236R  
- negative for TLN1 c.3707A>G p.Q1236R 
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TP63 gene 
This gene encodes a member of the p53 family of transcription factors and acts as 
a sequence specific DNA binding transcriptional activator or repressor. For this 
gene several isoforms have been identified. Different isoforms contain a varying 
set of transactivation and auto-regulating transactivation inhibiting domains thus 
showing an isoform specific activity. c.796C>T mutation causes the formation of a 
stop codon located in exon 4 (isoform 1) or exon 6 (isoform 6) encoding a beta 
strand domain. The gene is widely expressed, notably in heart, kidney, placenta, 
prostate, skeletal muscle, testis and thymus.  
 
Family #2 
Proband n° 41b, came to clinical evaluation for ACM after his brother’s sudden 
death at the age of 35 (II-2, Figure 4.5). Subject II-2 presented negative T waves 
at ECG and experienced 3 syncopes before death. Proband (II-4) showed a 
moderate form of ACM, with RV dilatation and initial biventricular involvement. 
Previous mutation screening of the 5 most mutated genes (PKP2, DSP, DSG2, 
DSC2, JUP) didn’t reveal the presence of any pathogenic mutation. Genetic 
analysis through Targeted gene panel identified a novel missense mutation in 
TJP1 gene (c.2006A>G, p.Tyr669Cys). Since the DNA of 8 family members was 
available (I-1, I-2, II-5, II-8, II-9, III-1, III-2, and III-4), the analysis was extended to 
the whole family (Figure 4.5). 
 
 
Figure 4.5. Family’s pedigree of patients n° 41b (pointed with the arrow). Black and white symbols 
represent clinically affected and unaffected individuals, respectively; grey symbols denote subjects 
with minor signs of the disease. 
+ TJP1 c.2006A>G p.Y669C 
- negative for TJP1 c.2006A>G p.Y669C 
 
The variant is present in 5 out of 8 family members including the two sons of the 
dead proband’s brother (III-1, III-2). Two other proband’s brothers showed the 
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variant, one (II-9) reporting minor signs of the disease (late potentials) but negative 
RMN, and subject II-5 with no clinical signs at last evaluation. The mutation is 
carried by the mother (I-2), who has minor ACM signs, but reporting a family 
history for sudden cardiac death. Subject III-3 is dead at young age, but not for 
cardiac causes. 
Since the variant is absent in all databases and affects a good candidate gene, 
which resulted mutated also in proband n° 37b (p.Arg265Trp), the analysis was 
carried on studying the effect of the amino acid change into the protein structures. 
 
TJP1 gene 
TJP1 (NM_003257) encodes for tight junction protein 1 (also called zonula 
occludens 1, ZO-1), that forms regulated intercellular barriers between both 
epithelial and endothelial cells. Barrier function can be further subdivided into 
protective barriers and functional barriers serving purposes such as material 
transport and maintenance of osmotic balance. TJP1 is located on the cytoplasmic 
membrane surface precisely at sites of cell-cell contact and interacts with different 
junctional proteins such as connexin-43, myozap, Ankrd2, other than with other 
tight junction proteins (TJP2/ZO-2 and TJP3/ZO-3). The N-terminal domain may 
be involved in transducing a signal required for tight junction assembly, while the 
C-terminal may have specific properties of tight junctions. 
Mutation p.Tyr669Cys affects a highly conserved residue at the guanylate kinase-
like (GUK) domain of protein ZO-1 (Figure 4.6). The mutation falls at the contact 
region between strands β2/β3, the two are members of a large five β-sheet which 
forms the GUK hydrophobic core. A 40 ns full atom molecular dynamics simulation 
was performed with Gromacs 4.6 using the CHARMM 27 force field, in order to 
investigate the structural impact of the p.Tyr669Cys mutation. When 
superimposed, the wild-type and the mutant proteins show a similar organization 
for the PDZ3 domain, while the GUK domain resulted to adopt a more opened 
conformation in the mutant protein (Figure 4.7). 
Moreover, network of interacting residues generated with RING around 10 Å from 
position 669 showed that several hydrophobic interactions were lost during the 
simulation of the mutant protein. In particular, the Tyr669Cys substitution breaks 
Van der Waals interactions between Tyr669 and Leu66, Ile789, promoting a clear 
structural rearrangement. 
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Figure 4.6. Schematic representation of protein ZO-1 and localization of the identified mutations 
p.Arg265Trp and p.Tyr669Cys. 
 
 
 
Figure 4.7. Graphical representation of both wild type and mutant protein ZO-1. A) Superimposition 
of the last frame (40 ns) obtained after two independent runs of molecular dynamics simulation. 
PDZ3 maintains the same fold, while GUK domain shows relevant variation suggesting a local 
unfold induced by p.Tyr669Cys substitution. B) Comparative view of the same structures shows a 
remarkable spatial reorganization of the region surrounding the position 669. Affected residues are 
presented in stick style. Analysis from Dr. Giovanni Minervini and Prof. Silvio Tosatto. 
 
Mutation p.Arg265Trp (found in proband n° 37b) is localized at the end of the 
second PDZ domain, in an intrinsically disordered region. To identify the 
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conservation rate of the amino acid Arg265, 43 orthologous sequences were 
aligned. Multi sequences alignment revealed that the position is fully conserved, 
albeit mapping outside the PDZ2 (Figure 4.8). Moreover, a high rate of 
conservation was observed for the 9 residues immediately after Arg265. 
Figure 4.8. Protein sequence alignment of TJP1 PDZ2 domain C-terminal flanking region. The 
extra boundary conserved region is marked with a black box, while red dot is used to mark 
residues corresponding to the human Arg265. 
 
 
a. Rare and low frequency variants 
Other than in patients described in the paragraphs above, in additional 17 
probands rare or low frequency variants (0.01%≤ MAF≤ 1%) were identified, 
whereas only in 2 samples (1b and 43b) no interesting variants were found (Table 
2, Appendix C). 
In our cohort of patients, some of these variants are present in more than one 
individual, thus resulting in most cases in a MAF ten times higher than the MAF 
reported by common SNP databases (Table 4.11). 
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gene variation global frequencies #probands 
frequency in 
44 subjects 
SCN5A rs45489199 
c.6016C>G p.P2006A  
EVS:0.1% 
ExAC:0.1% 2b, 10b, 21b 3.4% 
ANK3 
rs61845768 
c.10055A>G 
p.E3352G  
dbSNP:0.2% 
EVS:0.4% 
ExAC:0.4% 
3b, 16b, 21b,23b 4.5% 
XIRP1 rs146284335 
c.5352G>A p.M1784I 
dbSNP:0.5% 
EVS:1%  
ExAC:0.7% 
4b, 32b, 40b, 42b 4.5% 
STK3 rs187757501 
c.203G>A p.S68N  
dbSNP:0.2% 
EVS:0.4%  
ExAC:0.3% 
5b, 13b 2.3% 
ABCC9  rs61688134  
c.2200G>A p.V734I 
dbSNP:0.6% 
EVS:0.9% 
ExAC:0.7% 
8b, 16b, 23b 3.4% 
TJP1 rs2229517 c.1412A>G p.N471S  
dbSNP:0.7%  
EVS:0.1% 
ExAC:0.9% 
10b, 12b, 21b 3.4% 
AXIN1 rs140190126  
c.1532C>T p.S511L  ExAC:0.007% 17b, 31b 2.3% 
XIRP1 rs61736135  
c.1741C>A p.P581T  
dbSNP:0.6%  
EVS:0.9%  
ExAC:0.7% 
28b, 31b 2.3% 
FAT1 rs116784674 
c.7700G>A p.R2567H 
dbSNP:0.5%  
EVS:1%  
ExAC:0.9% 
2b, 12b 2.3% 
Table 4.11. ‘Common rare and low-frequency variants’ in 44 probands. 
 
 
4.2.3 TTN variants 
As described in paragraph 4.1.4, several variants in gene encoding for titin have 
been detected also in 44 probands sequenced with Targeted ‘ACM known and 
candidate genes panel’. 
Excluding the huge amount of synonymous variants, 48 ‘private variants’ (Table 3, 
Appendix C) have been found in addition to 9 variants present in more than one 
subject (Table 4.12). 
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TTN variant frequences predictions #probands 
rs55837610 c.71705T>C 
p.I23902T  
EVS:0.3%  
ExAC:0.2% SIFT: deleterious 5b, 38b 
rs72648972 c.23232C>G 
p.N7744K  
EVS:0.2% 
ExAC:0.4% SIFT: deleterious 10b, 22b, 39b 
rs72646819 c.55139T>C 
p.I18380T   SIFT: deleterious 10b, 22b 
 rs72677231 
c.47191C>T p.R15731C  
dbSNP:0.2%  
EVS:0.2%   
ExAC:0.2%  
PolyPhen2: 
p.damaging           
SIFT: deleterious  
17b, 27b, 33b 
 rs72677233 c.47315G>A 
p.R15772Q 
dbSNP:0.2%  
EVS:0.3% 
ExAC:0.3% 
SIFT: deleterious 19b, 25b 
 rs72648949  
c.18776C>G p.T6259S  
EVS:0.3% 
ExAC:0.3% SIFT: deleterious 19b, 25b 
rs72646885 c.69676A>G 
p.S23226G  
dbSNP:0.2%  
EVS:0.7% 
ExAC:0.8% 
PolyPhen2: 
p.damaging           
SIFT: deleterious  
22b, 32b, 42b 
rs72677237 c.47723G>A 
p.R15908H 
dbSNP:0.2%  
EVS:0.7% 
ExAC:0.6% 
PolyPhen2: 
p.damaging           
SIFT: deleterious  
22b, 32b 
rs33971253 c.11969C>T 
p.P3990L  
dbSNP:0.6% 
EVS:0.9% 
ExAC:0.7% 
SIFT: deleterious 20b, 37b 
Table 4.12. TTN ‘common variants’ detected in 44 ACM probands. 
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4.3 Whole exome sequencing 
In some particular familial cases, in which traditional mutation screening failed to 
identify mutations in the 5 most mutated genes in ACM, a different approach was 
applied. The entire coding part of the genome was captured and sequenced for at 
least two members of each family. 
 
Family #3 
 
 
Figure 4.9. Pedigree of Family#3. Black and white symbols represent clinically affected and 
unaffected individuals, respectively; grey symbols denote subjects with minor signs of the disease. 
Proband is pointed by the arrow. 
+ DSP c.3889C>T p.Q1297* 
- negative for DSP c.3889C>T p.Q1297* 
 
The proband (II-7) was diagnosed affected by ACM at the age of 30. She 
complained of palpitations. Twelve lead ECG showed intraventricular conduction 
delay and 24-Holter ECG documented the presence of numerous premature 
ventricular beats (PVBs) with left bundle branch block (LBBB) morphology, coming 
from the right ventricular outflow tract. The 2D-echocardiogram showed left and 
right ventricular dilatation with kinetic abnormalities in both ventricles. At the age of 
37 she had a syncopal episode and a sustained ventricular tachycardia was 
recorded, thus an ICD was implanted. 
All coding exons and 200 bp flanking intronic regions were captured and 
sequenced in two affected family members (II-4 and II-7, Figure 4.6). Overall, 89.5 
and 91.3 million paired-end sequencing reads were generated for patients II-4 and 
II-7, respectively. Among the total reads, 89% (for patient II-4) and 86% (for patient 
II-7) were aligned to the UCSC human reference genome (hg19 release) and 
64.5% of the total bases mapped to the targeted and enriched exons. Capture 
specificity (defined as percentage of uniquely mapped reads aligning to target 
region) was 73.1% and 72%. After filtering for alignment and sequence quality and 
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sequencing depth of the site , more than 50.000 SNPs and 5000 Insertion/Deletion 
(InDels) were identified in the whole exome of each patient. These high-
confidence variants were compared against those present in several databases 
(dbSNPs141, 1000 Genomes Project, YanHuang project, and two databases 
belonging to BGI) and the variants with a MAF >1% were removed. Among the 
remaining variants, a total of 141 SNPs and 246 InDels common to both family 
members were found. Among the most candidate variants identified, a non-sense 
mutation in DSP gene was found (c.3889C>T, p.Q1297*) (Figure 4.10). This 
heterozygous nucleotide substitution causes the formation of a stop codon in exon 
23 of DSP. The mutation is present in other 6 family members: two clinically 
affected (II-4 and III-4) who were diagnosed as having a biventricular form of the 
disease, two reporting minor signs of the disease as RV conduction delay at ECG 
(III-3) and PVBs (II-9), with normal 2D-echo findings in both cases. Moreover, one 
genotype-positive subject (III-5) had unremarkable ECG, echo and cardiac 
magnetic resonance findings. The father of the proband (I-1) was died at the age 
of 80 due to cardiac arrest with signs of heart failure, without cardiac evaluation. 
This nucleotide substitution in exon 23 of DSP gene was not detected at dHPLC 
analysis due to its localization in a region with a high denaturing temperature. 
 
 
Figure 4.10. IGV view: detection of DSP p.Q1297* heterozygous mutation. 
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Family #4 
 
 
Figure 4.11. Pedigree of Family#4. Black and white symbols represent clinically affected and 
unaffected individuals, respectively. Proband is pointed by the arrow. 
+ JUP c.1942 G>A p.V648I 
- negative for JUP c.1942 G>A p.V648I 
# CDH11 c.1814A>T p.N479I 
-  negative for CDH11 c.1814 A>T p.N479I 
• TTN c.97717 C>T p.R32573C 
- negative for TTN c.97717 C>T p.R32573C 
 
In Family #4, the proband reported minor alterations at echocardiography and 
inverted T waves in V1. The family had a case of sudden cardiac death (subject II-
2, Figure 4.11) at the age of 35, diagnosed affected with ACM at autopsy. 
Previous genetic screening performed in the proband allowed to identify a variant 
in the gene encoding for JUP (p.V648I). This variant is present in ExAC database 
with a MAF= 0.7% and predicted tolerated by both prediction tools (PolyPhen2 and 
SIFT). The research of the genetic cause, reason of the expression of the disease 
in this family was carried out by whole exome sequencing in 2 individuals (II-4 and 
III-5). 
The total clean reads produced were aligned to the human reference genome 
(GRCh37/hg19) using Burrows-Wheeler Aligner (BWA). On average, 99.75% 
mapped successfully. The duplicate reads were removed, resulting in the average 
of 186,556,723 effective reads. Of total effective bases, 43.40% mapped on target 
regions (capture specificity). The mean sequencing depth on target regions was 
111.72-fold. On average per sequencing individual, 47742 SNPs and 4919 InDels 
were identified. 
All the variants present in one or more databases (dbSNPs141, 1000 Genomes 
Project, EVS and in-house Radboud University database) with a MAF >1% were 
filtered out. Moreover only coding variants that cause an amino acid change 
(missense), a formation of a stop codon (non-sense), an alteration of the splicing 
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or the reading frame were considered. Among the 228 variants shared by subjects 
II-4 and III-5, two were selected as candidates, for the predicted pathogenicity and 
the gene involved. A missense TTN variant (p.R32573C) and a single nucleotide 
variant in CDH11 gene (p.N479I) encoding for a type II cadherin that mediate 
calcium-dependent cell-cell adhesion. The segregation of both variants is shown in 
Figure 4.11. Only the two affected subjects (II-4 and III-5) and the obligated carrier 
(II-5) present the combination of the three variants, whereas several healthy 
subjects carry the CDH11 variant and two (III-2 and III-3) the TTN variant only. 
 
Family #5 
 
 
Figure 4.12. Pedigree of Family#5. Black and white symbols represent clinically affected and 
unaffected individuals, respectively. Proband is pointed by the arrow. 
* TTN c.96592 C>A p.L32198M 
- Negative for TTN c.96592 C>A p.L32198M 
∆ CMYA5 c.10789 A>T p.K3597* 
- Negative for CMYA5 c.10789 A>T p.K3597*  
• MYBPC3 c.2980 C>T p.L994F 
- Negative for MYBPC3 c.2980 C>T p.L994F 
¤ RYR2 c.1258 C>T p.R420W 
 
In Family #5, two persons died suddenly at young age (III-1, III-3). Genetic 
analysis performed in the two subjects as well as in the affected brother (III-2), 
revealed the presence of a missense mutation in RYR2 gene (p.R420W), 
underlying the characteristic phenotype commonly associated with RYR2 
mutations and expressed by the patients. The mutation is carried by the father (II-
1), but also the mother (II-2) reported late potentials at ECG and a family history 
for ACM. The proband (II-4) was screened by dHPLC and direct sequencing for 
the 5 most important genes in ACM and resulted negative. 
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Whole exome sequencing of 3 DNA samples (subjects I-1, II-2 and II-4) was 
performed and averagely 18,813.86 Mb raw bases were produced by the Illumina 
sequencer. After removing low-quality reads averagely 188,079,352 clean reads 
were obtained. Total clean reads per sample were aligned to the human reference 
genome (GRCh37/hg19) using Burrows-Wheeler Aligner (BWA). On average, 
99.73% mapped successfully and from these the duplicate reads were removed by 
Picard tools. The capture specificity was 56.4%, 52.9% and 57.5% for sample I-1, 
II-2 and III-4, respectively. The mean sequencing depth on target regions was 
140.30-fold. On average per sequencing individual, 99.50% of targeted bases 
were covered by at least 1X coverage and 97.70% of the targeted bases had at 
least 10X coverage. A total of about 47600 SNPs were identified per sample, 98% 
of which were present in dbSNP database. Moreover, about 5180 InDels were 
detected per sample, 270 of which, on average, alter the reading frame. 
Variants present in either dbSNP141, 1000 Genomes Browser, Exome Variant 
Server, YanHuang project and databases belonging to BGI or to the in-house 
Radboud University database with a MAF >1% were excluded. Potentially 
pathogenic variants were searched among all the rare variants shared by both the 
affected subjects (II-2 and II-4) but not present in the healthy parent (I-1). Among 
the remaining 559 variants, 185 were located in a coding or splice site region and 
131 were non-synonymous. Within the 13 known-disease genes, only a missense 
TTN variant (p.L32198M) has been identified. The variant is present in 4 affected 
subjects and in 2 family members with no clinical signs. 
Filtering for the stopgain and stoploss variants, a SNV in CMYA5 gene has been 
identified (c.10789 A>T, p.K3597*). It is reported in the SNP databases 
(rs185458523) with a MAF between 0.04% and 0.19%. This loss-of-function 
variant was found in all the affected family members, with exception of subject III-
3, and in two healthy family members (II-5 and II-6).  
Then, considering also the variants present in subject I-1, a rare missense variant 
has been found in MYBPC3 gene (p.L994F) in the three exome data. In ExAC 
database this variant has a MAF=0.02% and is classified as a variant with 
“uncertain significance” in ClinVar database and associated with a HCM 
phenotype. Three healthy family members other than the two affected reported the 
same SNV (Figure 4.12). 
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4.4 Multiple approach 
 
Family #6 
The proband (IV-9, Figure 4.13) was diagnosed affected fulfilling ACM Revised 
Task Force Criteria. He reported RV dysfunction with ventricular arrhythmias of 
LBBB morphology. ECG showed late potentials other than inverted T waves in V1-
V3. Clinical evaluation of 25 available family members was performed and 7 of 
them resulted affected. Mutation screening of the exons and intronic flanking 
regions of the 5 most common ACM mutated genes has been performed in the 
proband. Only an intronic variant located in exon 14 splice acceptor site of PKP2 
gene was identified (c.2578-3 T>C). Studying the segregation within the family, his 
father and his brother (subjects IV-10 and III-8) resulted positive for the same 
mutation (Figure 4.13). 
 
 
 
Figure 4.13. Pedigree of Family #6. Proband is pointed by the arrow. Black and white symbols 
represent clinically affected and unaffected individuals, respectively; grey symbols denote subjects 
not investigated (deceased individuals) or with minor signs of the disease. 
+ PKP2 c.2578-3T>C 
 
Considering that the PKP2 mutation is carried by an external individual of the 
family (III-8) and is not present in other affected subjects, the analysis went on with 
genotyping and linkage analysis. 
 
4.4.1 Linkage analysis 
Individual genotyping was performed in 33 affected and unaffected family 
members using a SNP array containing approximately 370,000 markers. 
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Parametric linkage analysis was performed assuming autosomal dominant 
inheritance and an ‘‘affected only’’ design, which reduces the influence of 
unaffected persons carrying the disease gene on linkage results. 
Two different linkage analyses have been performed, including or excluding the 
nucleus composed by individuals III-8, IV-9 and IV-10. In both cases, different 
marker spacing was considered, avoiding false LOD score values positives 
caused by number and set of selected SNPs. 
Excluding the three subjects with the PKP2 mutation, multipoint linkage analysis 
highlighted the presence of a candidate locus on chromosome 11q21 with a 
maximum parametric LOD score of 2.87 (Figure 4.14, Table 4.13). 
 
Marker  chr. position (cM) pLODscore 
rs1447352 11 92.72 1.322 
rs1613 11 92.87 2.415 
rs6483232 11 93.03 2.697 
rs921983 11 93.20 2.877 
rs4753485 11 93.37 2.878 
rs644009 11 93.55 2.879 
rs11020619 11 93.70 2.879 
rs4073612 11 93.86 2.879 
rs672392 11 94.03 2.879 
rs499952 11 94.18 2.879 
rs593690 11 94.33 2.879 
rs4144617 11 94.49 2.878 
rs7103994 11 94.64 2.877 
rs547243 11 94.83 2.874 
rs922020 11 95.00 2.869 
rs541821 11 95.16 2.859 
rs2155354 11 95.31 2.849 
rs1255182 11 95.47 2.839 
rs693830 11 95.62 2.817 
rs7951485 11 95.77 2.772 
rs569977 11 95.92 2.666 
rs2186760 11 96.09 2.509 
rs10501856 11 96.24 2.286 
rs4594032 11 96.46 0.422 
Figure 4.14 and Table 4.13. 
Plot and pLOD values obtained 
for markers mapped on 
chromosome 11q21, in Family 
#6. Distance between markers: 
0.15cM 
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Analysis of haplotype segregation on chromosome 11q21 showed a common 
region shared among all affected subjects (Figure 4.18). The critical region was 
delimited by crossovers in the affected individual IV-8 on the centromeric side (at 
93.03 cM) and on the telomeric side (at 96.47 cM), refining the critical interval to a 
3 cM region, between rs6483232 and rs4594032 markers (Figure 4.15). 
 
Figure 4.15. Partial haplotype segregation on chromosome 11q21 in subpedigree of Family #6. The 
at-risk haplotype, shared by all affected subjects, is shown in dark blue. Key recombination events 
occurred in subject IV-8 are pointed with the arrows.  
 
The pLODscore in this region resulted negative if subjects III-8, IV-9 and IV-10 
were included in the analysis, but from this second linkage analysis a new locus 
on chromosome 19p13.3 reported positive pLODscore values (Figure 4.16, Table 
4.14).  
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Marker  chr. position (cM) pLODscore 
rs2312724 19 0.27 2.198 
rs740871 19 0.46 2.199 
rs2283575 19 0.63 2.205 
rs7250902 19 0.82 2.210 
rs2240152 19 1.00 2.213 
rs11667680 19 1.15 2.215 
rs1558134 19 1.31 2.217 
rs166451 19 1.48 2.219 
rs2012125 19 1.63 2.221 
rs757528 19 1.79 2.221 
rs10500203 19 1.94 2.222 
rs12104154 19 2.10 2.222 
rs10407022 19 2.25 2.222 
rs7254110 19 2.41 2.222 
rs2907335 19 2.56 2.222 
rs6510698 19 2.72 2.222 
rs9304900 19 2.88 2.222 
rs10412849 19 3.03 2.224 
rs3786944 19 3.18 2.224 
rs7247434 19 3.33 2.225 
rs10126 19 3.50 2.225 
rs2270083 19 3.65 2.225 
rs2052059 19 3.80 2.225 
rs7255123 19 3.96 2.224 
rs350897 19 4.12 2.222 
rs4807567 19 4.28 2.222 
rs243372 19 4.44 2.222 
rs10423119 19 4.59 2.222 
rs7508325 19 4.75 2.231 
rs2779173 19 4.90 2.222 
rs858422 19 5.05 2.222 
rs7260484 19 5.21 2.234 
rs875552 19 5.36 2.239 
rs11878567 19 5.52 2.240 
 rs4643459 19 5.67 2.240 
rs3763045 19 5.83 2.238 
rs4807830 19 5.98 2.236 
rs10417646 19 6.13 2.234 
rs8182608 19 6.29 2.231 
rs173229 19 6.46 2.226 
rs344580 19 6.61 2.095 
rs7258236 19 6.76 1.869 
rs466876 19 6.92 1.522 
rs2967636 19 7.07 0.463 
rs4804404 19 7.22 0.351 
Figure 4.16 and Table 4.14. 
Plot and pLOD values 
obtained for markers 
mapped on chromosome 
19p13.3, in Family #6. 
Distance between markers: 
0.15cM. 
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Analysis of haplotype segregation indicated the presence of the critical region on 
chromosome 19p13.3 in all affected subjects but one (V-13; Figure 4.15). The 
critical region was delimited by a centromeric cross-over in subject IV-9, thus 
defining a region of about 7 cM, between marker rs2312724 and marker 
rs2967636 (Figure 4.17).  
 
Figure 4.17. Partial haplotype segregation on chromosome 19p13.3  in subpedigree of Family #6. 
The at-risk haplotype is shown in brown. Key recombination event occurred in subject IV-9 is 
pointed with the arrows.  
 
The segregations of both critical regions on chromosomes 11q21 and 19p13.3 are 
shown in Figure 4.18. 
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Figure 4.18. Pedigree of Family #6 and haplotypes segregation. 
The two critical regions co-segregated in 5 out of 8 affected subjects but no one of 
the healthy family members. Some individuals reporting minor signs of the disease 
carried one or both critical haplotypes (III-7, IV-11, V-10, V-11, IV-6, V-8, V-9, V-
12). 
 
4.4.2 Whole exome sequencing (WES) 
Considering the large number of genes mapped into the two critical regions, to 
identify the disease-genes in this family the whole exome of 4 affected subjects 
was sequenced (samples IV-5, IV-8, IV-9, IV-12) using the HiSeq2000 platform 
provided by Illumina. An average of 89 milion paired-end reads were generated, 
with a percent reads on target of about 70% and a mean coverage depth of 80X. 
The detected variants were filtered for the alignment quality, sequence quality 
score, and sequencing depth of the site, to get high-confidence variants. 
All the variants shared by the 4 patients were compared with those present in 
several SNP databases (dbSNP141, 1000 Genomes project, Exome Variant 
Server, HapMap eight exomes, YanHuang project) in order to discard common 
polymorphisms. The presence of any novel coding variant shared by the 4 patients 
was excluded. Among the 610 shared variants with a MAF≤ 0.01%, 395 mapped 
in a coding region or in a splice site, and 191 out of 395 were non-synonymous 
variants (missense, stop or frameshift). All of these filtered variants are present at 
least in one SNPs database, but no information about the frequency is available. 
None of these 191 SNVs is located into the critical regions or within a candidate 
 94 
 
ACM gene. Considering all the exomes individually, the presence of novel variants 
predicted to be pathogenic by SIFT or PolyPhen2 and/or variants affected highly 
conserved residues was excluded. 
To exclude the presence of a pathogenic mutation in all the ACM genes in the 4 
affected subjects, the evaluation of the real sequence coverage depth on 11 
known-disease genes (PKP2, DSP, DSG2, DSC2, JUP, TMEM43, PLN, LMNA, 
DES, CTNNA3 and TGFβ3) was performed by using Integrative Genomic Viewer 
(IGV) for all the 4 samples separately. A total of 22 exons (Table 4.15) reported a 
low coverage (<20X) were re-sequenced by the dideoxy-chain termination method. 
All the four affected family members resulted negative for coding mutations in the 
11 known-disease genes. 
gene uncovered exons (<20X) 
PKP2 ex 1, ex 6 
DSP ex 1, ex 12 
JUP ex 5, ex 6, ex 11 
DSC2 ex 1, ex 2 
DSG2 ex 1, ex 5, ex 10 
DES ex 1, ex 8 
TMEM43 ex 10, ex 12 
CTNNA3 ex 10, ex 11 
LMNA ex 1, ex 9, ex 2, ex 10 
Table 4.15. Exons of known-disease genes resulted not sufficiently covered by WES and re-
sequenced with Sanger method. Primers used are listed in Table 1, Appendix D. 
 
Only an intronic novel variant located near a splice donor site of TMEM43 gene 
(c.766+8C>A) has been identified in subjects IV-5, IV-9 and IV-12. Analyzing the 
segregation within the family, this variant is absent in two affected individuals (IV-8 
and V-13) and present in several family members without disease manifestations 
(IV-3, V-1, V-2, V-3, V-4, V-5). 
 
4.4.3 Whole genome sequencing (WGS) 
Whole genome sequencing (WGS) has been performed in two affected subjects 
(IV-10 and IV-12) and an healthy individual (IV-3) of Family#6 at Novogene 
Bioinformatics Technology Co. 
According to the Illumina platform sequencing feature, for paired-end data the 
average percentage of Q30 above 80% and error rate below 0.1% is required. 
Sequencing data quality is summarized in Table 4.16 . 
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sample Raw data(G) 
Raw 
depth(x) Effective(%) Error(%) Q30(%) 
IV-3 172.41 59.57 99.73 0.05 85.37 
IV-10 176.34 60.93 99.57 0.03 89.06 
IV-12 173.05 59.79 99.75 0.04 86.61 
Table 4.16. Overview of data production quality. Raw data= the original sequence data; Raw 
depth= mean coverage depth; Effective= the percentage of clean reads in all raw reads; Error rate= 
the average error rate of all bases; Q30= percentage of reads with average quality>30. 
 
On average the sequencing coverage depth was 55.48X, 58.07X and 57.53X with 
97.36%, 97.14% and 98.09% of bases with depth ≥20X for samples IV-3, IV-10 
and IV-12, respectively. 
Generally, the human whole genome has about 3.6M SNVs and 350K InDels 
(insertion and deletion, less than 50bp). Most (above 95%) SNVs with high 
frequency (MAF ≥5%) have records in dbSNP database. The main difference 
between WES and WGS is that no capture step is required in WGS and 
SNVs/InDels are detected in both the coding and non-coding part of the human 
genome (Table 4.17). 
 
Sample type exonic intronic 3'UTR 5'UTR intergenic Up 
stream 
Down 
stream splicing 
IV-3 
SNVs 20059 1106395 22287 4783 1842438 18977 19036 2346 
InDels 603 174569 4224 747 280099 3590 3503 368 
IV-10 
SNVs 20064 1111991 22187 4752 1837266 19237 19459 2351 
InDels 617 179349 4177 788 284743 3746 3602 370 
IV-12 
SNVs 20314 1123008 22690 4871 1861374 19335 19481 2364 
InDels 617 181361 4268 756 290046 3768 3618 379 
 
Sample type ncRNA_exonic ncRNA_intronic ncRNA_3'UTR ncRNA_5'UTR ncRNA 
_splicing 
IV-3 
SNVs 8237 125703 531 89 228 
InDels 934 19978 91 18 37 
IV-10 
SNVs 7960 125997 499 88 240 
InDels 919 20303 94 18 35 
IV-12 
SNVs 7998 123693 564 78 230 
InDels 912 20278 98 13 41 
Table 4.17. The number of SNVs and InDels in different genomic region. Upstream=  the number 
of SNV/InDel in the 1kb upstream region of transcription start site; downstream= the number of 
SNV/InDel in the 1kb downstream region of transcription ending site; ncRNA= non-coding RNA. 
 
The majority of SNVs detected for each sample were missense or synonymous 
variants, whereas the distribution of different InDels types was more equal, as 
shown in pie charts below (Figure 4.19). 
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Figure 4.19. The number of different SNV types in coding region (left) and the number of different 
InDel types (right) for sample IV-3.  
 
Moreover, structural variations (SVs) such as deletion, insertion, duplication, copy 
number variations, inversion and translocation of fragments between 1kb and 3Mb 
have been detected in each sample (Table 2, Appendix D). 
The annotation step performed by ANNOVAR, allowed to extrapolate the whole 
exomes from the genome data and to filter for the frequency of each variant 
reported in public databases.  
Considering the whole exome, among the variants shared only by the two affected 
subjects (IV-10 and IV-12) with a MAF ≤0.5%, 49 were located in conserved 
(phyloP>2.5) coding or splice site regions. The majority were classified as 
‘complex variants’ and affected repetitive genomic regions. 3 out of 49 SNVs had 
no records in dbSNP database. None of these variants localized in a known or 
candidate ACM genes. (Table 3, Appendix D). 
All the variants inside the critical region on chromosome 19p13.3 and shared by 
subjects IV-10 and IV-12 were then considered. 56 variants reporting a MAF 
≤0.5% were identified, all but one (located in a splice acceptor site of THEG gene) 
mapped in an intronic or UTR region (Table 4, Appendix D). Among the genes 
included in this list of variants, Protein Tyrosine Phosphatase Receptortype Sigma 
(PTPRS) appeared the most candidate gene because of its possible role in 
intercellular adhesion and its myocardial expression. Three variants located in 
3’UTR of this gene have been identified (rs116644020, rs200486129, 
rs139183127) other than a deeply intronic SNV. The phyloP score for all the 56 
variants is below 2.5, indicating that the genomic regions where the variants 
mapped, are not conserved among species. 
For both the analyses described above, the annotation was carried out using the 
in-house pipeline and databases of the Radboud University medical center 
(Nijmegen). 
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Taking into account that a positive pLODscore value is associated also to a 3 cM 
region on chr11q21, all the variants in this region identified in subject IV-12 were 
considered. Patient IV-10 was excluded because he did not carry the same 
haplotype at chromosome 11. All the variants shared by subjects IV-12 and IV-3 
were excluded as well. Among the 378 unique variants called for sample IV-12 
with a MAF ≤0.5%, 158 localized inside a gene (Table 5, Appendix D), but only 
one in an exonic region (MTMR2, rs146572467, MAF= 0.04%). The majority of 
these 158 variants mapped in introns and in repetitive genomic regions. 
To summarize, WGS allowed to identify on average about 22500 SNPs and 984 
InDels in exonic or splice site regions per sample. After filtering for sharing 
between samples IV-10 and IV-12, and exclusion with sample IV-3, a short list of 
putative variants was defined (Table 3, Appendix D). No potential causative 
mutations have been identified. Moreover all the variants inside both regions 
showing a positive LODscore value have been checked, even though no obvious 
candidate genes map in these regions. Most of the variants are complex and 
located in repetitive intronic or intragenic regions. Only one maps in the coding 
region of MTMR2 gene, encoding for a member of the myotubularin family proteins 
and located on chromosome 11q21. 
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5. DISCUSSION 
 
Arrhythmogenic cardiomyopathy (ACM) is an inherited myocardial disorder 
characterized by progressive cardiomyocyte death, followed by fatty or fibrofatty 
replacement (Thiene et al, 1988; Nava et al, 1988). It is mainly transmitted as an 
autosomal dominant trait, characterized by incomplete penetrance and variable 
expressivity. The most typical clinical presentation has two aspects: i. 
electrocardiographic abnormalities (ventricular tachycardia with LBBB, T-wave 
inversion in the V1 to V3); and ii. functional and structural abnormalities mostly of 
the right ventricle (RV) (Thiene et al., 1990). Even though left ventricle (LV) 
involvement was first described as a late consequence of the disease progression, 
today it is well-known that it could also appear as a first sign of the disease 
(Corrado et al, 1997). Beyond the classical form of ACM, a biventricular and a left 
dominant form are now considered as different patterns of the wide spectrum of 
ACM (Sen-Chowdhry et al., 2007). ACM is a devastating disease given the fact 
that the first symptom is often SCD, which makes early detection and a family 
screening test the cornerstone in the diagnostic evaluation. Familial occurrence is 
rather common; at least 15 independent loci and 13 disease genes have been 
associated with ACM thus far, with a large involvement of the desmosomal genes. 
Most ACM causing mutations have been identified in genes encoding for 
desmoplakin (DSP, Rampazzo et al., 2002), plakophilin-2 (PKP2, Gerull et al., 
2004), desmoglein-2 (DSG2, Pilichou et al., 2006), desmocollin-2 (DSC2, Syrris et 
al., 2006) and plakoglobin (JUP, Asimaki et al., 2007). Recently, a novel ACM 
gene has been identified encoding for α-T-catenin, a protein highly expressed in 
cardiac area composita, a mixed type junctional structure, composed of both 
desmosomal and adherens junction proteins (van Hengel et al., 2013). 
However, comprehensive mutation screening of all the 13 known ACM genes can 
detect causative mutations in ≈60% of probands (Groeneweg et al., 2015). Thus, 
in the remaining ≈40% of patients other genes are probably involved in the 
pathogenesis of the disease. 
 
5.1 Targeted genes panels 
The advent of next generation sequencing (NGS) technologies has revolutionized 
the field of medical genomics, enabling fast and cost-effective generation of 
genome-scale sequence data with exquisite resolution and accuracy. Rapid 
sequencing of the entire genome/exome of a patient removes the necessity to 
prioritize candidate genes for sequencing and therefore is largely applied for the 
identification of novel disease genes (Gilissen et al., 2012). For polygenic or 
multifactorial pathologies in which more genes are involved, such as inherited 
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cardiomyopathies, NGS approach is successfully used for genetic diagnosis and 
as a research tool to identify novel disease genes. 
In the present study, three different NGS strategies have been considered to 
identify the genetic cause in both familial and sporadic ACM cases.  
Two different Targeted gene panels have been used to screen a total of 59 index 
cases. The first panel, named ‘Cardiomyopathies gene panel’ comprises 56 genes 
frequently associated with different cardiomyopathies such as dilated and 
hypertrophic cardiomyopathies (DCM, HCM), long QT syndrome, Brugada 
syndrome, etc. Among the 19 probands analyzed, 10 were previously investigated 
for mutations in the ‘three big ACM genes’ (PKP2, DSP and DSG2) with Sanger 
sequencing (SS). These 10 subjects have been considered not only to complete 
the genotyping for all of the ACM genes included in the panel, but also to assess 
the specificity and sensibility of this approach. It allowed to identify 96% of the 
variants previously detected by SS: the 3 mutations, the rare variant and 22 out of 
23 polymorphisms. The undetected polymorphism is located in a region showing 
low coverage (4X). Overall, 95% of the novel variants (38 out of 40) identified by 
NGS was confirmed by SS. The 2 unconfirmed variants were expected to be false 
positives since they correspond to unbalanced substitutions. Considering only the 
mutations (MAF ≤0.01%), in 15 out of 19 subjects at least one mutation has been 
identified. Taken together, these results in addition to the high representation of 
coverage (mean depth of 200X), suggest that it is a valuable tool for mutation 
screening in patients affected with inherited cardiomyopathies. Indeed, as reported 
by different research groups, customized targeted gene panels have been 
considered the gold standard method for the molecular diagnosis in hereditary 
cardiomyopathies because they are faster and cheaper than whole 
exome/genome approaches, they allow focusing on the most relevant genes for a 
particular disorder and minimize the problems associated with unsolicited findings 
(Sikkema-Raddatz et al., 2013).  
By using the second panel, conventionally called ‘ACM known and candidate 
genes panel’, 44 samples were sequenced for a total of 69 genes, including the 13 
known-disease genes and 56 potentially candidate genes. These genes have 
been selected on the basis of their cellular localization (e.g. mechanical junctions 
components), their role in pathways suggested to be involved in ACM (e.g. Wnt/β-
catenin pathway, TGFβ3 pathway, Hippo pathway), or their interacting network. 
This cohort of patients was previously screened by dHPLC and SS and mutations 
in the three most important ACM genes were excluded. In the past several studies 
have estimated dHPLC sensitivity and specificity around 98% and 100%, 
respectively (Ellis et al., 2000; Bagattin et al., 2004), and Sanger sequencing is still 
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considered the gold standard for mutation screening. Despite this, in 4 patients 
probably pathogenic mutations in one of these three genes have been identified 
(DSP c.3799C>T p.R1267*, DSP c.1267-2A>G, PKP2 c.1063C>T p.R355*, DSG2 
c.1557C>A p.D519E).  
In the last 10 years, from the introduction of the first high-throughput sequencing 
methods, the accuracy of these NGS techniques had a rapid increase, which 
corresponded to a constant decrease of their costs. A recent work reported an 
analytical sensitivity and specificity >99.5% for the NGS techniques (targeted gene 
panels and WES) comparable to Sanger sequencing, thus suggesting a possible 
shift from SS to massive parallel sequencing for routine genetic testing (Diekstra et 
al., 2014). 
As observed in probands screened with the ‘Cardiomyopathies gene panel’, also 
in this cohort of ACM patients there are 6 subjects carrying one or more mutations 
in genes associated with other diseases (Table 4.9). Particularly, sample n° 4b 
carried a LMNA mutation (c.569G>A, p.Arg190Gln) previously reported in 
association with DCM (Perrot et al., 2009) and Emery-Dreifuss Muscular dystrophy 
(Cenni et al., 2005). The R190Q mutation is a semi-conservative amino acid 
substitution as these residues share similar properties, but differ in size, charge, or 
other properties which may impact the secondary structure. The R190 residue is 
conserved across species. Mutations involving the same residue (R190W) or the 
nearby residues (L183P, E186K, R189W, D192V, D192G, N195K) have been 
reported in association with DCM, further supporting the functional importance of 
this residue and region of the protein. It is not surprising that DCM and ACM 
patients result to carry different mutations in the same gene. Mutations in DSP, 
PKP2 and DSG2 genes, frequently involved in ACM, have also been identified in 
DCM patients (Elliott et al., 2010; Posch et al., 2008). In fact, even though DCM 
and ACM have been considered distinct clinicopathologic entities, both can be 
caused by mutations in desmosomal protein genes. 
Another patient (n° 15b) showed a missense variant in TNNC1 gene (c.435C>A, p. 
Asp145Glu), previously described in a patient with HCM and demonstrated to 
cause an increased calcium sensitivity of force recovery (Landstrom et al., 2008). 
Finally other mutations have been found in SCN5A, MYL2 and TPM1 genes 
commonly associated with Brugada syndrome (BrS), HCM and DCM phenotypes, 
respectively. In particular, a genetic overlap between BrS and ACM was recently 
confirmed by the group of Di Resta, which identified a significant enrichment of 
DSG2 rare variants in a cohort of BrS patients (Di Resta et al., 2015). Overall, in 
the last 20 years, several examples clearly demonstrated that mutations in the 
same gene can be associated with different phenotypes. A classical example of 
this situation is the involvement of troponin and tropomyosin mutations both in 
 102 
 
HCM and DCM. In vitro and in vivo functional studies demonstrated that mutations 
in these genes reduce Ca2+-sensitivity, maximum activation, and Ca2+ affinity in 
DCM patients, whereas they have an opposite effect in HCM, in which calcium 
sensitivity is enhanced and predicted to increase contractility (Robinson et al., 
2007; Lakdawala et al., 2010). 
In addition, some phenotypes may be the result of variable expression of the same 
mutation and in these cases we should consider that such distinct phenotypes 
may be part of the same disease rather than being two or several separate 
diseases (Monserrat et al., 2015). 
Several rare or low-frequency variants (0.01%≤ MAF ≤1%) in both ACM and 
candidate genes have been identified in our cohort of patients. The interpretation 
of these variants is still controversial, but interestingly some of these are present in 
more than one individual (Table 4.11), thus resulting in most cases in a MAF ten 
times higher than the MAF reported by common SNP databases. A possible 
pathogenic role or a modifier effect of these variants should be taken into account. 
A particular case is represented by the giant gene encoding for titin and the huge 
amount of variants identified in this gene. The importance of titin in 
cardiomyopathies has only recently emerged because routine analysis of the 
whole TTN gene by traditional sequencing methods was very difficult due its 
enormous size and complexity (Chauveau et al., 2014). TTN is now considered 
the most common disease gene in dilated cardiomyopathy, accounting for up to 
25% of patients (Herman et al., 2012), but it is also associated with an ACM form 
phenotype, characterized by greater risk for supraventricular arrhythmias and 
conduction disease (Brun et al., 2014).  
Considering both the panels, a total of 81 ‘private’ missense TTN variants (variants 
identified in only one sample of our cohort) have been detected. Among these, 62 
could be considered mutations since they are absent in all SNP databases or they 
have a MAF ≤0.01%. Overall, an average of 1.2 TTN missense mutations per 
patient have been detected. The frequency of TTN rare missense variants in the 
general population is far above the expected frequency of disease causing 
mutations, suggesting that some of these could be either benign or could act as 
modifiers in genetically susceptible hosts (Brun et al., 2014; Golbus et al., 2012). 
Accordingly, the interpretation of these variants in our cohort of patients remains 
difficult as well. 
The principal aim of the application of this targeted gene panel was to identify 
mutations in putative candidate genes for ACM in a selected cohort of patients. 
Our results demonstrated that at least one missense/non-sense mutation in a 
candidate gene was found in 40.6% of the index cases negative for mutations in 
known-disease genes. The most mutated genes resulted FAT1 (4 mutations: 
 103 
 
p.D919N, p.V2380I, p.A4541T, p.V2980L) and DCHS1 (4 mutations: p.P557S, 
p.I2268T, p.G87S, p.I1069K) both encoding for members of the cadherin 
superfamily. However, the majority of these missense mutations were predicted 
‘tolerated’ from prediction tools. Moreover many rare or low-frequency variants in 
these two genes were also found in our cohort of patients. Considering the RVIS 
(Residual Variation Intolerance Score) for these two genes, both are just below 
zero (-0.39 for FAT1 and -1.38 for DCHS1), indicating that these genes have less 
common functional genetic variation relative to the genome wide expectation given 
the amount of apparently neutral variation. Taking into account all these 
predictions and the high number of variants in these two genes found among the 
44 samples, it is difficult to assess a probable pathogenicity for these mutations. 
Interesting missense and non-sense variants have been found in genes encoding 
for protein ZO-1, N-cadherin, p63, and talin1 genes. 
 
5.2 Identification of novel mutations in TP63 and TLN1 genes 
In Family #1, the proband (n°8b) resulted negative for mutations in the 5 most 
mutated genes in ACM, but showed two novel mutations in candidates genes: a 
missense variant in TLN1 gene (c.3707A>G p.Q1236R) and a stop mutation in 
TP63 gene (c.796C>T p.R266*). Even though TP63 mutation was called by only 
one variant caller, both the variants were validated by Sanger sequencing. The 
lack of identification of this variant by VarScan variant caller is probably due to the 
unbalanced representation of the two alleles. This fact highlights the importance of 
the application of different tools in the variant calling process. c.3707A>G mutation 
is absent in all SNP databases and affects a gene that encodes for the 
cytoskeletal protein talin 1, a cytoplasmic protein concentrated in areas of cell-
substratum and cell-cell contacts. The mutation is predicted to be possibly 
damaging by PolyPhen2 tool but tolerated by SIFT tool. The N-terminus of this 
protein contains elements for localization to cell-extracellular matrix junctions, 
whereas the C-terminus contains binding sites for proteins such as beta-1-integrin, 
actin, and vinculin (Burridge and Mangeat, 1984; Ben-Yosef and Francomano, 
1999). The mutation causes an amino acid change at position 1236 (2541 total 
amino acids), which does not represent a functional protein domain. Given that the 
mutation is absent in the affected proband’s mother, it is very likely that it has a 
tolerated effect. 
On the contrary, TP63 heterozygous mutation is carried also by the mother (II-2), 
who fulfilled ACM Task Force criteria, thus suggesting its possible pathogenic role. 
This gene encodes for different isoforms of the protein; two different N-termini and 
multiple C-termini are generated by alternative splicing, with a wide expression 
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among human tissues, such as in heart, kidney, placenta, prostate, skeletal 
muscle, testis and thymus (Yang et al., 1998). The mutation is located in an exon 
included in all the transcripts and it causes the formation of a stop codon in all of 
them.  
TP63 (p63) belongs to the p53 family of transcription factors, together with p53 
and p73 and acts as a sequence specific DNA binding transcriptional activator or 
repressor (Yang et al., 1998; Aylon and Oren, 2011). One of the key effector in the 
p63 developmental program is Perp, a critical component of the desmosome 
which plays an essential role in promoting a stable assembly of cell-cell adhesion 
complexes (Ihrie et al., 2005). In a case report, Valenzise et al. described a patient 
with ectodermal dysplasia associated with ACM in which a novel missense 
mutation of p63 has been identified (p.R298Q) (Valenzise et al., 2008). 
Nevertheless, a link between ACM and p63 mutation reported in this study 
remains debatable since mutations in the other desmosomal genes were not 
excluded. Conversely, mutations in p63 genes are widely associated with 
ectodermal syndromes such as ectrodactyly, ectodermal dysplasia, and cleft 
lip/palate syndrome 3, split-hand/foot malformation 4, ADULT syndrome and 
others (van Bokhoven and McKeon, 2002). More recently, TP63 has been 
demonstrated to be also a key endodermal cardiogenic factor, that modulates the 
specification and/or the proliferation of cardiac progenitors (Paris et al., 2012). In 
vitro studies of p63-null embryos revealed a severe dilated cardiomyopathy with a 
pronounced disorganization of the myofibrillar apparatus in cardiomyocytes (Paris 
et al., 2012). A large proportion of embryonic lethality was also observed in p63 
KO mice, similarly to what was demonstrated for DSP-/- mice (Jonkman et al., 
2005). All these findings are not sufficient to link p.R266* mutation to ACM 
phenotype in Family #1, even though the nature of the mutation, the segregation 
within the family and the recent involvement of p63 in heart development support 
its potential pathogenic role. Identification of additional mutation(s) in TP63 gene 
by genetic screening of a large cohort of ACM patients, negative for mutations in 
the known-disease genes, could support the effective involvement of this gene in 
the genetic determination of the disease.  
 
5.3 Identification of novel mutations in TJP1 gene 
In Family #2, the proband, who resulted negative for mutations in the 5 most 
important ACM genes, was then analyzed by using a Targeted gene panel. The 
analysis highlighted the presence of a novel missense mutation in TJP1 gene 
(c.2006A>G, p.Tyr669Cys), which encodes for a tight junction protein (ZO-1). The 
segregation of the variant among the family members has been studied. The 
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mutation is carried by 5 individuals including the two sons of the dead proband’s 
brother (III-1, III-2) and two other proband’s brothers. Moreover, the mutation is 
carried by the mother (I-2), who showed minor signs of the disease, but reporting a 
family history for sudden cardiac death.  
Another missense substitution (p.Arg265Trp) in TJP1 gene has been identified in 
proband n° 37b, but in this case no family members were available. 
Both mutations affect highly conserved amino acid residues and are predicted to 
be deleterious by PolyPhen2, SIFT, and Mutation Taster prediction tools. All these 
findings together with the evidence that protein ZO-1 colocalizes with N-cadherin 
at the intercalated discs of cardiomyocytes (Barker et al., 2002), suggest that TJP1 
gene may be a good candidate disease gene. 
Protein ZO-1 is a member of the membrane-associated guanylate kinase 
(MAGUK) family of proteins that function in protein targeting, signal transduction, 
and determination of cell polarity (Anderson et al., 1996). It has been 
demonstrated the interaction between connexin43 (Cx43) and the second of three 
PDZ domain of ZO-1 in cardiac myocytes, and that ZO-1 regulates Cx43 plaque 
size (Toyofuku et al., 1998; Hunter et al., 2005). A key role in the localization and 
stabilization of adherens and gap junctions has also been ascribed to the 
cytoskeletal scaffold protein ZO-1 since it is a linker between the cadherin/catenin 
complex and gap junctions (Bruce et al., 2008; Palatinus et al., 2011). The two 
identified mutations are localized in different protein domains: Arg265 is located at 
the end of the second PDZ domain, whereas position 669 localizes inside the GUK 
domain. Due to its localization outside the PDZ2, mutation Arg265Trp may be 
apparently not relevant for the correct domain fold. Conversely, conservation 
analysis showed an accessory conserved extension beyond the canonical PDZ2 
domain boundaries, suggesting a functional role for this PDZ2 extension. PDZ C-
terminus flanking regions are known to frequently assume a regulative role in 
several PDZ containing proteins, such as improve domain stability and/or 
modulate the ligand binding specificity (Wang et al., 2010). The second mutation, 
p.Tyr669Cys, falls at the contact region between strands β2/β3, the two are 
members of a large five β-sheet, which forms the GUK hydrophobic core. For this 
domain a crystal structure is available. Molecular dynamics simulation revealed 
that the mutant protein is less stable than the wild-type. Moreover, GUK domain 
resulted to adopt a more opened conformation, closer to what observed for protein 
ZO-3 (Lye et al., 2010). Finally, the substitution of a tyrosine with a cysteine at 
position 669 causes a remarkable loss of hydrophobic interactions around the 
mutation area, promoting a clear structural rearrangement. All these predictions 
led to believe in a damaging effect of both mutations in the protein structure and 
function, thus causing a possible impairment and rearrangement of the gap 
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junctions at the intercalated discs. Laing and colleagues in 2007 demonstrated a 
significant reduction of ZO-1 at the IDs in failing hearts (patient with ischemic 
disease and dilated cardiomyopathy) coincident with reduced Cx43 staining in 
these hearts (Laing et al., 2007). The precise mechanism by which ZO-1 regulates 
gap junction formation is not completely clear, but different studies indicated that 
there is a link between the presence of adherence junctions and the formation of 
the gap junctions (Barker et al., 2002; Toyofuku et al., 1998). Subsequently, it can 
be speculated that loss of ZO-1 at IDs in heart failure may contribute to abnormal 
impulse propagation and arrhythmogenesis, thereby predisposing patients in heart 
failure to sudden cardiac death. 
 
5.4 Identification of novel mutations in CDH2 gene 
Two novel nucleotide substitutions (c.1478A>G p.E493G, c.1472T>G p.V491G) 
were identified in the same proband (n°40b) in the gene encoding for N-cadherin 
(CDH2). The mutations are very close and localized in exon 10 of CDH2 gene, 
which encodes for a portion of the extracellular protein domain, reported to 
determine the basic localization pattern together with E-cadherin in epithelial cells 
(Ozaki et al., 2010). 
N-cadherin is a cell adhesion molecule, which mediates strong homophilic cell-cell 
adhesion via linkage to the actin cytoskeleton. Different research groups 
demonstrated the importance of N-cadherin in cardiac myocyte adhesion and 
myofibrillogenesis. Luo and colleagues reported that N-cadherin-deficient 
myocytes beat and myofibrils were well formed, but alignment of the myofibrils 
through regions of cell-cell contact was lost, resulting in their random orientation 
(Luo et al., 2003). Furthermore, a strong relation and interaction between N-
cadherin and gap junction proteins, such as Cx43 was reported (Kostetskii et al., 
2005; Li J et al., 2005 and 2008; Swope et al., 2012). Consequently, perturbation 
of the N-cadherin/catenin complex in heart disease may be an underlying cause, 
leading to the establishment of the arrythmogenic substrate by destabilizing gap 
junctions at the cell surface. 
Since the proband resulted heterozygote for both mutations, two hypotheses must 
be considered. The mutations could be carried in cis, meaning that the patient has 
a wild-type allele and a double-mutated allele or in tras. In this latter case, the 
patient resulted to be a compound heterozygote, and this could better explain the 
manifestation of the disease in this subject and not in his parents. It is well-known 
that in some ACM cases, concomitant mutations in the same gene or in a second 
disease-gene are required for the overt clinical phenotype to develop or for 
modification of disease severity (Bauce et al., 2010). To discriminate between 
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these two hypotheses, clinical evaluation and genetic test in proband’s parents will 
be necessary. 
 
After the novel description of the intercalated disc (ID) organization, proposed by 
Franke and colleagues (Franke et al., 2006), ACM is today considered a ‘disease 
of the ‘area composita’ rather than a purely ‘desmosomal disease’, due to the 
recent involvement of αT-catenin mutations in the disease expression (van Hengel 
et al., 2013). In addition to the mechanical structures represented by area 
composita and desmosomes, IDs contain also gap junctions, fundamental 
structures in maintaining the electrical and chemical coupling between cells 
(Saffiz, 2005). Different evidences support the notion that gap junction formation 
requires the presence of neighbouring mechanical junctions, likely to provide 
stability for the docking and/or assembly of functional gap junction channels 
(Delmar and McKenna, 2010). The emerging picture is that ID is not a summation 
of independent structures, but rather an “organelle” where macromolecular 
complexes interact to maintain synchrony within cell populations (Delmar, 2004). 
In this scenario, novel mutations identified in protein ZO-1 and N-cadherin, two key 
proteins of the IDs functional unit, appear of particular interest.  
Further essential studies for demonstrating the involvement of these candidate 
genes in the disease are necessary and will come from functional in vitro studies. 
To provide meaningful mechanistic information of novel ACM gene mutations, their 
effects on protein localization and protein-protein interaction will be analyzed using 
different cell lines (HL-1 and HEK293T cells). 
 
5.5 Whole exome sequencing 
In some familial cases, in which traditional mutation screening failed to identify 
mutations in the 5 most mutated genes for ACM (DSP, PKP2, DSG2, DSC2 and 
JUP), the entire coding part of the genome was sequenced for at least two 
members of each family by using the whole exome sequencing (WES) approach. 
In Family #3, NGS technique allowed to identify a stop mutation in DSP gene 
(c.3889C>T p.Q1297*), which was not identified with the previous mutation 
screening. The variant is located in a very wide DSP exon (exon 23, 2294 bp) and 
the analysis by dHPLC was carried out fragmenting the exon in different 
amplicons. The failure of c.3889C>T mutation detection is probably due to the high 
denaturing temperature of the region where the variant is located. The mutation 
co-segregated with the disease phenotype in this family, even if the penetrance is 
incomplete. 
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WES analysis in Family #4 allowed to identify a missense variant in CDH11 
(NM_001797, c.1436 A>T, p.N479I) and another one in TTN gene (c.97717 C>T 
p.R32573C), shared by both affected subjects (II-4 and III-5). CDH11 variant is 
present in ExAC database with a MAF=0.005% and located in a conserved site 
(phyloP=3.24). This gene encodes a type II classical cadherin from the cadherin 
superfamily, integral membrane proteins that mediate calcium-dependent cell-cell 
adhesion. Other than in osteogenic, chondrogenic and adipogenic differentiation, 
CDH11 (OB-cadherin) together with CDH2 plays an important role in wound 
healing when fibroblasts turn into myofibroblasts to increase wound contraction 
and promote wound closure (Alimperti et al., 2015). CDH11, but not CDH2 is also 
necessary for mesenchymal stem cell differentiation into smooth muscle cell and 
mediates cell-cell contacts in both valvular fibroblasts and myofibroblasts 
(Alimperti et al., 2015, Wang et al., 2014). Despite the fact that CDH11 may be a 
good candidate gene in ACM, and the mutation p.N479I is predicted damaging by 
different tools, it is identified also in 6 healthy subjects of Family #4 discouraging 
its potential pathogenic effect. TTN missense variant is also very rare in the 
general population (dbSNP MAF= 0.02%, ExAC MAF=0.02%) and was found in 
other 3 family members with no clinical signs. Considering both the variants 
together with the rare variant in JUP gene (c.1942 G>A p.V648I) previously 
identified, only the two affected subjects (II-4 and III-5) and the obligate carrier (II-
5) present the combination of the three. Thus, we can speculate that none of the 
variants is pathogenic by itself, but the combination of the three could be involved 
in the genetic determination of the disease in this family. While in the past genetic 
screening through traditional methods forced researches to select a subset of 
most candidate genes, now with NGS technology, this process is no more 
necessary. Consequently, more and more frequently, multiple mutations in known 
and candidate disease genes are detected in each patient, and the difficulty to 
assess the pathogenicity to one of them increases. On the other hand, it is not 
surprising that many cardiomyopathy variants initially published as causative, turn 
out to be present at low frequency in large exome sequencing data sets and result 
false positive mutations (Norton et al., 2012). 
In Family #5, after the premature death of two young members (III-1, III-3) a 
genetic test was performed and revealed the presence of a RYR2 mutation 
(p.R420W) in subjects II-1, III-1, III-2 and III-3. In the genetic-negative affected 
mother (II-2), as well as in her affected brother (II-4) and in the healthy father (I-1), 
WES was performed. Also in this family a novel missense TTN variant (c.96592 
C>A, p.L32198M) co-segregated with the disease phenotype. Moreover, among 
the most putative variants identified, a stop-mutation in CMYA5 gene 
(NM_1536104, rs185458523, c.10789 A>T, p.K3597*) was selected. This variant 
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is reported in all considered SNP databases with a MAF that span from 0.04% to 
0.19%. This gene encodes for myospryn, a rather novel protein, found to interact 
with dysbindin, implicated in the molecular pathology of Duchenne muscular 
dystrophy (DMD) (Benson et al., 2004). Western and northern blot analysis 
detected myospryn both in skeletal and heart muscle. In the heart, it has been 
demonstrated that it is localized to intercalated discs and colocalized with desmin 
in a perinuclear punctate distribution (Kouloumenta et al., 2007). More precisely, 
the N-terminal domain of mouse desmin interacted with the C-terminal of human 
myospryn. The p. K3597* mutation detected in this family, causes a formation of a 
stop codon in exon 4 of the protein composed by 13 total exons, thus losing the C-
terminal domain. The C-terminal domain of myospryn was found to interact with 
the C-terminal domains of titin in human fetal and adult skeletal muscle other than 
with the muscle-specific protease calpain-3 (CAPN3) (Sarparanta et al., 2010). 
Despite the fact that c.10789 A>T myospryn variant has a frequency of about 0.1% 
in the general population, all these findings lead to speculate a possible reduction 
of the interactions between these proteins at the intercalated discs. In addition, the 
novel TTN mutation found in these patients could contribute to this probable 
rearrangement at the cellular junctions. To better understand the role of these 
mutations, a clinical re-evaluation of subjects II-5 and II-6 will be necessary and in 
vitro functional studies would be helpful in the characterization of their possible 
functional effects. 
Due to the reduced costs, the less amount of data obtained and the easier 
interpretation of the results, targeted NGS approaches remain the most common 
approaches for genetic diagnosis. Despite the large application of customized 
gene panels, WES allows to discover novel variants in unsuspected disease 
genes. It is in fact estimated that only 44.51% of pathogenic mutations are found in 
the exonic region of candidate genes compared to the theoretical 85% in the entire 
exome (Biswas et al., 2014). 
 
5.6 Multiple approach 
In the present study, a large family (Family #6) in which ACM segregated among 5 
generations has been considered and studied by using different genetic 
approaches. 
Traditional mutation screening of the 5 genes most frequently mutated in the 
proband (IV-9) revealed the presence of a novel mutation near exon 14 splice 
acceptor site of PKP2 (c.2578-3T>C). The same mutation is present also in the 
affected brother (IV-10), but carried by the father (III-8), who is an external family’s 
member. Considering that this mutation has not been previously described and is 
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located in a splice site of PKP2 gene, it could be considered a probable 
pathogenic mutation. 
Due to the high number of affected and unaffected subjects in this family, a 
multipoint linkage analysis has been carried out. Supposing that c.2578-3T>C 
PKP2 mutation may have a role in the phenotypic expression in subjects IV-9 and 
IV-10, the first linkage analysis was performed excluding this branch. The analysis 
highlighted the presence of a candidate locus on chromosome 11q21 with a 
maximum parametric LOD score of 2.87. Analysis of haplotype segregation 
showed a common region shared by all the affected subjects and delimited by 
crossovers in the affected individual IV-8, refining the critical interval to a 3 cM 
region. Extending the linkage analysis to the whole family, a new locus on 
chromosome 19p13.3 reported positive pLODscore values (2.22). Both the 
analyses have been carried out assuming an “affected-only’’ design, which 
classifies all individuals with no or minor clinical manifestations as “unknown’’, thus 
avoiding decrease of LOD score values due to low penetrance. Last analysis 
allowed to define a critical region of 7cM shared by all the affected subjects 
exception made for individual V-5. In both cases the pLOD score value is positive 
but lower than 3.0, the threshold of statistical significance for accepting linkage. 
According to the data obtained by the two linkage analyses performed in the 
family, two different hypotheses could be taken into account. The first analysis 
pointed out the identification of a novel locus on chromosome 11q21 shared by all 
the affected subjects, exception made for the two brothers sharing the same PKP2 
mutation, that could be involved in their phenotypic expression. The second 
analysis pointed out the identification of a novel locus on chromosome 19p13.3 
shared by all the affected subjects, but one. In this last subject, the clinical 
expression could be due to a mutation in a different locus or could be due to a 
different disease mimicking ACM.  
On the other hand, the two critical regions co-segregated in 5 out of 8 affected 
subjects but no one of the healthy family members (Figure 4.18). There were no 
evidences for a specific correlation between the presence of the critical haplotypes 
and the expression of the phenotype. Moreover, no candidate genes mapped 
inside these critical regions. 
As reported by different studies, traditional linkage analysis was combined to NGS 
approaches in order to increase the likelihood to discover the genetic cause of the 
disease expression in this family (Bailey-Wilson and Wilson, 2011; Ott et al., 
2015). The whole exomes of 4 affected subjects were sequenced (samples IV-5, 
IV-8, IV-9, IV-12), but no novel variants shared by all the 4 individuals have been 
found, neither inside both critical regions, nor in the entire exome. By now, it is 
well-known that one of the limits of WES approach is the lack coverage in a small 
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percentage (usually <5%) of the exonic regions, thus resulting in a loss of 
information (Gilissen et al., 2012; Rehm et al., 2013). Therefore, to guarantee the 
absence of coding mutations in one of the known-disease genes, the coverage in 
these genes was checked for the 4 samples and all the exons with a coverage 
<20X have been re-sequenced. 
Only an intronic novel variant located near a splice donor site of TMEM43 gene 
(c.766+8C>A) has been identified in subjects IV-5, IV-9 and IV-12. It is possible to 
exclude its potential pathogenic role due to the genotype-negative affected 
individuals IV-8 and V-13, other than for the presence of the variant in several 
family members without disease manifestations. 
With the rapid improvements in technology and decreasing costs, whole genome 
sequencing (WGS) has become a feasible and effective approach for mutation 
detection. The absence of the capture/enrichment step in the process allows to 
better analyze all the coding regions other than to identify possible non-coding 
variants. Moreover, WGS allows more reliable detection of structural variants and 
copy-number variations (Gilissen et al., 2014; Spielmann and Klopocki, 2013). 
Recently, it has also been demonstrated that WGS performed better than WES, 
providing a more even coverage, no strand bias, and a higher proportion of coding 
regions completely covered (Lelieveld et al., 2015). 
For all these reasons, WGS has been performed in two affected members (IV-10 
and IV-12) and an healthy individual (IV-3) of Family#6. Firstly, exome data was 
extrapolated from the genomes and, among the variants shared by the two 
affected individuals, all those present also in subject IV-3 were excluded. Only 
variants reporting a MAF ≤0.5% and located in a conserved (phyloP >2.5) coding 
or splice site regions have been considered as the most probable “causative” 
mutations. Different filters have also been applied to increase the probability to 
identify the causative mutation. None of these remaining variants was located in a 
putative candidate gene and the majority are classified as ‘complex variants’, 
represented by repetitive elements. In these subjects WGS didn’t detect any novel 
variant not previously identified with WES. Secondly, due to the presence of two 
linkage regions on chromosome 11 and chromosome 19, all the coding and non-
coding variants inside these regions were checked. In the 7 cM region on 
chromosome 19p13.3, 56 variants were selected for the frequency (MAF ≤0.5%), 
but all of them were located in unconserved genomic regions (phyloP <2.5). All the 
variants mapped in an intronic or UTR region, exception made for a single 
nucleotide substitution in a splice donor site of THEG gene, a gene specifically 
expressed in the nucleus of haploid male germ cells and then excluded to be 
associated with ACM. Among the mutated genes Protein Tyrosine Phosphatase 
Receptortype Sigma (PTPRS) appeared the most candidate gene because of its 
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possible role in intercellular adhesion and its myocardial expression. Three 
variants located in 3’UTR of this gene have been identified (rs116644020, 
rs200486129, rs139183127) other than an intronic SNV. Looking at the 
alignments, two of the UTR variants are close and located in a poly-A stretch, 
whereas the SNV is located between exon 1 and exon 2, in a site not predicted to 
be spliced. Actually, it is very difficult to assess a correlation between one of these 
variants and the expression of the disease. 
Finally, positive LODscore values were reported also in a 3cM region on 
chromosome 11q21, shared by all affected family members with exclusion of 
subjects IV-9 and IV-10. 378 variants with a MAF≤0.5% have been identified in 
subject IV-12, with the large representation of intergenic and deeply intronic 
variants. No putative pathogenic mutations have been identified also in this 
genomic critical region. 
Although WGS is considered the most comprehensive genetic test so far, it 
obviously has some limitations. The lack of the identification of the causative 
mutation in this family may be due to low sequencing coverage, bioinformatics 
variant calling issue or the misinterpretation of the variants. The huge amount of 
non-coding variants identified in both critical regions as well as into the entire 
genome remains of difficult interpretation since the knowledge of all protein-coding 
exons in the genome is still incomplete and the disease gene could be yet 
unknown or not annotated. Therefore, even though this data does not allow, at 
present, to perform a genotype-phenotype correlation, it should be considered 
‘permanent data’, that may be re-analysed in the future. 
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6. CONCLUSIONS 
 
Arrhythmogenic cardiomyopathy is an inherited cardiomyopathy commonly 
transmitted as an autosomal dominant trait, characterized by incomplete 
penetrance and variable expressivity. 
Due to its significant clinical and genetic heterogeneity, the diagnosis of ACM is 
challenging and requires a multifaceted approach to patient and families 
evaluation. Whilst, on the one hand, NGS technologies allows to parallel sequence 
a large amount of genes, on the other hand, several thousand of genetic variants 
are identified per patient. It appears evident that the crucial point is no more the 
identification of a possible causative mutation but the interpretation and validation 
of the huge amount of variants of uncertain clinical significance (VUS) that we 
found by using these approaches. As a patient affected with ACM or reporting 
minor signs of the disease requires life-long follow-up, NGS results need to be re-
evaluated in the future considering new insights and published data. 
This is especially true for wider NGS strategies, such as whole exome/genome 
sequencing. Therefore, customized targeted gene panels seem to be the gold 
standard method for the molecular diagnosis in hereditary cardiomyopathies. 
While this heterogeneous group of diseases is composed by clinical distinct 
entities, the genetic overlap between them appears increasingly more evident. 
In the present study, targeted gene panel approach pointed out two novel putative 
candidate genes: TJP1 and CDH2. Both genes encode for proteins localized at the 
cardiac intercalated disc, which was recently described as a macromolecular 
complex that acts to maintain synchrony and adhesion between cells. It is within 
this “organelle” that the desmosome resides and where most ACM-relevant 
mutations have been found. According to the literature, these findings suggest to 
consider the overall functional unit of the intercalated disc and its interacting 
proteins to understand the pathogenetic mechanism of ACM. 
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APPENDIX A 
Table 1. Genes included in the ‘Cardiomyopathies gene panel’ 
 Gene NM Refseq Related disease 
PLN NM_002667 DCM; HCM; ACM 
DES NM_001927 DCM; ACM 
LMNA NM_001282625 DCM; ACM; LVNC 
MYBPC3 NM_000256 DCM; HCM; LVNC 
MYH7 NM_000257 DCM; HCM; LVNC 
TNNT2 NM_001276345; NM_001001432; NM_001276347 DCM; HCM; LVNC 
TNNI3 NM_000363 DCM; HCM; LVNC 
TPM1 
NM_001018004; NM_001018006; 
NM_001018007; NM_001018020; NM_000366; 
NM_001018005;NM_001018008;NM_001018020 
DCM; HCM; LVNC 
TNNC1 NM_003280 DCM; HCM 
MYH6 NM_002471 DCM; HCM 
VCL NM_014000 DCM; HCM 
TAZ NM_000116 DCM; LVNC 
LDB3 NM_001171610; NM_001080116; NM_007078 DCM; HCM; LVNC 
SCN5A NM_198056; NM_001099404 DCM; BrS; LQTS; LVNC 
PSEN1 NM_000021 DCM 
PSEN2 NM_000447 DCM 
SGCD NM_000337 DCM 
ACTC1 NM_005159 DCM; HCM; LVNC 
ABCC9 NM_020297; NM_005691 DCM; BrS 
DMD NM_000109 DCM; LVNC 
ANKRD1 NM_014391 DCM 
NEXN NM_144573 DCM 
CSRP3 NM_003476 DCM; HCM 
TCAP NM_003673 DCM; HCM 
ACTN2 NM_001103;  NM_001278344 DCM; HCM 
PRKAG2 NM_016203 HCM 
MYOZ2 NM_016599 HCM 
MYL2 NM_000432 HCM 
MYL3 NM_000258 HCM 
CACNA2D1 NM_000722  SQTS; BrS 
LAMP2 NM_013995; NM_002294; NM_001122606 HCM; DCM 
CASQ2 NM_001232 CPVT 
PKP2 NM_004572 ACM; DCM; BrS 
DSP NM_004415 ACM; DCM; LVNC 
DSG2 NM_001943 ACM; DCM 
DSC2 NM_024422 ACM; DCM 
JUP NM_002230 ACM; DCM 
TGFB3 NM_003239 ACM 
CTNNA3 NM_013266 ACM 
TMEM43 NM_024334 ACM 
TTN NM_001267550 ACM ; DCM; HCM 
RYR2 NM_001035 CPVT; DCM; ACM 
KCNQ1 NM_000218; NM_181798 LQTS, SQTS 
KCNH2 NM_000238; NM_001204798 LQTS, SQTS 
CAV3 NM_033337 LQTS, DCM 
ANK2 NM_001127493; NM_001148 LQTS, CPVT 
KCNE1 NM_000219; NM_001270405; NM_001127668; NM_001127670 LQTS 
KCNE2 NM_172201 LQTS 
KCNJ2 NM_000891 LQTS, SQTS, CPVT 
CACNA1C NM_001167624; NM_001167625; NM_199460; NM_001129829 BrS, LQTS, SQTS, 
GPD1L NM_015141 BrS 
CACNB2 NM_201597; NM_001167945; NM_000724; NM_201590; NM_201590; NM_201570 BrS, SQTS 
SCN1B NM_001037; NM_199037 BrS 
KCNE3 NM_005472 BrS 
SCN3B NM_018400 BrS 
KCND3 NM_004980 BrS 
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Table 2. Genes included into ‘ACM known and candidate genes panel’ 
Gene NM Refseq 
PLN NM_002667 
DES NM_001927 
LMNA NM_001282625 
TAZ NM_000116 
SCN5A NM_198056; NM_001099404 
ACTC1 NM_005159 
ACTN2 NM_001103;  NM_001278344 
MYL2 NM_000432 
MYL3 NM_000258 
CASQ2 NM_001232 
PKP2 NM_004572 
DSP NM_004415 
DSG2 NM_001943 
DSC2 NM_024422 
JUP NM_002230 
TGFB3 NM_003239 
CTNNA3 NM_013266 
TMEM43 NM_024334 
TTN NM_001267550 
RYR2 NM_001035 
KCNE1 NM_000219; NM_001270405; NM_001127668; NM_001127670 
CDH2 NM_001792 
CTNNA1 NM_001903 
CTNNB1 NM_001904 
MYZAP NM_001018100 
CTNND1 NM_001206885; NM_001206886 
TJP1 NM_003257 
ARVCF NM_001670 
TJP2 NM_001170414; NM_001170630; NM_001170416; NM_001170415.1 
TP63 NM_003722; NM_001114982 
PERP NM_022121 
GJA1 NM_000165 
GJD4 NM_153368 
GJC1 NM_005497; NM_001080383 
JAM3 NM_032801 
XIRP1 NM_194293 
CASR NM_000388; NM_001178065 
CDH11 NM_001797 
LAMR1/RPSA NM_002295 
PTPLA NM_014241 
PNN NM_002687 
PKP4  NM_003628 
KCNJ11 NM_000525, NM_001166290 
PRKCA NM_002737 
NF2 NM_181825.2, NM_016418.5  
YAP1 NM_001195045.1, NM_001282101.1  
TEAD1 NM_021961.5  
FAT1 NM_005245 
DCHS1 NM_003737 
ATP2A2 NM_170665, NM_001681 
TLN1 NM_006289 
STRN NM_003162 
DLG1 NM_001290983; NM_001204387.1 ; NM_001204386.1 
MST1 NM_020998 
MST2/STK3 NM_001256312.1;  NM_006281.3   
EB1/MAPRE1 NM_012325 
AXIN1 NM_003502.3   
AXIN2 NM_004655 
GSK3B  NM_002093.3 
KAZN NM_201628.2, NM_001018000.3,  NM_001018001.2, NM_001017999.2     
HSPA2 NM_021979 
 133 
 
ANK3 NM_001149.3, NM_020987.3, NM_001204403.1, NM_001204404.1    
TNNC1 NM_003280 
GPD1L NM_015141 
TNNI3 NM_000363 
ABCC9 NM_020297; NM_005691 
VCL NM_014000 
TPM1 
NM_001018004; NM_001018006; NM_001018007; 
NM_001018020; NM_000366;  
NM_001018005; 
NM_001018008 
PSEN2 NM_000447 
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APPENDIX B 
 
 
 
 
Figure 1. Pedigree of Family #1. Proband is indicated by the arrow. Both subject III-1 and II-2 
present a clear ACM form reporting infundibular arrhythmias and late potentials (III-1) and fibrous 
substitution at RMN (II-2). DNA sample from subject II-3 is available, but not clinical data. 
 
 
 
 
Figure 2. Pedigree of Family #2. Proband is indicated by the arrow and present a moderate ACM 
form with initial biventricular involvement. Black and white symbols represent clinically affected and 
unaffected individuals, respectively. Deceased individual II-2 presented negative T waves at ECG 
and experienced 3 syncope before death. Grey symbols denote subjects with minor signs of the 
disease. Subject III-3 died at young age but cardiac involvement was excluded. 
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Figure 3. Pedigree of Family #3. Proband is indicated by the arrow and present a severe ACM 
form with sustained ventricular tachycardia and biventricular dilatation with kinetic abnormalities in 
both ventricles. Black symbols represent clinically affected individuals (II-4 and III-4) as having 
biventricular form of the disease. Grey symbols denote subjects with minor signs of the disease: 
RV conduction delay at ECG (III-3) and premature ventricular beats (II-9); or not investigated 
subjects(I-2). 
 
 
 
 
 
 
Figure 4. Pedigree of Family #4. Proband is indicated by the arrow and reported minor alterations 
at echocardiography and inverted T waves. Subject II-2, died suddenly aged 35 and was 
diagnosed affected with ACM at autopsy.  
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Figure 5. Pedigree of Family #5. Proband is indicated by the arrow and present a minor form of the 
disease. Black and white symbols represent clinically affected and unaffected individuals, 
respectively. Two sudden cardiac death at young age occurred (III-1, III-3). 
 
 
 
 
 
Figure 6. Pedigree of Family #6. Proband is indicated by the arrow. Black and white symbols 
represent clinically affected and unaffected individuals, respectively. Proband reported RV 
dysfunction with ventricular arrhythmias of LBBB morphology, late potentials and inverted T waves 
in V1-V3. Proband’s brother present a severe form of the disease as well. Grey symbols denote 
subjects with minor signs of the disease such as ECG alterations (IV-6, V-8) or hypokinesia (V-11, 
V-12); or not investigated subjects (III-2). 
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APPENDIX C 
 
Table 1. ‘Private’ TTN variants identified in 19 probands with the ‘Cardiomyopathies gene panel’ 
#proband variant frequences predictions 
             
1a 
rs199901448 c.37735G>A p.Ala12579Thr  Polyphen: benign           SIFT: tolerated 
c.21844G>A p.Glu7282Lys  
Polyphen: possibly 
damaging                  
SIFT: deleterious 
2a 
rs200166942 c.100400T>G p.Val33467Gly  Polyphen: p.damaging        SIFT: deleterious 
rs186624523 c.11788G>A p.Glu3930Lys  Polyphen: benign           SIFT: deleterious 
4a c.37583C>T p.Ala12528Val  Polyphen: benign           SIFT: tolerated 
5a rs376874956 c.33856G>A p.Glu11286Lys  Polyphen: p.damaging        SIFT: deleterious 
7a c.82021C>T p.Arg27341Trp  Polyphen: p.damaging        SIFT: deleterious 
8a 
c.84411G>T p.Lys28137Asn  Polyphen: benign           SIFT: deleterious 
rs71423569 c.56483A>C p.Asn18828Thr  
Polyphen: possibly 
damaging                  
SIFT: deleterious 
9a 
rs56173891 c.102751A>G p.Met34251Val  Polyphen: benign           SIFT: deleterious 
rs2857279 c.96409G>A p.Val32137Ile  
Polyphen: possibly 
damaging                  
SIFT: deleterious 
c.73261G>A p.Asp24421Asn  
Polyphen: possibly 
damaging                  
SIFT: deleterious 
rs372975579 c.68210C>T p.Ala22737Val  Polyphen: p.damaging        SIFT: deleterious 
rs77351975 c.60232G>A p.Val20078Met  Polyphen: p.damaging        SIFT: deleterious 
rs72677243 c.48953T>C p.Ile16318Thr  Polyphen: p.damaging        SIFT: deleterious 
10a rs150223722 c.38929C>T p.Pro12977Ser   
12a 
c.99833C>T p.Thr33278Ile  Polyphen: p.damaging        SIFT: deleterious 
c.63139G>A p.Gly21047Arg  Polyphen: p.damaging        SIFT: deleterious 
13a 
c.100460C>T p.Pro33487Leu   Polyphen: p.damaging        SIFT: deleterious 
rs182428755 c.34474C>A p.Pro11492Thr dbSNP:0.3%  
15a 
rs72650011 c.30274C>T p.His10092Tyr EVS:0.3% Polyphen: benign            SIFT: deleterious 
rs72647894 c.9359G>A p.Arg3120Gln EVS:0.3% Polyphen: p.damaging        SIFT: deleterious 
16a 
rs72646885 c.69676A>G p.Ser23226Gly dbSNP:0.2% EVS:0.7% Polyphen: p.damaging        SIFT: deleterious 
rs72677237 c.47723G>A p.Arg15908His dbSNP:0.2% EVS:0.7% Polyphen: p.damaging        SIFT: deleterious 
17a 
c.104564C>A p.Ser34855Tyr  Polyphen: p.damaging        SIFT: deleterious 
rs267599025 c.95806G>A p.Asp31936Asn  Polyphen: p.damaging        SIFT: deleterious 
c.66311A>T p.Lys22104Met  Polyphen: p.damaging        SIFT: deleterious 
rs139636676 c.4291C>T p.Arg1431Trp  Polyphen: p.damaging        SIFT: deleterious 
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#proband variant frequences predictions 
18a rs72650035 c.33059A>G p.Tyr11020Cys  Polyphen: benign            SIFT: deleterious 
19a 
c.68083G>A p.Ala22695Thr   
Polyphen: possibly 
damaging                  
SIFT: deleterious 
rs199954570 c.48751G>A p.Asp16251Asn   Polyphen: p.damaging        SIFT: deleterious 
rs72650031 c.32624C>T p.Pro10875Leu     
 
 
 
 
 
Table 2. Rare and low-frequency variants identified in our cohort of patients by using the ‘ACM 
known and candidate genes panel’. 
 
#proband gene variant frequences predictions class 
2b 
SCN5A rs45489199 c.6016C>G p.Pro2006Ala  
EVS:0.1%  
ExAC:0.1% 
Polyphen: benign 
SIFT: tolerated IIb 
FAT1 rs116784674 c.7700G>A p.R2567H 
dbSNP:0.5%  
EVS:1%  
ExAC:0.9% 
    
3b ANK3 rs61845768 c.10055A>G p.Glu3352Gly  
dbSNP:0.2%  
EVS:0.4%  
ExAC:0.4% 
    
5b 
STK3 rs187757501 c.203G>A p.Ser68Asn  
dbSNP:0.2%  
EVS:0.4%  
ExAC:0.3% 
  VIII/IV 
CTNNA3 rs190073606 c.779A>G p.Gln260Arg  
dbSNP:0.1%  
ExAC:0.1%     
8b ABCC9  rs61688134  
c.2200G>A p.V734I  
dbSNP:0.6%  
EVS:0.9% 
ExAC:0.7% 
  IIb/IV 
7b ANK3 rs148904927 c.7225T>C p.Ser2409Pro  
dbSNP:0.5%  
EVS:0.5%  
ExAC:0.5% 
    
9b 
ANK3 rs147527383 c.10688A>G p.Glu3563Gly  
dbSNP:0.2%  
EVS:0.2%  
ExAC:0.2% 
    
ANK3 rs140183285  c.9997A>T p.Thr3333Ser  
dbSNP:0.2%  
EVS:0.2%  
ExAC:0.2% 
    
SCN5A rs41311123 p.Gly1406Gly  
c.4218G>A 
EVS:1%  
ExAC:0.8%   IX 
10b 
SCN5A rs45489199 p.Pro2006Ala  
c.6016C>G 
EVS:0.1%  
ExAC:0.1% 
Polyphen: benign 
SIFT: tolerated IIb 
TJP1 rs2229517 c.1412A>G p.Asn471Ser  
dbSNP:0.7%  
EVS:1%  
ExAC:0.9% 
    
13b STK3 rs187757501 p.Ser68Asn  
c.203G>A 
dbSNP:0.2%  
EVS:0.4%  
ExAC:0.3% 
  VIII/IV 
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#proband gene variant frequences predictions class 
16b 
AXIN2 rs115931022  
c.1235A>G p.N412S 
dbSNP:0.3%  
EVS:0.5%  
ExAC:1%   
ANK3  rs61845768  
c.10055A>G p.E3352G  
dbSNP:0.2%  
EVS:0.4%  
ExAC:0.4%   
ABCC9  rs61688134  
c.2200G>A p.V734I  
dbSNP:0.6%  
EVS:0.9% 
ExAC:0.7%  
IIb/IV 
18b KAZN  rs146471978  
c.1406C>T p.Thr469Met  
EVS:0.2%  
ExAC:0.2%     
19b FAT1 rs56007012 c.3373A>C p.I1125L  
EVS:0.1%  
ExAC:0.1%   
20b PNN  rs145307846 c.1576G>A p.Glu526Lys  
EVS:0.4%  
ExAC:0.4%     
21b 
SCN5A rs45489199 c.6016C>G p.Pro2006Ala  
EVS:0.1%  
ExAC:0.1% 
Polyphen: benign 
SIFT: tolerated IIb 
TJP1 rs2229517  
c.1412A>G  p.Asn471Ser 
dbSNP:0.7%  
EVS:1%  
ExAC:0.9% 
    
ANK3 rs61845768   
c.10055A>G p.Glu3352Gly  
dbSNP:0.2%  
EVS:0.4%  
ExAC:0.4% 
    
22b XIRP1  rs145699338 c.1156G>A p.Glu386Lys  
dbSNP:0.1%  
EVS:0.5%  
ExAC:0.4% 
    
23b 
ANK3 rs61845768  
c.10055A>G p.Glu3352Gly  
dbSNP:0.2%  
EVS:0.4%  
ExAC:0.4% 
    
CTNND1 rs145191455   
c.155A>G p.Asn52Ser   
EVS:0.3%  
ExAC:0.3%     
ABCC9  rs61688134  
c.2200G>A p.Val734Ile  
dbSNP:0.6%  
EVS:0.9% 
ExAC:0.7% 
  IIb/IV 
24b ARVCF rs113625788  
c.448G>A p.D150N  
dbSNP:0.1%  
EVS:0.3%  
ExAC:0.3%   
26b(2a) 
ANK3 rs141939315 c.5558G>A p.R1853Q 
dbSNP:0.3%  
EVS:0.5%  
ExAC:0.5%   
FAT1  rs200633985 c.3503C>T p.S1168L  
EVS:0.4%  
ExAC:0.4%   
TJP2 rs28556975 c.2810T>C  p.L937P  
dbSNP:1%  
EVS:1%  
ExAC:0.3%   
28b 
CTNNA3 rs140913916 c.1453A>T p.Thr485Ser  
EVS:0.1%  
ExAC:0.1%     
XIRP1 rs61736135  
c.1741C>A p.Pro581Thr  
dbSNP:0.6%  
EVS:0.9%  
ExAC:0.7% 
    
29 
FAT1 rs373140687 c.10498T>A p.Ser3500Thr  ExAc:0.013%     
TMEM43 rs35028636 c.82C>T p.Arg28Trp  
dbSNP:0.5%  
EVS:0.7%  
ExAC:0.3% 
  III 
ARVCF rs199498113 c.1822C>T p.Arg608Cys  
EVS:0.1%  
ExAC:0.1%     
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#proband gene variant frequences predictions class 
30b SCN5A rs36210423 c.1715C>A p.A572D  
EVS:0.2%  
ExAC:0.4%    I/VIII 
31b 
PKP2 rs143004808 c.76G>A p.D26N  
dbSNP:0.3%  
EVS:0.5%  
ExAC:0.6%   
ATP2A2  rs140234740 c.3064A>G p.I1022V  
EVS:0.1%  
ExAC:0.1%   
KCNE1 rs1805128 c.253G>A p.D85N  EVS:0.9%  ExAC:0.9%   
XIRP1  rs61736135  
c.1741C>A p.P581T  
dbSNP:0.6%  
EVS:0.9%  
ExAC:0.7%   
34b PKP4 rs148019751 c.329A>G p.Gln110Arg ExAC:0.1%     
37b 
DSC2 
rs200056085 c. 
28647999_28648000ins2 
p.A897KfsX4 
dbSNP:0.6%  
EVS:1% 
ExAC:0.8%  
DCHS1 rs142972252  
c.1546G>A p.A516T  ExAC:0.1%   
AXIN1  rs367788267  
c.1868C>T p.S623L  ExAC:0.04% 
PolyPhen2: benign     
SIFT: tolerated  
39b DSC2 rs148185335 c.1787C>T p.Ala596Val  
EVS:0.1%  
ExAC:0.1%   IX 
40b XIRP1 rs146284335 c.5352G>A p.M1784I 
dbSNP:0.5%  
EVS:1%  
ExAC:0.7%   
41b PKP2 rs143004808 c.76G>A p.D26N  
dbSNP:0.3%  
EVS:0.5%  
ExAC:1.4% 
  I 
42b(16a) 
TMEM43 rs145619906 c.424G>A p.Glu142Lys  
dbSNP:0.1%  
EVS:0.1% 
Polyphen: p.damaging 
SIFT:deleterious III 
CTNND1 rs76817459 c.257A>G p.Asn86Ser  
EVS:0.1%  
ExAC:0.1%     
DCHS1 rs60443131 c.8672G>A p.Arg2891Gln  ExAC:0.02% 
Polyphen: benign 
SIFT:deleterious   
XIRP1 rs146284335 c.5352G>A p.Met1784Ile 
dbSNP:0.5%  
EVS:1%  
ExAC:0.7% 
    
FAT1 rs142805532 c.3749A>G p.Tyr1250Cys  
dbSNP:0.3%  
EVS:0.2%  
ExAC:0.2% 
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Table 3. ‘Private’ TTN variants identified in 44 probands with the ‘ACM known and candidate genes 
panel’. 
 
 
#proband variant frequences predictions 
1b c.27133A>G p.Thr9045Ala    SIFT: deleterious 
3b 
rs375198596 c.87367A>C 
p.Ser29123Arg    
Polyphen: p.damaging     
SIFT: deleterious 
rs56391938 
c.77216C>Gp.Ala25739Gly  
EVS:0.1%   
ExAC:0.1%  SIFT: deleterious 
c.33259C>G p.Pro11087Ala    SIFT: deleterious 
4b 
c.102841A>C p.Ile34281Leu    Polyphen: p.damaging     SIFT: deleterious 
rs376988498 c.74063G>A 
p.Arg24688His    
Polyphen: p.damaging     
SIFT: deleterious 
7b c.75053T>C p.Val25018Ala    Polyphen: p.damaging     SIFT: deleterious  
8b rs374093805 c.10457C>T p.Ala3486Val  
  
Polyphen: p.damaging     
SIFT: deleterious  
12b rs201738153 c.32557C>T p.Pro10853Ser  
  
SIFT: deleterious 
14b 
rs72648925 c.14870C>G 
p.Thr4957Ser  
EVS:0.3% 
ExAC:0.3% SIFT: deleterious 
rs397517756  
c.92782G>C p.Asp30928His   
Polyphen: p.damaging     
SIFT: deleterious  
rs72647868 c.3133G>A 
p.Val1045Met    SIFT: deleterious 
c.105787_105788delGCinsTT 
p.Ala35263Phe    
  
16b c.37735G>A p.Ala12579Thr      
17b c.87922T>C p.Tyr29308His Polyphen: p.damaging     SIFT: deleterious 
21b rs200118743 p.Gly6933Ala  
c.20798G>C 
EVS:0.1%  
ExAC:0.1%  SIFT: deleterious 
23b 
rs200697681 c.81892G>A 
p.Asp27298Asn    
Polyphen: p.damaging     
SIFT: deleterious  
rs201614524 p.Arg21635Cys  
c.64903C>T   
Polyphen: p.damaging     
SIFT: deleterious  
rs72648940 c.16546G>T 
p.Asp5516Tyr    
Polyphen: p.damaging     
SIFT: deleterious  
24b 
c.107657A>G p.Lys35886Arg    SIFT: deleterious 
c.65351A>G p.Asp21784Gly    Polyphen: p.damaging     SIFT: deleterious  
c.7613G>A p.Gly2538Asp    Polyphen: p.damaging     SIFT: deleterious  
25b 
rs55945684 c.103688T>C 
p.Val34563Ala  
 EVS:0.1%  
ExAC:0.1%  SIFT: deleterious 
rs372787601 c.74305A>G 
p.Asn24769Asp    SIFT: deleterious 
26b 
 rs200166942 c.100400T>G 
p.Val33467Gly    
Polyphen: p.damaging     
SIFT: deleterious  
rs186624523  
c.11788G>A p.Glu3930Lys  dbSNP:0.2% SIFT: deleterious 
27b rs72646808 c.53096G>A p.Arg17699His  
EVS:0.2% 
ExAC:0.2% 
Polyphen: p.damaging     
SIFT: deleterious  
28b c.75127G>C p.Val25043Leu    Polyphen: p.damaging     SIFT: deleterious  
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#proband variant frequences predictions 
29b 
c.3241G>T p.Ala1081Ser    Polyphen: p.damaging     SIFT: deleterious  
c.4076A>G p.Glu1359Gly    Polyphen: p.damaging     SIFT: deleterious  
c.94079A>G p.Asn31360Ser    Polyphen: p.damaging     SIFT: deleterious  
rs181189778  
c.43690T>A p.Ser14564Thr  dbSNP:0.1%  
Polyphen: p.damaging     
SIFT: deleterious  
31b c.68642G>A p.Arg22881Gln    SIFT: deleterious 
32b rs72648923 c.14698G>A p.Ala4900Thr  
EVS:0.2%  
ExAC:0.3% 
Polyphen: p.damaging     
SIFT: deleterious  
33b 
 rs199761901  
c.98500G>A p.Glu32834Lys    
Polyphen: p.damaging     
SIFT: deleterious  
c.60197C>T p.Pro20066Leu    Polyphen: p.damaging     SIFT: deleterious  
35b rs368607833 c.36391C>T p.Arg12131Cys    SIFT: deleterious 
36b 
rs72648273  
c.98294C>G p.Ala32765Gly  
EVS:0.3% 
ExAC:0.3% 
Polyphen: p.damaging     
SIFT: deleterious  
rs199895260  
c.61922G>A p.Arg20641Gln  
EVS:0.3% 
ExAC:0.3% 
Polyphen: p.damaging     
SIFT: deleterious  
39b 
 rs201043950  
c.69821G>A p.Gly23274Asp  
EVS:0.2% 
ExAC:0.1%  
Polyphen: p.damaging     
SIFT: deleterious  
 c.4102A>C p.Asn1368His   Polyphen: p.damaging     SIFT: deleterious  
40b 
rs149001703 c.98390A>G 
p.Asn32797Ser  
dbSNP:0.6%  
EVS:0.6% 
ExAC:0.4% 
SIFT: deleterious 
c.72254C>A p.Thr24085Asn    Polyphen: p.damaging     SIFT: deleterious  
41b 
rs55866005  
c.104560G>C p.Val34854Leu  
dbSNP:0.4%  
EVS:0.6% 
ExAC:0.5% 
SIFT: deleterious 
rs55886356  
c.101766G>C p.Gln33922His  
dbSNP:0.6%  
EVS:0.8%  
ExAC:0.7% 
Polyphen: p.damaging     
SIFT: deleterious  
c.21166G>T p.Val7056Leu      
44b 
c.104564C>A p.Ser34855Tyr    Polyphen: p.damaging     SIFT: deleterious  
rs267599025   
c.95806G>A p.Asp31936Asn   
Polyphen: p.damaging     
SIFT: deleterious  
 rs139636676   
c.4291C>T p.Arg1431Trp   
Polyphen: p.damaging     
SIFT: deleterious  
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APPENDIX D 
 
Table 1. Primers used to resequence the uncovered exons of the 11 know-disease genes in the 4 
affected individuals of Family#6. 
gene exon primer forward primer reverse 
PKP2 
1 ACTCGAGCGGGGCGGGGCTCG ACTCCCAGCACGCGGGGTGAG 
6 TTCAGGGGAGGTGATGTTTG GGATTACAGGCGCAGACC 
DSP 
1 GGTAGCGAGCAGCGACCTC AAAACCTTTCCACCTTCGGG 
12 TCAGCTTCATTTGAGGGGAAA GGCAAGGCATCGTGTGTCTA 
JUP 
5 ATATTTCCAGAGGGGCGTCA CCAAGGCTGTGCAGGATAGA 
6 GAACTATTCGTGCTTTAGCTG AGATTTAGAGCCCCCAGTCC 
11 ATTGCTACAGGGTGGAGGTG AGGAGACCCCCAAAAGTGTT 
DSC2 
1 TCAGACCTCGCTCTGTAATTGA TATCCCCGTTCCCCTAGTTT 
2 TTGTCCTGATTTCTTTCTCCAA CTCCATCCACATCCCTTCC 
DSG2 
1 CCAGGGAGGAGCCGAGTG GATTTTCCGAAGCCCCAGGT 
5 TCTTGATCGAGAAGAAACACCA AAGCAATGGCATGTAAAGTCC 
10 AGAGGTTTCCAATTCATGCAG CTTGACCTCGTGATCCACCT 
DES 
1a GGGGGCTGATGTCAGGAG GTAGTTGGCGAAGCGGTCAT 
1b TCTAAGGGCTCCTCCAGCTC AGGCCTAGCCTCCTGTGC 
8 CTTGGTCAGGCTGAGTGTGC CACAGCTGGGTGGAAGACAG 
TMEM43 
10 TGGAGCTTTGAATGGAGCA CTGGCTATGACCCCTGGTAG 
12 GATCTGCTGAGCTGGTGAGG AAAATTGACCGGGGCTCCTG 
CTNNA3 
10 TTTTGTTTTTCCAGTCTCACAA  AGGAAGCAGAAGTTGCAGTC 
11 TTCCTATTGTCGATGATGAAT  ACCATGCCTGTCCCAGTATT 
LMNA 
1  CCGAGCAGTCTCTGTCCTTC GCCCTCTCACTCCCTTCCT 
2 CAAACCAACCTAATGCAAGGA AGGACAGGTGAATGGCTCTG 
9 ATGGAGATGATCCCTTGCTG ATTGGCAAACTTGGGTTGG 
10 CCATCACCACAGAGGACAGA CCAGCGAGTAAAGTTCCAAAA 
Table 2. Number of structural variants (SVs) identified by WGS. 
sample varType total cds splicing utr5 utr3 intron Up 
stream 
Down 
stream 
Nc 
RNA intergenic 
IV-12 
Inversion 199 67 0 0 0 35 2 0 13 82 
Transl. 476 10 0 1 13 133 2 2 28 287 
Deletion 3372 76 2 2 9 1109 23 26 108 2017 
Insertion 373 4 0 3 3 139 4 5 13 202 
IV-10 
Inversion 185 50 0 2 0 38 2 0 11 82 
Transl. 459 4 0 1 13 128 4 3 30 276 
Deletion 2960 66 2 1 9 974 14 25 117 1752 
Insertion 587 8 0 2 2 222 2 7 22 322 
IV-3 
Deletion 3135 70 3 2 10 1006 19 29 111 1885 
Inversion 185 41 0 0 1 43 1 0 12 87 
Transl. 424 8 0 1 9 136 1 0 23 246 
Insertion 538 2 2 3 1 190 3 9 19 309 
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Table 3. Variants identified in the exomes extracted from the genomes and shared by subjects IV-
10 and IV-12 with a MAF ≤0.5% and phyloP>2.5. 
Chr. Start position 
Variant 
type Variant/SNP ID SNP Freq Gene name 
Gene 
component phyloP 
16 71956511 cx rs112755068 -1 IST1 EXON 5,23 
5 74021846 cx rs76339998 -1 GFM2 EXON 4,774 
4 88231392 cx rs72613567 -1 HSD17B13 SD_SITE 3,087 
12 103352171 cx rs71438488 -1 ASCL1 EXON 4,413 
16 18908104 cx rs35487751 -1 SMG1 SD_SITE 3,651 
7 286468 cx rs139364156 -1 FAM20C EXON 5,264 
2 3749151 cx rs201406139 -1 ALLC EXON 3,267 
1 240255568 cx rs71168893 -1 FMN2 EXON 3,895 
6 170871046 cx rs113440919 -1 TBP EXON 4,325 
1 248059779 cx rs80255919 -1 OR2W3 EXON 4,525 
11 55861277 cx rs138372442 -1 OR8I2 EXON 4,436 
12 974308 cx rs72649808 -1 WNK1 EXON 5,681 
5 60628153 cx rs374788320 -1 ZSWIM6 EXON 3,331 
7 15725797 cx rs138679259 -1 MEOX2 EXON 5,18 
8 96047806 cx rs34960210 -1 NDUFAF6 SD_SITE 4,421 
11 48285981 cx rs76457745 -1 OR4X1 EXON 3,063 
14 105996049 cx rs5811180 -1 TMEM121 EXON 3,885 
1 185108542 sb  A>T -1 TRMT1L EXON 5,025 
2 20867122 cx rs71839776 -1 GDF7 EXON 2,974 
17 67190536 cx rs147311261 -1 ABCA10 EXON 3,595 
11 56344843 cx rs148438199 -1 OR5M10 EXON 5,183 
1 154842199 cx rs56352724 -1 KCNN3 EXON 5,12 
19 1621907 cx   -1 TCF3 EXON 2,971 
3 42251577 cx rs10546421 -1 TRAK1 EXON 3,996 
1 170135646 sb C>T rs183687510 0,1377 METTL11B EXON 2,698 
21 34860749 cx rs71804651 -1 DNAJC28 EXON 5,229 
12 7045891 cx rs142596770 -1 ATN1 EXON 4,281 
8 145617534 cx rs148509143 -1 ADCK5 EXON 3,897 
1 44125962 cx rs74416524 -1 KDM4A SA_SITE 4,637 
19 41173892 cx rs72024235 -1 NUMBL EXON 2,605 
2 85360828 cx   -1 TCF7L1 EXON 3,609 
12 51723598 cx rs75442020 -1 CELA1 EXON 5,839 
14 77493761 cx rs78762909 -1 IRF2BPL EXON 3,703 
17 67145190 cx rs77569683 -1 ABCA10 EXON 4,529 
6 16327915 cx rs199744696 -1 ATXN1 EXON 4,398 
7 149518532 cx rs11353848 -1 SSPO EXON 4,74 
7 149503916 cx rs66470151 -1 SSPO EXON 3,928 
3 63898360 cx rs34631248 -1 ATXN7 EXON 4,152 
3 49395673 cx rs2836258862 -1 GPX1 EXON 3,027 
11 73020375 cx rs10682858 -1 ARHGEF17 EXON 4,183 
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Chr. Start position 
Variant 
type Variant/SNP ID SNP Freq Gene name 
Gene 
component phyloP 
22 37465385 cx rs368080841 -1 TMPRSS6 SA_SITE 5,306 
22 38482352 cx rs113792005 -1 BAIAP2L2 EXON 4,074 
1 109792735 cx rs144034706 -1 CELSR2 EXON 2,566 
3 8671319 cx rs6147701 -1 SSUH2 EXON 2,794 
12 53184619 cx rs140653778 -1 KRT3 SD_SITE 3,356 
11 124750447 cx rs71859853 -1 ROBO3 EXON 3,539 
11 130298117 cx rs55808430 -1 ADAMTS8 EXON 2,903 
12 89866054 cx rs191378952 -1 POC1B SA_SITE 5,119 
1 226924875 cx rs200752967 -1 ITPKB EXON 3,815 
For complex variants only one dbSNP record (rs#) is listed in the table. In bold type are the 3 
variants without a correspondence in dbSNP database. Sb=substitution; cx=complex. 
 
Table 4. Variants identified inside the critical region of chr19p13.3 shared by subject IV-10 and IV-
12 with a MAF ≤0.5%. 
Chr. Start position Ref. Variant Var. type SNP ID 
SNP 
Freq. Gene name 
Gene 
component phyloP 
19 1414297 G A sb   -1 DAZAP1 INTRON 0,187 
19 5051840 C A sb rs2620815 -1 KDM4B INTRON -3,772 
19 632004 A T sb   -1 POLRMT INTRON 0,08 
19 4996450 A G sb   -1 KDM4B INTRON 0,366 
19 5206273 T A sb rs116644020 -1 PTPRS UTR -0,669 
19 2942172 C T sb rs77664718 -1 ZNF77 INTRON 0,178 
19 3635708 T C sb   -1 PIP5K1C INTRON 0,121 
19 615247 C T sb rs62132645 -1 HCN2 INTRON -0,408 
19 1075035 A C sb rs3214170 -1 HMHA1 INTRON -0,782 
19 5206276 A G sb rs200486129 -1 PTPRS UTR -0,08 
19 5469849 G C sb   -1     0,543 
19 4372207 G C sb   -1 SH3GL1 INTRON 0,646 
19 1295883 C A sb rs201782617 0,04591 EFNA2 INTRON 0,219 
19 3152391 C A sb   -1 GNA15 INTRON -0,06 
19 1930489 A T sb rs76335243 -1     -1,284 
19 5319616 C A sb   -1 PTPRS INTRON -0,363 
19 2938682 C T sb   -1 ZNF77 INTRON 0,122 
19 4729069 A G sb   -1     0,159 
19 1295921 G T sb   -1 EFNA2 INTRON 0,546 
19 3928004 C T sb   -1 ATCAY UTR -0,632 
19 1593292 G T sb   -1     0,17 
19 2960913 G A sb   -1     -100 
19 5469404 C A sb rs185545586 0,1837     0,317 
19 2411841 G T sb rs12609648 -1 TMPRSS9 INTRON -3,734 
19 2411841 G C sb rs12609648 -1 TMPRSS9 INTRON -3,734 
19 5698541 G T sb rs117261656 -1 LONP1 INTRON 0,642 
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Chr. Start position Ref. Variant Var. type SNP ID 
SNP 
Freq. Gene name 
Gene 
component phyloP 
19 604988 G T sb rs113541645 -1 HCN2 INTRON 0,222 
19 2580141 C A sb rs4335872 -1 GNG7 INTRON 0,444 
19 5786073 C T sb rs190862396 0,04591 DUS3L INTRON -0,238 
19 6329458 G A sb   -1 ACER1 INTRON -0,409 
19 4705100 C G sb   -1 DPP9 INTRON -0,111 
19 4836610 A C sb rs80320354 0,04591     -0,433 
19 6241686 T G sb   -1 MLLT1 INTRON 1,155 
19 5658862 A G sb   -1 SAFB INTRON 0,1 
19 1085608 T C sb rs139132266 0,04591 HMHA1 INTRON -1,089 
19 1216565 G A sb   -1 STK11 INTRON 0,21 
19 4835884 G A sb   -1     -1,233 
19 4745422 C T sb   -1     0,189 
19 6172483 G C sb   -1 ACSBG2 INTRON 0,135 
19 1980376 G A sb rs377669285 -1 CSNK1G2 UTR 0,512 
19 4548013 A G sb rs200320836 0,3673 SEMA6B INTRON 0,097 
19 375655 G A sb   -1 THEG SD_SITE -2,7 
19 1792210 C T sb rs117609099 -1 ATP8B3 INTRON -2,71 
19 387281 T C sb   -1     -100 
19 5206274 G T sb rs139183127 -1 PTPRS UTR -0,721 
19 2210328 C T sb   -1 DOT1L INTRON -0,803 
19 946630 G A sb   -1 ARID3A INTRON 0,2 
19 3081764 G T sb   -1     0,317 
19 3930761 G A sb   -1     -0,611 
19 3131446 C A sb rs10164384 -1     -1,659 
19 1930487 A T sb rs60152900 -1     0,162 
19 4374743 G A sb   -1 SH3GL1 INTRON -0,164 
19 4521456 G A sb rs189471903 0,3673     -0,805 
19 689146 T C sb rs12978248 -1 PRSS57 INTRON -1,48 
19 493369 G C sb   -1     0,164 
19 5759325 T A sb rs190201024 0,04591 CATSPERD INTRON 0,068 
Sb= substitution. In bold type are the variants identified in PTPRS gene. 
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Table 5. Variants identified inside the critical region on chr11q21 in subject IV-12 with a MAF 
≤0.5% 
Chr. Start position   Variant type Variant/SNP ID Gene name Gene component 
11 93112917 cx 
 
CCDC67 intronic 
11 93118413 cx 
 
CCDC67 intronic 
11 93122711 cx rs140335781 CCDC67 intronic 
11 93125844 cx 
 
CCDC67 intronic 
11 93126086 cx 
 
CCDC67 intronic 
11 93133579 cx 
 
CCDC67 intronic 
11 93139645 cx 
 
CCDC67 intronic 
11 93151510 sb A>C rs374560834 CCDC67 intronic 
11 93164261 cx 
 
CCDC67 intronic 
11 93170909 cx 
 
CCDC67 UTR3 
11 93211879 cx 
 
SMCO4 UTR3 
11 93211879 cx 
 
SMCO4 UTR3 
11 93266015 cx rs71978895 SMCO4 intronic 
11 93267379 cx 
 
SMCO4 intronic 
11 93267535 cx 
 
SMCO4 intronic 
11 93267537 cx 
 
SMCO4 intronic 
11 93272455 sb G>C rs72966968 SMCO4 intronic 
11 93275070 sb A>G rs72966970 SMCO4 intronic 
11 93401618 cx 
 
CEP295 intronic 
11 93402580 cx 
 
CEP295 intronic 
11 93410461 sb G>A CEP295 intronic 
11 93418866 cx 
 
CEP295 intronic 
11 93446022 cx rs56969423 CEP295 intronic 
11 93446022 cx 
 
CEP295 intronic 
11 93447068 sb G>A CEP295 intronic 
11 93454831 cx rs71064775 SCARNA9 ncRNA_exonic 
11 93482001 cx 
 
C11orf54 intronic 
11 93483802 sb G>A C11orf54 intronic 
11 93486498 cx 
 
C11orf54 intronic 
11 93486526 cx 
 
C11orf54 intronic 
11 93493679 cx 
 
C11orf54 intronic 
11 93557080 cx 
 
VSTM5 intronic 
11 93570177 cx 
 
VSTM5 intronic 
11 93576624 cx rs59069636 VSTM5 intronic 
11 93764497 cx 
 
HEPHL1 intronic 
11 93782784 cx 
 
HEPHL1 intronic 
11 93782784 cx 
 
HEPHL1 intronic 
11 93789822 cx 
 
HEPHL1 intronic 
11 93789822 cx 
 
HEPHL1 intronic 
11 93789823 cx 
 
HEPHL1 intronic 
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11 93793258 cx 
 
HEPHL1 intronic 
11 93817502 cx 
 
HEPHL1 intronic 
11 93826266 cx 
 
HEPHL1 intronic 
11 93826266 cx 
 
HEPHL1 intronic 
11 93827137 cx 
 
HEPHL1 intronic 
11 93831127 cx 
 
HEPHL1 intronic 
11 93862252 cx 
 
PANX1 UTR5 
11 93875290 sb G>A PANX1 intronic 
11 94112137 cx 
 
GPR83 UTR3 
11 94114724 cx rs56180709 GPR83 intronic 
11 94114724 cx 
 
GPR83 intronic 
11 94152631 cx 
 
MRE11A UTR3 
11 94184604 sb C>T MRE11A intronic 
11 94191053 cx rs59279005 MRE11A intronic 
11 94218676 cx rs71459730 MRE11A intronic 
11 94218791 sb G>T MRE11A intronic 
11 94246110 cx 
 
C11orf97 intronic 
11 94247416 cx rs373026301 C11orf97 intronic 
11 94248857 sb C>T C11orf97 intronic 
11 94249794 cx 
 
C11orf97 intronic 
11 94250020 sb G>T rs676521 C11orf97 intronic 
11 94251022 cx 
 
C11orf97 intronic 
11 94252608 cx rs61528058 C11orf97 intronic 
11 94264603 cx 
 
C11orf97 intronic 
11 94264603 cx 
 
C11orf97 intronic 
11 94279080 sb T>A FUT4 UTR3 
11 94305383 sb A>C PIWIL4 intronic 
11 94307722 cx 
 
PIWIL4 intronic 
11 94313801 cx 
 
PIWIL4 intronic 
11 94316198 cx 
 
PIWIL4 intronic 
11 94316210 cx rs58072951 PIWIL4 intronic 
11 94316342 cx 
 
PIWIL4 intronic 
11 94334520 cx rs372273598 PIWIL4 intronic 
11 94345106 cx rs71459738 PIWIL4 intronic 
11 94345346 cx rs144175515 PIWIL4 intronic 
11 94350519 cx 
 
PIWIL4 intronic 
11 94527703 sb T>C AMOTL1 intronic 
11 94606941 cx 
 
AMOTL1 UTR3 
11 94699391 cx rs58215154 CWC15 intronic 
11 94699391 cx 
 
CWC15 intronic 
11 94708334 sb A>G rs6483383 KDM4D intronic 
11 94708335 sb G>A rs6483384 KDM4D intronic 
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11 94717787 sb A>G KDM4D intronic 
11 94824141 cx 
 
ENDOD1 intronic 
11 94831936 sb G>A rs75098296 ENDOD1 intronic 
11 94836260 cx 
 
ENDOD1 intronic 
11 94836264 sb G>T rs674973 ENDOD1 intronic 
11 94841658 cx 
 
ENDOD1 intronic 
11 94841658 cx 
 
ENDOD1 intronic 
11 94855753 cx 
 
ENDOD1 intronic 
11 94856752 cx 
 
ENDOD1 intronic 
11 94889358 cx 
 
LOC101929295 ncRNA_intronic 
11 94889358 cx 
 
LOC101929295 ncRNA_intronic 
11 94906293 sb A>C SESN3 UTR3 
11 94915046 sb T>C rs191030205 SESN3 intronic 
11 94919358 cx 
 
SESN3 intronic 
11 94919358 cx 
 
SESN3 intronic 
11 94939003 sb G>T rs2199057 SESN3 intronic 
11 94939529 cx rs3032056 SESN3 intronic 
11 94959199 sb A>T rs7944086 SESN3 intronic 
11 95527512 sb C>A CEP57 intronic 
11 95547233 cx 
 
CEP57 intronic 
11 95547233 cx rs369609536 CEP57 intronic 
11 95548682 cx 
 
CEP57 intronic 
11 95553074 cx 
 
CEP57 intronic 
11 95578167 sb C>T rs146572467 MTMR2 exonic 
11 95583439 cx 
 
MTMR2 intronic 
11 95586200 cx 
 
MTMR2 intronic 
11 95632800 cx 
 
MTMR2 intronic 
11 95638491 cx 
 
MTMR2 intronic 
11 95656529 sb A>C MTMR2 intronic 
11 95737611 cx 
 
MAML2 intronic 
11 95741204 sb T>A rs4998067 MAML2 intronic 
11 95748747 cx 
 
MAML2 intronic 
11 95748747 cx 
 
MAML2 intronic 
11 95752846 cx rs373815878 MAML2 intronic 
11 95767572 cx 
 
MAML2 intronic 
11 95767596 cx 
 
MAML2 intronic 
11 95801602 cx 
 
MAML2 intronic 
11 95801602 cx 
 
MAML2 intronic 
11 95809365 sb G>A rs76820499 MAML2 intronic 
11 95809594 cx 
 
MAML2 intronic 
11 95809594 cx 
 
MAML2 intronic 
11 95810936 sb G>A MAML2 intronic 
 152 
 
Chr. Start position   Variant type Variant/SNP ID Gene name Gene component 
11 95814678 cx 
 
MAML2 intronic 
11 95846348 cx 
 
MAML2 intronic 
11 95855661 cx 
 
MAML2 intronic 
11 95855661 cx 
 
MAML2 intronic 
11 95881823 cx rs71040133 MAML2 intronic 
11 95881823 cx 
 
MAML2 intronic 
11 95887116 sb T>A rs11021451 MAML2 intronic 
11 95899318 cx 
 
MAML2 intronic 
11 95899318 cx rs372154381 MAML2 intronic 
11 95899341 cx 
 
MAML2 intronic 
11 95902823 cx rs35274204 MAML2 intronic 
11 95911080 cx 
 
MAML2 intronic 
11 95917603 cx 
 
MAML2 intronic 
11 95917773 sb G>T MAML2 intronic 
11 95920956 cx 
 
MAML2 intronic 
11 95945272 cx 
 
MAML2 intronic 
11 95945272 cx 
 
MAML2 intronic 
11 95958996 cx rs36112117 MAML2 intronic 
11 95965635 cx 
 
MAML2 intronic 
11 95985338 cx 
 
MAML2 intronic 
11 96016768 sb G>A rs76683564 MAML2 intronic 
11 96024191 cx 
 
MAML2 intronic 
11 96048385 cx 
 
MAML2 intronic 
11 96059522 cx rs35138919 MAML2 intronic 
11 96092755 cx 
 
CCDC82 intronic 
11 96110521 cx 
 
CCDC82 intronic 
11 96123734 cx 
 
JRKL UTR5 
11 96125435 cx 
 
JRKL UTR3 
11 96207166 cx 
 
JRKL-AS1 ncRNA_intronic 
11 96222166 cx 
 
JRKL-AS1 ncRNA_intronic 
11 96226382 cx 
 
JRKL-AS1 ncRNA_intronic 
11 96230212 cx 
 
JRKL-AS1 ncRNA_intronic 
11 96231183 cx 
 
JRKL-AS1 ncRNA_intronic 
11 96231580 cx 
 
JRKL-AS1 ncRNA_intronic 
For complex variants only one dbSNP record (rs#) is listed in the table. In bold type is the only one 
exonic variant inside the critical region. Sb=substitution; cx=complex. 
 
 
